| Section |
Name |
Details |
| 14.04 |
23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 14.07 |
23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved as test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017) Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- Diagnose or exclude antibody deficiency including CVID and SAD (UMC March 2017)
- WH:
|
| 13.08.01 |
5-aminolevulinic acid 78mg/g gel Ameluz® |
Approved for first-line treatment in actinic keratosis and superficial basal cell carcinoma (JFC June 2019).
Provider notes
- NMUH:
- RFL:
- First-line treatment of actinic keratosis and basal cell carcinoma
- RNOH:
- UCLH:
- WH:
- First-line treatment of actinic keratosis and basal cell carcinoma
|
| 05.03.01 |
Abacavir |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Abacavir + Lamivudine |
Provider notes
- NMUH:
- To be prescribed as per BHIVA Guidelines by the HIV team only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Abacavir + Lamivudine + Zidovudine Trizivir® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Abatacept |
Approved for:
- Rheumatoid arthritis in line with the NCL RA pathway
- Juvenile Idiopathic Arthritis (JIA; see NICE TAs)
Provider notes
- NMUH:
- This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Rheumatologists ONLY.
- Check MHRA Drug Safety Updates.
- See links below.
- RFL:
- Approved for Rheumatoid Arthritis and Juvenile Idiopathic Arthritis, in line with NICE guidance
- RNOH:
- Restricted to Rheumatology Consultants ONLY.
- UCLH:
- WH:
|
| 08.01.05 |
Abemaciclib tabs |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.02 |
Abiraterone |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. To be prescribed as per NICE guidance
- See links below
- RFL:
- As per NICE TAs
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 04.10.01 |
Acamprosate |
Provider notes - NMUH:
- RFL:
- RNOH:
- Requires psychiatrist approval. For use in accordance with NICE CG115.
- UCLH:
- WH:
|
| 06.01.02.03 |
Acarbose |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 10.01.01 |
Acemetacin |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Rheumatology only.
|
| 02.08.02 |
Acenocoumarol |
Provider notes - NMUH:
- Restricted for patients allergic to Warfain only.
- Check MHRA Drug Safety Updates
- RFL:
- Restricted for patients allergic to warfarin only
- RNOH:
- UCLH:
- WH:
|
| 04.14 |
Acetazolamide |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Acetazolamide |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Adjunctive therapy for Open Angle Glaucoma And Ocular Hypertension
Provider notes
- NMUH:
- See link below
- Immedidate release and modified release formulations are both available
- RFL:
- RNOH:
- UCLH:
- WH:
- As per NCL glaucoma guideline
|
| 11.08.02 |
Acetylcholine intra-ocular irrigation Miochol-E®, Miphtel® |
Provider notes |
| 03.07 |
Acetylcysteine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Respiratory consultants only
- Injection (200mg/ml) can be used orally
- Tablets 600mg also available
- RNOH:
- Restricted to ITU use only after trailling NaCl 0.9%, NaCl 3% and carbocysteine
- UCLH:
- WH:
|
| 07.06 |
Acetylcysteine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 18 |
Acetylcysteine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- See MHRA Drug Safety Update
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.08.01 |
Acetylcysteine 5% + Hypromellose 0.35% eye drops Ilube® |
Provider notes |
| 11.08.01 |
Acetylcysteine eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for tear deficiency and impaired/abnormal mucus production (restricted to Ophthalmology)
- With preservative: 5% (1st line), 10% and 20%
- Preservative-free bottles: 5%
- RNOH:
- UCLH:
- WH:
- Acetylcysteine 5% preservative-free drops (10mL) is an unlicensed special and restricted to Ophthalmology.
|
| 05.03.02.01 |
Aciclovir |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.03.03 |
Aciclovir 3% eye ointment |
Provider notes
- NMUH:
- RFL:
- Approved for herpes simplex keratitis & conjunctivitis (1st line)
- RNOH:
- UCLH:
- WH:
|
| 13.10.03 |
Aciclovir 5% cream |
Provider notes |
| 13.05.02 |
Acitretin |
Provider notes
- NMUH:
- Restricted to Dermatology
- RFL:
- Restricted to Dermatology
- Females of childbearing potential must meet the requirements of the pregnancy prevention programme (PPP) - maximum 30 days supply at at time
- Acitretin prescriptions should be restricted to a 12 week supply for men and postmenopausal women
- RNOH:
- UCLH:
- WH:
- Restricted to Dermatology use only
|
| A5.03.03 |
Actisorb Silver 220 |
Provider notes - NMUH:
- We stock 10.5 cm x 10.5 cm. To be used on the recommendation of the Tissue Viability Nurse only.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 18 |
Activated charcoal |
Provider notes - NMUH:
- Carbomix and Charcodote available
- RFL:
- Actidose-Aqua Advance, Carbomix, Charcodote available
- RNOH:
- UCLH:
- WH:
|
| 01.05.03 |
Adalimumab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- Red List Medicine – Hospital Only Prescribing PbR (Payment by Results) excluded drug.
- Restricted to Consultant Gastroenterologists for NICE approved indications.
- Check MHRA Drug Safety Update
- RFL:
- Restricted to Consultant Gastroenterologists for NICE approved indications.
- RNOH:
- UCLH:
- WH:
- Restricted to consultant gastroenterologists
- NICE TA187 and TA329 applies
- JFC (Oct 17): Approved for fistulising Crohn's disease in patients not able to receive infliximab.
|
| 10.01.03 |
Adalimumab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for:
- Rheumatoid arthritis in line with the NCL RA pathway
- Juvenile Idiopathic Arthritis (JIA; see NICE TA)
- Ankylosing Spondylitis (see NICE TAs)
- Psoriatic Arthritis (PsA; see NICE TAs)
Provider notes
- NMUH:
- Check MHRA Drug Safety Updates
- This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Restricted to Consultant Rheumatologists
- See links below
- RFL:
- Approved for use in Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis
- RNOH:
- Restricted to Rheumatology Consultants Only
- UCLH:
- WH:
|
| 11.99.99.99 |
Adalimumab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.05.03 |
Adalimumab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Restricted to Consultant Dermatologists for NICE approved indications.
- See links below
- Check MHRA Drug Safety Updates
- RFL:
- Approved for Psoriasis and Hydradenitis Suppurativa (NHSE)
- Approved for Pyoderma gangrenosum – prior funding approval required
- RNOH:
- UCLH:
- WH:
|
| 13.06.01 |
Adapalene 0.1% + Benzoyl peroxide 2.5% gel Epiduo® |
Provider notes - NMUH:
- RFL:
- Approved for Dermatology for acne vulgaris
- RNOH:
- UCLH:
- WH:
- Prescribing by Consultant Dermatologists only for acne
|
| 13.06.01 |
Adapalene 0.1% cream Differin® |
Approved for acne (JFC April 2016)
Provider notes
- NMUH:
- RFL:
- Approved for Dermatology for acne vulgaris
- RNOH:
- UCLH:
- WH:
|
| 05.03.03.01 |
Adefovir Dipivoxil |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal BUT IS NOT LISTED IN THE TRUST FORMULARY AS AN ALTERNATIVE NICE APPROVED MEDICINE IS USED.
- RFL:
- Restricted to Hepatology/Virology
- As per NICE guidance
- RNOH:
- UCLH:
- WH:
|
| 02.03.02 |
Adenosine 6mg/2mL injection Adenocor® |
Provider notes |
| 02.07.03 |
Adrenaline 1:10,000 (100 mcg/1 ml) injection |
Provider notes |
| 03.04.03 |
Adrenaline 1:10,000 (100 mcg/1 ml) injection |
Provider notes |
| 03.04.03 |
Adrenaline 1:1000 (1 mg/1 ml) injection |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- The use of epinephrine 1 in 1,000 units Min-I-Jet injection is reserved for treatment of anaphylaxis in children < 15 kg in weight.
|
| 03.04.03 |
Adrenaline autoinjector Emerade® |
Provider notes
- NMUH:
- Check for MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 03.04.03 |
Adrenaline autoinjector Jext® |
Provider notes
- NMUH:
- RFL:
- As an alternative if supply problems with EpiPen
- RNOH:
- UCLH:
- WH:
|
| 03.04.03 |
Adrenaline autoinjector EpiPen® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
Adrenaline eye drop |
Provider notes
- NMUH:
- RFL:
- Approved for diagnostic, testing for pupils, and to control bleeding during surgery, or prevent rapid loss of sub-conjunctival injections into systemic circulation (0.01% & 0.1%)
- RNOH:
- UCLH:
- WH:
|
| A5.02.07 |
Advadraw |
Provider notes |
| A5.02.03 |
Advazorb Border |
Provider notes |
| 08.01.05 |
Afatinib |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See link below
- RFL:
- As per NICE TA
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Aflibercept infusion Zaltrap® |
Provider notes - NMUH:
- Non-formulary
- See MHRA Drug Safety Update
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.08.02 |
Aflibercept intraocular injection Eylea® |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultant Ophthalmologists ONLY
- See links below
- RFL:
- Approved for (as per NICE TAs):
- To be prescribed by consultant ophthalmologists only
- RNOH:
- UCLH:
- WH:
|
| 09.08.01 |
Agalsidase alfa and beta Fabrazyme® |
Provider notes
- NMUH:
- RFL:
- Restricted to the lysosomal storage disorders unit
- RNOH:
- UCLH:
- WH:
|
| 09.08.01 |
Agalsidase alfa and beta Replagal® |
Provider notes
- NMUH:
- RFL:
- Restricted to the lysosomal storage disorders unit
- RNOH:
- UCLH:
- WH:
|
| 02.14 |
Ajmaline |
Provider notes
- NMUH:
- Restricted to Consultant Cardiologists ONLY.
- Ajmaline 50mg in 10mL injection - available from 'special-order' manufacturers or specialist importing companies.
- See Trust guideline via intranet
- RFL:
- Approve for diagnosis of Brugada syndrome (August 2016)
- RNOH:
- UCLH:
- WH:
|
| 05.05.01 |
Albendazole |
Provider notes
- NMUH:
- For use for named patients only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.02.02.02 |
Albumin Solution |
Provider notes - NMUH:
- RFL:
- Available via the blood bank
- RNOH:
- UCH approvals:
- WH:
|
| 08.01.05 |
Alectinib tabs |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic).
- RNOH:
- UCLH:
- WH:
|
| 08.02.03 |
Alemtuzumab Lemtrada® |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.04 |
Alemtuzumab Free-Of-Charge |
Provider notes
- NMUH:
- RFL:
- Available for islet cell transplant – contact pharmacy for advice
- RNOH:
- UCLH:
- WH:
|
| 06.06.02 |
Alendronic Acid |
Provider notes - NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.06.04 |
Alfacalcidol One-Alpha® |
Provider notes |
| 15.01.04.03 |
Alfentanil |
Provider notes
- NMUH:
- RFL:
- Restricted to Anaesthetics and Palliative Care only
- RNOH:
- UCLH:
- WH:
|
| 07.04.01 |
Alfuzosin immediate release |
Provider notes |
| 07.04.01 |
Alfuzosin modified release |
Provider notes - NMUH:
- Restricted to Urology Department, second line use only.
- RFL:
- RNOH:
- UCLH:
- WH:
- The use of alfuzosin is reserved for the Urology Department only
|
| 09.08.01 |
Alglucosidase Alfa |
Provider notes
- NMUH:
- RFL:
- Restricted to the lysosomal storage disorders unit
- RNOH:
- UCLH:
- WH:
|
| 03.04.01 |
Alimemazine tabs/solution |
Not recommended for any indication - do not prescribe (JFC November 2018)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.12 |
Alirocumab |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed on the recommendation of Consultant Cardiologists and Endocrinologists ONLY
- See links below
- RFL:
- As per NICE guidance
- Restricted to Lipid Clinic
- Prescriptions are supplied monthly for first 4 months then 3 monthly. Homecare service also available
- RNOH:
- UCLH:
- WH:
|
| 13.05.01 |
Alitretinoin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Check MHRA Drug Safety updates
- RFL:
- For severe chronic hand eczema in line with NICE guidance
- Females of childbearing potential must meet the requirements of the pregnancy prevention programme (PPP) - maximum 30 days supply at at time
- Alitretinoin prescriptions should be restricted to a 12 week supply for men and post menopausal women
- RNOH:
- UCLH:
- WH:
|
| 21.01 |
Alitretinoin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Pityriasis rubra pilaris
Evaluation at RFL site only (JFC August 2016). Prior funding approval required. |
| 10.01.04 |
Allopurinol |
Provider notes
- NMUH:
- Access Trust guideline via intranet
- RFL:
- RNOH:
- First choice for long-term control of gout
- UCLH:
- WH:
|
| 09.06.05 |
Alpha Tocopheryl Acetate |
Provider notes - NMUH:
- RFL:
- Oral suspension and injection 100mg/2ml kept at the RFH.
- RNOH:
- UCLH:
- WH:
|
| 07.04.05 |
Alprostadil intracavernous injection Caverject® |
  (hospital only prescribing) if used for non-SLS indications
 for SLS indications
Provider notes
- NMUH:
- Red List Medicine – Hospital Only Prescribing
- RFL:
- Restricted to Urology and Endocrinology consultants
- RNOH:
- UCLH:
- WH:
|
| 07.04.05 |
Alprostadil intracavernous injection Viridal® Duo |
(hospital only prescribing) if used for non-SLS indications
for SLS indications
Provider notes
- NMUH:
- RFL:
- Restricted to Urology and Endocrinology Consultants
- RNOH:
- UCLH:
- WH:
|
| 07.04.05 |
Alprostadil 3mg/g cream Vitaros® |
(hospital only prescribing) if used for non-SLS indications
for SLS indications
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- For Erectile Dysfunction under the Selected List Scheme (SLS) - as per JFC August 2019
|
| 07.04.05 |
Alprostadil urethral stick MUSE® |
(hospital only prescribing) if used for non-SLS indications
for SLS indications
Provider notes
- NMUH:
- Red List Medicine – Hospital Only Prescribing Restricted to Consultants in Urology and Sexual Health (St. Ann's) use only.
- RFL:
- Restricted to Urology and Endocrinology Consultants
- RNOH:
- UCLH:
- WH:
|
| 01.10 |
Alteplase |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Restricted to hepatology only for portal vein thrombosis
- RNOH:
- UCLH:
- WH:
|
| 02.10.02 |
Alteplase |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Restricted for use in Pulmonary Embolism (PE).
- RFL:
- Restricted to vascular surgery, MI and for use in the treatment of PE
- RNOH:
- UCLH:
- WH:
- For massive PE and PE causing cardiac arrest
|
| 02.14 |
Alteplase |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Non-formulary
- Any suitable patients to be referred to RFH as per guidelines
- RFL:
- Approved for:
- Iliofemoral DVT with (i) May-Thurner syndrome OR extensive clots AND (ii) who have severe symptoms despite 5-7 days anticoagulation OR where a limb is threatened (JFC July 2018)
- Paget-Schroetter Syndrome
- Not approved for:
- Massive or high risk PE (defined as acute PE with sustained hypotension [SBP ≤ 90 mm Hg for at least 15 min or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or LV dysfunction], pulselessness or persistent profound bradycardia [pulse < 40 bpm], with signs or symptoms of shock) (JFC July 2018)
- RNOH:
- UCLH:
- Approved for:
- Iliofemoral DVT with (i) May-Thurner syndrome OR extensive clots AND (ii) who have severe symptoms despite 5-7 days anticoagulation OR where a limb is threatened (UMC June 2018)
- Upper Limb Central Venous Catheter (CVC) Related Thrombosis as last-line therapy (UMC June 2018)
- Not approved for:
- Paget-Schroetter Syndrome- Refer patient to RFH (UMC June 2018)
- Stent rethrombosis (UMC June 2018)
- Massive or high risk PE (defined as acute PE with sustained hypotension [SBP ≤ 90 mm Hg for at least 15 min or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or LV dysfunction], pulselessness or persistent profound bradycardia [pulse < 40 bpm], with signs or symptoms of shock) (UMC June 2018)
- WH:
|
| 21.01 |
Alteplase + dornase alpha intrapleural infusion |
Approved as intrapleural fibrinolytics (alteplase + dornase alfa) for ongoing sepsis in association with a persistent pleural collection, who have not responded to 12-24 hours of antibiotics and simple tube drainage, or there is radiological evidence (either on ultrasound and/or CT) that the effusion is unlikely to drain due to multiple loculation; rather than referring for surgical intervention. Evaluation sites to be approved at DTCs (JFC March 2019)
Notes: The majority of trials use dornase alfa (DNase) 5 mg and alteplase (t-PA) 10 mg administered intrapleurally twice daily for up to 3 days. Administration was followed by clamping of the drain to permit the study drug to remain in the pleural space for 1 hour. One study used dornase alfa (DNase) 5 mg and alteplase (t-PA) 5 mg twice daily.
Provider notes
- NMUH:
- RFL:
- To be used as per protocol for complex pleural infections (under evaluation)
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
Alteplase 25mcg/0.1ml intravitreal injection |
Provider notes
- NMUH:
- RFL:
- Restricted for eye procedures
- RNOH:
- UCLH:
- WH:
|
| A2.02.02.03 |
Altraplen Compact |
- Bottle (125mL)
- Banana, hazel-chocolate, strawberry, vanilla
- Clinically lactose and gluten-free
- Suitable for vegetarian, Halal and Kosher diets (except strawberry)
Primary care notes
For patients who did not tolerate first-line choices and lower volume is indicated or fluid restricted- see Primary Care Guidance |
| 13.12 |
Aluminimum chloride 20% Anhydrol Forte® |
Provider notes - NMUH:
- Suitable for use in children, adults and the elderly. NOT suitable for use in pregnancy and lactation.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.12 |
Aluminimum chloride 20% Driclor® |
Provider notes - NMUH:
- Suitable for use in pregnancy and lactation.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.01.01 |
Aluminium hydroxide + Magnesium hydroxide + Simeticone Maalox Plus® |
Provider notes |
| 04.09.01 |
Amantadine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 05.03.04 |
Amantadine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Virology/Microbiology/ID approval only
- RNOH:
- Microbiologist approval only
- UCLH:
- WH:
- Microbiologist approval only
|
| 14.04 |
Ambirix® Hepatitis A vaccine with Hepatitis B vaccine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.05.01 |
Ambrisentan |
Provider notes - NMUH:
- RFL:
- Prior funding approval required. Restricted to the treatment of pulmonary hypertension
- RNOH:
- UCLH:
- WH:
|
| 11.03.01 |
Amikacin 0.4mg/0.1mL intravitreal pack |
Provider notes
- NMUH:
- RFL:
- Approved for bacterial endophthalmitis (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
- Intravitreal use - this is an unlicensed special and restricted to Ophthalmology.
|
| 11.03.01 |
Amikacin 1.5% eye drops |
Provider notes
- NMUH:
- RFL:
- Restricted to ophthalmology
- RNOH:
- UCLH:
- WH:
- Restricted to ophthalmology
|
| 11.03.01 |
Amikacin 2.5% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for bacterial and mycobacterial keratitis (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
| 24.01 |
Amikacin 2.5% eye drops |
 unlicensed
MEH: Bacterial & Mycobacteria keratitis |
| 05.01.04 |
Amikacin injection |
Provider notes
- NMUH:
- Restricted to Microbiology approval only
- RFL:
- Refer to amikacin prescribing guidelines in Microguide
- RNOH:
- UCLH:
- WH:
- Microbiology approval only
|
| 02.02.03 |
Amiloride Hydrochloride |
Provider notes |
| 03.01.03 |
Aminophylline Phyllocontin Continus® |
Provider notes |
| 03.01.03 |
Aminophylline IV |
Provider notes |
| 05.01.09 |
Aminosalicylic acid |
Provider notes
- NMUH:
- Available from 'special order' manufacturers
- RFL:
- Available from 'special order' manufacturers
- MDR-TB only
- Restricted to ID / Microbiology
- RNOH:
- UCLH:
- WH:
|
| 02.03.02 |
Amiodarone |
Provider notes |
| 04.02.01 |
Amisulpride |
Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team.
- RNOH:
- UCLH:
- WH:
- Restricted for initiation by a Consultant Psychiatrist only.
|
| 01.10 |
Amitriptyline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for irritable bowel syndrome, if first-line antispasmodic has failed (JFC May 2020).
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.03.01 |
Amitriptyline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- Oral solution available as 25 mg/5mL
- UCLH:
- WH:
- CIFT:
- BEHMT:
|
| 04.07.03 |
Amitriptyline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- See Trust guideline via intranet for more information
- RFL:
- RNOH:
- See link below
- Oral solution available as 25 mg/5mL
- UCLH:
- WH:
|
| 04.07.04.02 |
Amitriptyline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.06.02 |
Amlodipine |
Provider notes |
| 13.10.02 |
Amorolfine 5% nail lacquer |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.01.01.03 |
Amoxicillin |
Provider notes - NMUH:
- RFL:
- RNOH:
- Oral suspension available as 125 mg/5mL and 250 mg/5mL
- UCLH:
- WH:
|
| 11.03.02 |
Amphotericin 0.15% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for
- Candida fungal infections (Ophthalmologist use only)
- Keratitis (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
- Restricted to ophthalmology
|
| 11.03.02 |
Amphotericin 5mcg/0.1ml intravitreal injection |
Provider notes
- NMUH:
- RFL:
- Approved for fungal endophthalmitis
- RNOH:
- UCLH:
- WH:
|
| 05.02 |
Amphotericin infusion Fungizone® |
Provider notes
- NMUH:
- RFL:
- Not for intravenous use
- Microbiology/ID approval only
- RNOH:
- UCLH:
- Approved for:
- Cryptococcosis – treatment (Restricted to Microbiology approval)
- Serious fungal infections (Restricted to Microbiology approval for intraventricular disease)
- WH:
|
| 05.02 |
Amphotericin liposomal infusion AmBisome® |
Provider notes
- NMUH:
- RFL:
- Restricted to OLT prophylaxis (2nd transplant/hepatic artery thrombosis)
- Microbiology/ID approval required for all other indications
- RNOH:
- Microbiology approval only
- UCLH:
- WH:
- Microbiology approval only
|
| 08.01.05 |
Anagrelide caps |
Approved for essential thrombocythaemia, if first-line hydroxycarbamide is unsuitable (JFC February 2020).
Provider notes
- NMUH:
- Approved for essential thrombocythaemia (see above)
- This drug for the treatment of malignant disease must be prescribed on chemocare
- RFL:
- Approved for essential thrombocythaemia
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Anakinra |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for adult-onset Stills disease in line with NHSE commissioning policy (JFC October 2018) Provider notes - NMUH:
- RFL:
- Approved for AOSD in line with NHSE policy (see below)
- RNOH:
- UCLH:
- WH:
|
| 10.04 |
Anakinra |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for secondary haemophagocytic lymphohistiocytosis subject to individual funding approval (JFC September 2018). Additional information: Evidence to support SC or IV (local practice is to administer in 100mL sodium chloride 0.9%w/v over 1 hour).
Provider notes
- NMUH:
- RFL:
- Prior funding required
- Restricted to Rheumatology
- RNOH:
- UCLH:
- WH:
|
| 10.04 |
Anakinra |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for gout for patients who are hospitalised and refractory to all other treatments. The usual dose is 100 mg daily subcutaneously for 3 days (JFC September 2014)
Provider notes
- NMUH:
- To be prescribed/ recommended by Rheumatology Consultants ONLY
- Anakinra has been approved for gout. This is an unlicensed indication and the recommended dose is 100mg by subcutaneous injection ONCE a day for 3 days.
- Check MHRA Drug Safety Updates
- RFL:
- RNOH:
- Restricted to Rheumatology Consultants ONLY.
- Unlicensed for the treatment of gout, 100mg daily for 3 days
- UCLH:
- WH:
- Restricted to Rheumatology Consultants ONLY
|
| 16.01 |
Anakinra |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- National Amyloidosis Clinic use only
- Approval for
- Chronic Granulomatous Disease (January 2013). Prior funding approval required
- Familial Mediterranean Fever, Pericarditis and DIRA (RFL only; JFC May 2016). Prior funding approval required
- Cryopyrin-Associated Periodic Syndrome (CAPS)
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.01 |
Anastrozole |
Provider notes - NMUH:
- Restricted to Oncology department use only.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.02.04 |
Anidulafungin |
Approved for invasive candidiasis, subject to local Antimicrobial Committee approval (JFC February 2019). Provider notes - NMUH:
- To be used as per Trust antifungal guidelines
- RFL:
- RNOH:
- UCLH:
- WH:
- Microbiology approval only
|
| 12.03.01 |
Antacid + Oxetacaine oral suspension |
Approved for oral mucositis post radiotherapy (JFC February 2019).
Provider notes
- NMUH:
- For oral mucositis and oesophageal lesions following radiotherapy.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.04.02 |
Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 14.05.03 |
Anti-D (Rh0) Immunoglobulin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary.
- It is available via the blood bank
- RFL:
- Not available through pharmacy - obtain from the blood bank
- RNOH:
- UCLH:
- WH:
- Available from Haematology (Ext 5035)
|
| 02.11 |
Antithrombin III Kybemin® |
Provider notes - NMUH:
- RFL:
- Available through the haemophilia centre
- RNOH:
- UCLH:
- WH:
|
| 08.02.02 |
Antithymocyte immunoglobulin - rabbit Thymoglobuline® |
Provider notes
- NMUH:
- RFL:
- Renal transplant: For transplant induction and rejection
- Liver transplant: For transplant rejection only
- RNOH:
- UCLH:
- WH:
|
| 01.07.02 |
Anusol-HC® |
Provider notes - NMUH:
- RFL:
- Ointment and suppositories both stocked
- RNOH:
- UCLH:
- WH:
- Ointment containing hydrocortisone 0.25%. Suppositories containing hydrocortisone acetate 10 mg
|
| 02.08.02 |
Apixaban tabs |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
See NICE TA for eligibity criteria
Rivaroxaban is the preferred DOAC for VTE, apixaban may be considered in line with NCL JFC Position Statement (JFC February 2020).
Provider notes
- NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See JFC note above
- Check MHRA Drug Safety Update
- A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
- A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
- A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
- RFL:
- As per NICE guidance
- Follow NCL DOAC prescribing guide
- RNOH:
- UCLH:
- WH:
- 2nd Choice DOAC - For Atrial Fibrillation / Stroke prevention.
|
| 02.08.02 |
Apixaban tabs |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for (JFC January 2019):
- Multiple myeloma starting chemotherapy with thalidomide, lenalidomide or pomalidomide who would previously have received LMWH
- Newly diagnosed multiple myeloma with additional VTE risk factor
Dose is 2.5mg twice-daily.
Provider notes
- NMUH:
- RFL:
- Approved for thromboprophylaxis for patients have thalidomide, lenalidomide, pomalidomide
- RNOH:
- UCLH:
- WH:
|
| 04.09.01 |
Apomorphine |
Provider notes
- NMUH:
- Non-formulary
- Check MHRA Drug Safety Update
- RFL:
- Restricted to neurology only
- RNOH:
- UCLH:
- WH:
|
| 11.08.02 |
Apraclonidine eye drops (various strengths) Iopidine® |
Provider notes
- NMUH:
- Apraclonidine 0.5% used short-term to delay laser treatment or surgery in patients with glaucoma not adequately controlled by another drug
- See link below
- RFL:
- 0.5% approved for
- Short term reduction of elevated IOP (3rd line)
- Horner’s syndrome test
- 1% approved for
- Post-laser
- To low lower IOP in certain circumstances
- RNOH:
- UCLH:
- WH:
- Apraclonidine 1% preservative-free is restricted to Ophthalmology
|
| 10.01.03 |
Apremilast |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for: - Psoriatic Arthritis (PsA; see NICE TA)
Provider notes - NMUH:
- This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Rheumatologists ONLY
- See links below
- Check MHRA Drug Safety Updates
- RFL:
- As per NICE guidance for PsA
- RNOH:
- Rheumatology Consultants ONLY
- UCLH:
- WH:
|
| 13.05.03 |
Apremilast |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below.
- Check MHRA Drug Safety Updates.
- RFL:
- For the treatment of Psoriasis in line with NICE guidance
- RNOH:
- UCLH:
- WH:
- In line with NICE TA and JFC pathway
|
| 04.06 |
Aprepitant |
Provider notes
- NMUH:
- Restricted to Oncology Consultants only
- RFL:
- Restricted to oncology and haematology only
- RNOH:
- Restricted for severe emetogenesis.
- Restricted to Dr Kofi Agyare
- UCLH:
- WH:
- Reserved for the prophylaxis of nausea & vomiting associated with cisplatin (CINV)
|
| A5.02.04 |
Aquacel |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Hydrocolloid dressing 10 cm * 10 cm (10), 15 cm * 15 cm(5)
|
| 13.02.01 |
Aquadrate® cream Urea 10% |
Provider notes |
| 13.02.01.01 |
Aqueous Cream BP |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.06.03 |
Arachis Oil Enema |
Provider notes - NMUH:
- RFL:
- RNOH:
- Requires gastroenterologist approval
- UCLH:
- WH:
|
| 02.08.01 |
Argatroban |
Anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II who require parenteral antithrombotic therapy and have renal failure (February 2013)
Provider notes
- NMUH:
- RFL:
- As per restrictions above
- Haemophilia recommendation only
- RNOH:
- Requires Haematologist approval. See restriction above.
- UCLH:
- Restricted to consultant haematologists. For patients with severe renal impairment (CrCl<30ml/min)
- WH approval:
|
| 09.08.01 |
Arginine |
Provider notes
- NMUH:
- RFL:
- For peritoneal dialysis patients only (arginine deficiency)
- Non-formulary for other indications (inc. paediatrics)
- RNOH:
- UCLH:
- WH:
|
| 06.05.02 |
Argipressin |
Provider notes |
| 04.02.01 |
Aripiprazole |
(hospital only prescribing) for aripiprazole intramuscular injection
 for aripiprazole oral formulations
Approved (7.5mg/1mL IM formulation) for the rapid control of agitation and disturbed behaviours in adult patients with schizophrenia or with manic episodes in Bipolar I Disorder when oral therapy is not appropriate and where IM haloperidol is not recommended (JFC January 2019).
Provider notes
- NMUH:
- As per indication stated above for IM formulation, after psychiatry advise only
- Oral formulations are on the formulary for CONTINUATION ONLY. Not to be initiated at NMUH
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- Initiation with Psychiatry advice only
- UCLH:
- WH:
- Restricted for initiation by a Consultant Psychiatrist only
- CIFT:
- Approved for
- Mania
- Schizophrenia
- Persistent aggression in moderate to severe Alzheimer’s dementia where risk of harm to self & others (off-label)
- Depression (adjunctive treatment)
- Challenging behaviour in learning disabilities - 2nd line
- BEHMT:
- Approved for
- Mania
- Schizophrenia
- Rapid tranquillisation
|
| 04.02.02 |
Aripiprazole depot injection Abilify Maintena® |
Approved for use by Mental Health Trusts only & restricted to patients with schizophrenia already stabilised & responding to oral aripiprazole (JFC February 2015).
Provider notes
- NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- CIFT:
- Restricted formulary - requested via non-form route
- BEHMT:
- Restricted consultant only
- See 'Prescribing guidelines: Second-generation antipsychotic Long-Acting Injections' below
|
| 05.04.01 |
Artemether + Lumefantrine |
Provider notes
- NMUH:
- To be used as per the NMUHT Malaria Guidelines, sccess via intranet
- RFL:
- RNOH:
- UCLH:
- WH:
- First line for uncomplicated falciparum malaria, chloroquine-resistant non-falciparum malaria, and PO step down from IV artesunate
- See link below
|
| 05.04.01 |
Artesunate |
Approved for severe falciparum malaria (November 2015)
Provider notes
- NMUH:
- To be used on the recommendation of the Infectious Diseases Team or Microbiology according to the NMUHT malaria guidelines.
- See Trust guideline via intranet
- Available from ‘special-order’ manufacturers or specialist importing companies
- RFL:
- Microbiology/ID approval only
- RNOH:
- UCLH:
- WH:
|
| 15.02 |
Articaine hydrochloride + Adrenaline injection |
Provider notes
- NMUH:
- RFL:
- For dental use at BCF only
- RNOH:
- UCLH:
- WH:
|
| 07.04.03 |
Ascorbic Acid Vitamin C |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Acidification may prevent encrustation of indwelling catheters, excess mucus formation in bladder augmentation and urinary tract infections. Many patients find high dose ascorbic acid unpalatable and may prefer to take cranberry juice drinks that are now widely available in the high street.
|
| 09.06.03 |
Ascorbic Acid Vitamin C |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Tablets 50mg,100mg, 200mg and 500mg
- Injection 500mg
- RNOH:
- UCLH:
- WH:
|
| A5.03.03 |
Askina Calgitrol |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Use restricted to Tissue Viability Nurse (TVN) specialist
|
| 02.09 |
Aspirin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- See NCL JFC summary of antiplatelet options in cardiovascular disease for specific indications
- RNOH:
- UCLH:
- WH:
|
| 04.07.01 |
Aspirin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Injection: Restricted to neurology for Chronic intractable daily headache, Chronic migraine or Drug withdrawal headache
- Oral: Mild to moderate pain
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Atazanavir |
Provider notes
- NMUH:
- To be prescribed as per BHIVA Guidelines by HIV team only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Atazanavir + cobicistat Evotaz® |
Provider notes - NMUH:
- To be initiated by Consultants in HIV Medicine only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.04 |
Atenolol |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Tablets available. Oral syrup available as 5 mg/mL
- UCLH:
- WH:
- Tabs 50 mg, 100 mg; Syrup 25 mg/5 ml
|
| 08.01.05 |
Atezolizumab inj |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- As per NICE TA492, TA520, TA525, TA584, TA638 & TA639
- RFL:
- As per NICE TA492, TA520, TA525, TA584/ CDF criteria
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 04.04 |
Atomoxetine |
Provider notes
- NMUH:
- RFL:
- Restricted to the Child & Adolescent Mental Health Service only
- RNOH:
- UCLH:
- WH:
- CIFT
- Approved for adults with ADHD (off-label)
- BEHMT
- Approved for adults with ADHD (off-label)
|
| 02.12 |
Atorvastatin |
Provider notes
- NMUH:
- See NCL JFC Statins Guideline
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.01.03 |
Atosiban |
Provider notes
- NMUH:
- RFL:
- Not a preferred choice agent
- See ‘Pre-Term Labour’ policy on Freenet
- RNOH:
- UCLH:
- WH:
- Atosiban is to be used only in accordance with protocol
|
| 05.04.08 |
Atovaquone |
Provider notes - NMUH:
- RFL:
- Microbiology/ID approval only
- RNOH:
- UCLH:
- WH:
- For Microbiology use only
|
| 05.04.01 |
Atovaquone + Proguanil |
Provider notes
- NMUH:
- To be used as per the NMUHT Malaria Guidelines, access via intranet
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 15.01.05 |
Atracurium besilate |
Provider notes |
| A5.01.01 |
Atrauman |
Provider notes |
| A5.03.03 |
Atrauman AG |
Provider notes - NMUH:
- 10cm x 10 cm is available on the recommendation of the Tissue Viability Nurse only.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.05 |
Atropine + Adrenaline + Procaine 0.3mL subconjunctival injection |
Provider notes
- NMUH:
- RFL:
- Approved for rapid dilatation of pupil (atropine 0.5mg with adrenaline 1 in 1,000 0.06mL with procaine 3mg; atropine 1mg with adrenaline 1 in 1,000 0.12mL with procaine 6mg)
- RNOH:
- UCLH:
- WH:
|
| 11.05 |
Atropine eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for mydriasis and cycloplegia (1% only)
- RNOH:
- UCLH:
- WH:
- Eye-drops 0.5% not available
|
| 11.05 |
Atropine eye drops - preservative free |
Provider notes
- NMUH:
- No restriction stated (single-use drops)
- RFL:
- Approved for mydriasis and cycloplegia (single-use drops + bottle)
- RNOH:
- UCLH:
- WH:
- No restriction stated (single-use drops)
|
| 15.01.03 |
Atropine injection |
Provider notes |
| 15.01.03 |
Atropine Minijet® injection |
Provider notes |
| 01.02 |
Atropine tabs |
Provider notes |
| 09.01.04 |
Avatrombopag tabs |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 14.04 |
Avaxim® Hepatitis A vaccine Single Component |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.02.01.01 |
Aveeno® Bath Oil |
- NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
- Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)
Secondary care notes
- NMUH:
- RFL:
- Approved for ichthyosis and epidermolysis bullosa
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
Aveeno® cream |
Provider notes |
| 08.01.05 |
Avelumab |
Provider notes
- NMUH:
- RFL:
- As per NICE/CDF criteria
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 07.04.05 |
Aviptadil + phentolamine Invicorp® |
Erectile dysfunction in men who have failed to respond to oral PDE5i (sildenafil and tadalafil) and intracavernosal/urethral alprostadil. Secondary care initiation, primary care continuation (SLS only) (JFC November 2017) Provider notes - NMUH:
- To be prescribed by Urology Consultants ONLY. To be used as a second line option after treatment failure or intolerance with oral PDE5i (tadalafil or sildenafil) and intracavernosal/ urethral alprostadil.
- RFL:
- RNOH:
- UCLH:
- WH:
- Approved by NCL as 2nd line treatment for erectile dysfuntion if alprostadil fails (JFC November 2016)
|
| 08.01.05 |
Axitinib |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- As per NICE TA
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| A2.02.01.02 |
AYMES ActaSolve Smoothie |
- Sachets - requires a patient to be able to mix with water
- Mango, peach, pineapple, strawberry & cranberry
- Gluten-free
- Halal certified
- Suitable for vegetarians and vegans
- Not suitable for
- Patients requiring complete nutrition e.g. reliant entirely on supplements, patients requiring enteral feeding
- Patients with soya intolerance
- Children under 3 years of age
- Caution in diabetic patients
Provider notes
Non-formulary
Primary care notes
First-choice product for patients - see Primary Care Guidance |
| A2.02.02.01 |
AYMES Complete |
- Bottle (200mL)
- Banana, vanilla, chocolate, strawberry
- Contains lactose
- Gluten Free
- Halal certified (except strawberry)
- Suitable for Kosher and vegetarians diets (except strawberry)
Provider notes
Non-formulary
Primary care notes
Second-choice product - for patients who did not tolerate first-line choices - see Primary Care Guidance |
| A2.02.01.02 |
AYMES Shake |
- Sachets - requires a patient to be able to mix with full-fat milk
- Vanilla, banana, strawberry, chocolate, neutral
- Gluten-free
- Halal certified (except for chicken flavour)
- Suitable for vegetarians (except for chicken flavour)
- May not be appropriate in the following patients
- Patients requiring complete nutrition e.g. reliant entirely on supplements, patients requiring enteral feeding
- Renal patients (CKD stage 4 and 5)
- Vegans and patients with lactose intolerance
Provider notes
Non-formulary
Primary care notes
First-choice product - see Primary Care Guidance |
| A2.02.02.03 |
AYMES Shake Compact |
- Sachets - requires a patient to be able to mix with full-fat milk
- Vanilla, banana, strawberry, chocolate, neutral
- Gluten-free
- Halal certified (except strawberry)
- Suitable for vegetarians (except strawberry)
- May not be appropriate in the following patients
- Patients requiring complete nutrition e.g. reliant entirely on supplements, patients requiring enteral feeding
- Renal patients (CKD stage 4 and 5)
- Vegans and patients with lactose intolerance
Provider notes
Non-formulary
Primary care notes
First-choice product for patients who cannot tolerate 200mL presentation - see Primary Care Guidance |
| 08.01.03 |
Azacitidine |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- Approved for Haematology for MDS, CMML and AML in line with NICE TA
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 01.05.03 |
Azathioprine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Azathioprine should be initiated only by the Gastroenterology team for difficult cases. FBC and LFT monitoring is required.
|
| 01.05.03 |
Azathioprine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for autoimmune hepatitis (JFC February 2018)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Specialist initiation, continuation in primary care
|
| 08.02.01 |
Azathioprine |
(hospital only prescribing) for renal transplant
for other indications
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Regular monitoring of FBC and LFTs is required.
|
| 10.01.03 |
Azathioprine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- Restricted to Rheumatology Consultants ONLY
- See links below
- UCLH:
- WH:
|
| 13.05.03 |
Azathioprine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.05.03 |
Azathioprine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for Pemphigus Vulgaris (PV), Mucous membrane pemphigoid (MMP), Recurrent apthous stomatitis (RAS), Oral lichen planus (OLP), Oral Crohn’s disease (OCD) (JFC June 2017)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.06.01 |
Azelaic acid 15% gel Finacea® |
Provider notes
- NMUH:
- RFL:
- Restricted to Dermatology
- RNOH:
- UCLH:
- WH:
|
| 13.06.01 |
Azelaic acid 20% cream Skinoren® |
Provider notes
- NMUH:
- RFL:
- Restricted to Dermatology
- RNOH:
- UCLH:
- WH:
|
| 12.02.01 |
Azelastine + Fluticasone nasal spray Dymista® |
Approved for allergic rhinitis when 1st line betamethasone monotherapy and 2nd line fluticasone monotherapy have failed (JFC September 2015) Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Approved for the indication outlined above
|
| 11.04.02 |
Azelastine 0.5 mg/ml eye drops |
Provider notes
- NMUH:
- RFL:
- Restricted to allergy clinic only
- RNOH:
- UCLH:
- WH:
|
| 12.02.01 |
Azelastine nasal spray Rhinolast® |
Provider notes - NMUH:
- RFL:
- Restricted to the allergy clinic only
- RNOH:
- UCLH:
- WH:
- The use of azelastine hydrochloride nasal spray is restricted to ENT department only
|
| 11.03.01 |
Azithromycin 15 mg/g (1.5%) single-use eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for
- Ocular chlamydia infections (Ophthalmologist use only)
- Blepharitis (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
| 05.01.05 |
Azithromycin tabs/caps/suspension |
Provider notes
- NMUH:
- RFL:
- Refer to Microguide for agreed indications, all other indications require microbiology approval
- Used for prophylaxis and treatment of Mycobacterium avium intracellulare in HIV
- RNOH:
- Oral suspension available as 200 mg/5mL
- UCLH:
- WH:
- Suspension is reserved for Paediatric and Neonatal use only
|
| 24.01 |
Azithromyin 1.5% single use eye drops |
MEH: Ocular Chlamydia infections; blepharitis |
| 05.01.02.03 |
Aztreonam |
Provider notes
- NMUH:
- Consultant Microbiologist recommendation only
- RFL:
- Microbiology approval only
- RNOH:
- UCLH:
- WH:
|
| 10.02.02 |
Baclofen intrathecal |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Unlicensed - Intrathecal baclofen 1000 micrograms/mL, 2000 micorgrams/mL and 3000 micrograms/mL are unlicensed products
- UCLH:
- WH:
|
| 10.02.02 |
Baclofen oral |
Provider notes - NMUH:
- RFL:
- RNOH:
- Oral liquid available as 5 mg/5mL
- UCLH:
- WH:
|
| 13.02.01.01 |
Balneum® bath oil |
- NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
- Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)
Provider notes - NMUH:
- RFL:
- Only approved for above indications
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
Balneum® cream Urea 5% |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Use as per Hertfordshire Emollients Guideline
- UCLH:
- WH:
|
| 13.02.01.01 |
Balneum® Plus bath oil |
Provider notes - NMUH:
- RFL:
- Approved for ichthyosis and epidermolysis bullosa only (JFC January 2019)
- RNOH:
- UCLH:
- WH:
- Restricted to Dermatology use ONLY
|
| 13.02.01 |
Balneum® Plus cream Urea 5% |
Provider notes
- NMUH:
- RFL:
- Preferred urea containing emollient
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Baricitinib |
Approved for: - Rheumatoid arthritis (see NICE TA)
Provider notes - NMUH:
- This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines - TO AWAIT UPDATED NCL JFC PATHWAY PRIOR TO PRESCRIBING
- See link below
- RFL:
- As per NICE guidance for the treatment of RA
- RNOH:
- Rheumatology Consultants Only
- UCLH:
- WH:
|
| 08.02.02 |
Basiliximab |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal but service is not offered at NMUH.
- Check MHRA Drug Safety Alerts
- RFL:
- Prior funding required for treatment of lymphoma with radiolabelled basiliximab.
- Approved for Renal (as per TA) and Liver (contact Pharmacy) for transplant patients.
- RNOH:
- UCLH:
- WH:
|
| 08.02.04 |
BCG bladder instillation OncoTICE® |
Provider notes |
| 08.02.04 |
BCG bladder instillation ImmuCyst® |
Provider notes |
| 14.04 |
BCG diagnostic agent - Intradermal injection |
Provider notes - NMUH:
- Tuberculin Purified Protein Derivative (PPD)
- RFL:
- RNOH:
- UCLH:
- WH:
- Tuberculin PPD SSI is an unlicensed product
|
| 14.04 |
BCG vaccine - Intradermal injection |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- BCG Vaccine SSI is an unlicensed product
|
| 12.02.01 |
Beclometasone dipropionate 50mcg/spray nasal spray |
Provider notes |
| 03.02 |
Beclometasone dipropionate inhaler (pMDI) Clenil Modulite® |
Provider notes - NMUH:
- RFL:
- Clenil Modulite® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
- RNOH:
- Clenil Modulite® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
- UCLH:
- WH:
- First choice
- CFC-free beclometasone inhalers are not equipotent and should be prescribed by brand name
- Inhaler 50 micrograms, 100 micrograms, 200 micrograms, 250 micrograms/metered inhalation ONLY
|
| 03.02 |
Beclometasone dipropionate inhaler (pMDI) Qvar® |
Provider notes
- NMUH:
- RFL:
- Qvar® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
- MDI, Autohaler and Easi-Breathe available
- RNOH:
- Restricted for continuation of treatment. Qvar® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
- UCLH:
- WH:
- Turbohalers, Accuhalers and Autohalers are reserved for unable to tolerate an MDI with a spacing device.
- Inhaler CFC-Free 50 micrograms, 100 micrograms/metered inhalation (Qvar) & Qvar Autohaler 50 micrograms, 100 micrograms, /metered inhalation ONLY
|
| 03.02 |
Beclometasone diproponate + Formoterol + Glycopyrronium inhaler (pMDI) Trimbow® |
Approved for COPD when ICS + LAMA + LABA inhalation therapy is indicated, as per NICE guidance (JFC September 2019)
Provider notes
- NMUH:
- As per recommendations stated above
- RFL:
- As per NICE & NCL JFC recommendations
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Beclometasone diproponate + Formoterol inhaler (pMDI) Fostair® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- For continuation of therapy only
- UCLH:
- WH:
- Fostair should only be supplied when prescribed by, or on the recommendation of, the Respiratory Team. This is to ensure that it is prescribed appropriately.
|
| 05.01.09 |
Bedaquiline |
Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017) Provider notes - NMUH:
- RFL:
- Approved for XDR-TB and MDR-TB in line with NHSE policy
- Restricted to ID team only
- RNOH:
- UCLH:
- Pulmonary multidrug-resistant tuberculosis
- WH:
|
| 03.04.02 |
Bee and Wasp Allergen Extracts Pharmalgen® |
Provider notes - NMUH:
- Non-formulary.
- This medicine has a positive NICE Technology Appraisal, however, VENOM IMMUNOTHERAPY SERVICE IS NOT PROVIDED AT NMUH.
- RFL:
- RNOH:
 Restricted
- UCLH:
- WH:
|
| 10.01 |
Belimumab |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH - for intiation at specialist centres.
- See MHRA Drug Safety Update.
- RFL:
- Approved for use in the treatment of SLE in line with NICE guidance
- RNOH:
- UCLH:
- WH:
- As per NICE technology appraisal.
- See link below.
|
| 08.01.01 |
Bendamustine infusion |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- As per NICE TA216, TA629 and NHSE Commissioning Policies
- RFL:
- Approved for relapsed low-grade NHL and MM (3rd line) as per CDF criteria
- Approved for use as per NICE TA216
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- For relapsed multiple myeloma in line with Cancer Drugs Fund only
- WH:
|
| 02.02.01 |
Bendroflumethiazide |
Provider notes |
| 04.02.01 |
Benperidol |
Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team.
- RNOH:
- UCLH:
- WH:
|
| 03.04.02 |
Benralizumab injection |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- Non-formulary
- This medicine has a positive NICE Technology Appraisal, however, the service is not provided at NMUH.
- RFL:
- In line with NICE TA only, restricted to respiratory
- RNOH:
- UCLH:
- WH:
|
| 13.09 |
Benzalkonium chloride 0.5% shampoo Dermax® |
Provider notes
- NMUH:
- RFL:
- Restricted to dermatology
- RNOH:
- UCLH:
- WH:
|
| 05.01.01.01 |
Benzathine benzylpenicillin |
Provider notes
- NMUH:
- Used in the treatment of early syphilis and late latent syphilis
- Benzathine Benzylpenicillin 2.4 mega unit injection, available from ‘special-order’ manufacturers or specialist importing companies
- RFL:
- Microbiology/ID approval only
- RNOH approvals
- UCLH:
- WH:
|
| 10.04 |
Benzbromarone |
Provider notes
- NMUH:
- RFL:
- Rheumatology and Renal initiation only – hospital only prescribing
- RNOH:
- UCLH:
- WH:
|
| 13.10.02 |
Benzoic Acid Ointment, Compound BP Whitfield's ointment |
Provider notes |
| 13.06.01 |
Benzoyl peroxide - Topical PanOxyl® |
Provider notes - NMUH:
- Formulary options:
- NON-FORMULARY
- Aquagel 5%
- Cream 5%
- Gel 10%
- Panoxyl wash
- RFL:
- 2.5% and 5% gel available
- RNOH:
- UCLH:
- WH:
|
| 13.06.01 |
Benzoyl peroxide 5% + Clindamycin 1% gel Duac® Once Daily |
Provider notes - NMUH:
- RFL:
- Restricted to Dermatology
- RNOH:
- UCLH:
- WH:
- Duac gel is restricted to Dermatology
|
| 12.03.01 |
Benzydamine 0.15% spray or mouthwash |
Provider notes
- NMUH:
- RFL:
- Mouthwash and Spray available
- RNOH:
- UCLH:
- WH:
|
| 13.10.04 |
Benzyl Benzoate Application BP 25% |
Provider notes |
| 05.01.01.01 |
Benzylpenicillin |
Provider notes |
| 04.06 |
Betahistine Dihydrochloride |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 10.01.02.02 |
Betamethasone |
Provider notes |
| 13.04 |
Betamethasone dipropionate 0.05% - Topical Diprosone® |
Provider notes
- NMUH:
- Diprosone cream and Diprosone ointment are FORMULARY.
- Diprosone lotion is NON-FORMULARY.
- RFL:
- Diprosone cream and Diprosone ointment are FORMULARY
- Diprosone lotion is NON-FORMULARY
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Betamethasone dipropionate 0.05% + Salicylic acid 3% - Topical Diprosalic® |
Provider notes - NMUH:
- RFL:
- Ointment and Scalp Application available
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Betamethasone dipropionate 0.064% + Clotrimazole 1% - Topical Lotriderm® |
Provider notes - NMUH:
- Restricted to Dermatology department use ONLY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.04.01 |
Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Ophthalmology
|
| 12.01.01 |
Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 12.02.03 |
Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 12.01.01 |
Betamethasone sodium phosphate 0.1% drops |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 12.02.01 |
Betamethasone sodium phosphate 0.1% drops |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.04.01 |
Betamethasone sodium phosphate 0.1% drops/ointment |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 12.03.01 |
Betamethasone soluble tablets |
Approved for oral mucosal inflammatory disease (JFC March 2018) Provider notes |
| 06.03.02 |
Betamethasone systemic injection |
Provider notes |
| 06.03.02 |
Betamethasone tablets |
Provider notes |
| 13.04 |
Betamethasone valerate 0.025% - Topical |
Provider notes
- NMUH:
- RFL:
- cream and ointment available
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Betamethasone valerate 0.1% - Topical |
Provider notes
- NMUH:
- When Betnovate cream or ointment are requested/prescribed, the non-proprietary version, betamethasone valerate 0.1% cream or ointment will be supplied.
- When Betnovate scalp application is prescribed/requested, Betacap (betametasone valerate 0.1%) scalp application will be supplied.
- Bettamousse® is NON-FORMULARY
- RFL:
- Cream, Ointment, Scalp application and Foam available
- RNOH:
- No restriction stated
- Bettamousse® is not available
- UCLH:
- WH:
- No restriction stated
- Betacap® and Bettamousse® are not available
|
| 13.04 |
Betamethasone valerate 0.1% + Clioquinol 3% - Topical |
Provider notes
- NMUH:
- RFL:
- Cream and Ointment available
- RNOH:
- UCLH:
- WH:
- Restricted to Dermatology only
|
| 13.04 |
Betamethasone valerate 0.1% + Fucidic acid 2% - Topical |
Provider notes
- NMUH:
- Fucibet cream is FORMULARY
- Fucibet lipid cream is NON-FORMULARY
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Dermatology use ONLY
- Cream ONLY available
|
| 13.04 |
Betamethasone valerate 0.1% + Neomycin 0.5% - Topical |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Betaxolol 0.25% & 0.5% eye drops |
See NCL guideline for place in therapy.
Provider notes
- NMUH:
- See link below
- Check MHRA Drug Safety Update
- RFL:
- Approved for open-angle glaucoma and ocular hypertension (0.25% only)
- RNOH:
- UCLH:
- WH:
- No restriction stated (0.5% only)
|
| 11.06 |
Betaxolol 0.25% eye drops - preservative free |
See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open-angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Bevacizumab |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- Discuss with cancer pharmacy team before prescribing
- RNOH:
- UCLH:
- WH:
|
| 11.08.02 |
Bevacizumab intravitreal injection |
Approved for:
- Neovascular glaucoma (single-dose intravitreal) as an adjunct to panretinal photocoagulation (January 2017)
- Pre-operative adjunct to diabetic vitrectomy (MEH only; April 2017)
- Coats' disease and Familial exudative vitreoretinopathy (FEVR) (November 2015)
Provider notes
- NMUH:
- RFL:
- Approved for use in neovascular glaucoma as an adjunct to panretinal photocoagulation
- RNOH:
- UCLH:
- WH:
|
| 14.04 |
Bexsero® Meningococcal group B Vaccine |
Approved in line with Public Health England Men B immunisation programme (JFC August 2015)
Provider notes
- NMUH:
- RFL:
- Restricted to paediatrics, patients with asplenia or splenic dysfunction, complement deficiencies including complement inhibitor therapy and patients receiving eculizumab
- RNOH:
- UCLH:
- WH:
|
| 01.10 |
Bezafibrate |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for Primary Biliary Cholangitis as second-line therapy after ursodeoxycholic acid if intolerant to obeticholic acid. Notes: daily dose of 400 mg modified-release once-daily (JFC January 2019)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.12 |
Bezafibrate |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes - NMUH:
- Immediate and modified release
- No restriction stated
- RFL:
- Immediate and modified release
- Restricted to Lipid Clinic
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.02 |
Bicalutamide |
Provider notes - NMUH:
- Restricted to Consultant Oncologist and Urologist use only.
- RFL:
- RNOH:
- UCLH:
- WH:
- Bicalutamide 150mg is reserved for the treatment of locally advanced prostate cancer where it is important to maintain sexual potency.
|
| 11.06 |
Bimatoprost 0.01% eye drops |
See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open-angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Bimatoprost 0.03% + Timolol 0.5% eye drops Ganfort® |
Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open-angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Bimatoprost 0.03% + Timolol 0.5% eye drops - preservative free Ganfort® |
Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy.
Combination therapies to be used when compliance/cost issues arise. See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open-angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Bimatoprost 0.03% eye drops- single use |
See NCL guideline for place in therapy.
Provider notes
- NMUH:
- Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes
- See link below
- RFL:
- Approved for open angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Binimetinib tabs |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- Non-formulary
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 09.08.01 |
Biotin |
Provider notes
- NMUH:
- RFL:
- Restricted to paediatrics and neonates
- RNOH:
- UCLH:
- WH:
|
| 12.03.05 |
BioXtra® oral gel |
Provider notes |
| 06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
Provider notes |
| 06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix25, Humalog® Mix50 |
Approved for: - First choice biphasic analogue insulin in Type 2 diabetes. See NCL guideline for insulin in Type 2 diabetes guideline.
- Type 1 diabetes
Provider notes |
| 06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
Provider notes |
| 06.01.01.02 |
Biphasic Isophane Insulin Insuman® Comb 25, Insuman® Comb 50 |
First choice biphasic human insulin. See NCL guideline for insulin in Type 2 diabetes guideline.
Insuman® Comb 15 removed from the market (January 2020)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.06.02 |
Bisacodyl |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Please note: Suppositories 10 mg, Paediatric suppositories 5 mg only
|
| 01.03.03 |
Bismuth subsalicylate Pepto-Bismol® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for eradication of H.Pylori, after first-line treatment and previous exposure to levofloxacin (JFC April 2019).
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.04 |
Bisoprolol |
Provider notes |
| 02.08.01 |
Bivalirudin |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information
- RFL:
- RNOH:
- UCLH:
- WH:
- NICE TA230 applies. Not routinely stocked at WH.
|
| 08.01.02 |
Bleomycin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- As per local chemotherapy algorithms
- WH:
|
| 14.04 |
Boostrix-IPV |
Provider notes |
| 08.01.05 |
Bortezomib injection |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by the Haematology Team ONLY
- See links below
- RFL:
- As per NICE guidance/CDF criteria
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 02.05.01 |
Bosentan |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for digital ulceration in systemic sclerosis in line with NHSE Clinical Commissioning Policy A13/P/e (May 2015) Provider notes - NMUH:
- RFL:
- In line with NHSE clinical comissioning policy
- RNOH:
- UCLH:
- WH:
|
| 02.05.01 |
Bosentan |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Prior funding approval required
- Restricted to the treatment of pulmonary hypertension
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Bosutinib |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 01.07.04 |
Botulinum toxin type A Botox®, Dysport®, Xeomin® |
NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Botox brand only - restricted to Colorectal team
- RNOH:
- UCLH:
- WH:
|
| 01.10 |
Botulinum toxin Type A Botox®, Dysport®, Xeomin® |
NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications.
Approved for Sphincter of Oddi Dysfunction (JFC January 2013)
Provider notes
- NMUH:
- Xeomin is formulary when used in the treatment of achalasia (other brands and indications are non-formulary)
- RFL:
- Botox brand for Sphincter of Oddi Dysfunction, achalasia and gastroparesis
- RNOH:
- UCLH:
- WH:
- As above for Sphincter of Oddi Dysfunction
|
| 04.07.04.02 |
Botulinum Toxin Type A Botox® |
NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Positive NICE TA but service not offered at NMUH.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.09.03 |
Botulinum Toxin Type A Botox®, Dysport®, Xeomin® |
NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Dysport: Restricted to Spasticity clinic only
- Botox: Restricted to blepharospasm, facial palsy, hand spasticity patients with scleroderma (restricted to named Plastic Surgeon consultant)
- RNOH:
- UCLH:
- WH:
|
| 07.04.02 |
Botulinum toxin Type A Botox® |
NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications.
Approved for neurogenic bladder dysfunction for patients refractory to oral therapies (JFC January 2013)
Provider notes
- NMUH:
- Botox brand only
- Restricted to consultants Dr Yoong, Mr Nair and Mr Godbole for use in Overactive Bladder (OAB) only
- RFL:
- Restricted to urology only
- RNOH:
- Restricted to Consultant Urologists only for neurogenic detrusor overactivity
- UCLH:
- WH:
- See Botulinum Toxin Management Algorithm Diagram for direction of use
|
| 07.06 |
Botulinum toxin Type A Botox®, Dysport®, Xeomin® |
NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications.
Approved for urinary retention secondary to Fowlers Syndrome (JFC February 2020).
Provider notes
- NMUH:
- RFL:
- Restricted to urology only (Botox®)
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
Botulinum toxin Type A Botox® |
Provider notes
- NMUH:
- RFL:
- Approved for ophthalmology procedures
- RNOH:
- UCLH:
- WH:
|
| 13.12 |
Botulinum toxin type A |
NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Approved for use in dermatology for the treatment of hyperhidrosis
- Botox brand used
- RNOH:
- UCLH:
- WH:
|
| 04.09.03 |
Botulinum Toxin Type B NeuroBloc® |
Provider notes |
| 08.01.05 |
Brentuximab vedotin infusion |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- As per NICE TA478, TA524, TA641
- TA577 does not apply at NMUH as service is not offered
- RFL:
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL elecctronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
- As per NICE TA478, TA524, TA577.
|
| 08.01.05 |
Brigatinib tabs |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See link below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Brimonidine 0.2% + Timolol 0.5% eye drops Combigan® |
Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Brimonidine 0.2% eye drops |
See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open-angle glaucoma and ocular hypertension (3rd line; after travoprost and travoprost+timolol or brinzolamide)
- RNOH:
- UCLH:
- WH:
- Not to be used for first-line treatment - see link below
|
| 13.06.01 |
Brimonidine 3 mg/g gel |
Approved for moderate to severe rosacea causing psychological distress or reduced quality of life - initiation by secondary care Dermatologist and continuation in primary care (JFC September 2014)
Provider notes
- NMUH:
- Check MHRA Drug Safety Update
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Brinzolamide 0.1% eye drops |
See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open-angle glaucoma and ocular hypertension (2nd line; after travoprost)
- RNOH:
- UCLH:
- WH:
- Use in line with NCL guideline below
|
| 11.06 |
Brinzolamide 1% + Timolol 0.5% eye drops Azarga® |
Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open-angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
|
| 04.08.01 |
Brivaracetam |
Approved as an adjunct for refractory partial onset seizures epilepsy who have not responded to levetiracetam, and had to stop due to off-target effects before effectiveness could be established. All initiations require individual patient applications to be considered by JFC Support to ensure adherence to criteria (JFC October 2018). Restricted to epilepsy specialist services at UCLH/NHNN and RFL.
Provider notes
- NMUH:
- RFL:
- Individual patient approval via JFC Support, see above
- RNOH:
- UCLH:
- WH:
|
| 13.05.03 |
Brodalumab |
Provider notes
- NMUH:
- This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines - TO AWAIT UPDATED NCL JFC PATHWAY PRIOR TO PRESCRIBING
- See links below
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.09.01 |
Bromocriptine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 06.07.01 |
Bromocriptine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Restricted to Endocrinology and Gynaecology
- RNOH:
- UCLH:
- WH:
|
| 01.05.02 |
Budesonide Entocort® |
Provider notes
- NMUH:
- RFL:
- Capsules: Restricted to left-sided ulcerative colitis
- Enema: 2nd line when prednisolone enema not tolerated
- RNOH:
- UCLH:
- WH:
- Crohn's disease and microscopic colitis
- Only controlled-release capsules available
|
| 01.05.02 |
Budesonide Budenofalk® |
Budenofalk® 2mg/dose rectal foam approved for active ulcerative colitis limited to the rectum and sigmoid colon as second-line (prednisolone retention enema is the first-line choice) (JFC October 2018).
Provider notes
- NMUH:
- RFL:
- Tablets: Non-formulary
- Enema: See indication above
- RNOH:
- UCLH:
- WH:
- As above
- Enteric coated capsules also available
|
| 03.02 |
Budesonide + Formoterol inhaler (DPI) Symbicort® Turbohaler, DuoResp Spiromax® |
Not approved as the sole inhaler for asthma (SMART), may be used twice daily for asthma (JFC September 2015).
Provider notes
- NMUH:
- To be prescribed as per JFC Asthma / COPD guidelines
- See links below
- RFL:
- RNOH:
- UCLH:
- WH:
- To be prescribed as per JFC Asthma guideline
- See link below
|
| 12.02.01 |
Budesonide 64mcg/spray nasal spray |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Budesonide inhaler (DPI) Pulmicort® Turbohaler |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.10 |
Budesonide nebuliser suspension |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved as second-line choice (after fluticasone inhaler) for eosinophilic oesophagitis in both adults and children. Dose should be dispersed in viscous suspending agent (e.g. Splenda slurry). Starting dose is 1 mg twice-daily for adults and children > 10 years old, 1 mg once-daily for children < 10 years old; down titrate dose for maintenance dosing (JFC February 2018)
Provider notes
- NMUH:
- RFL:
- See local policy for information on use
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Budesonide nebuliser suspension |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Nebulised budesonide should only be prescribed on the advice of a Consultant Paediatrician or a Respiratory Consultant.
|
| 02.02.02 |
Bumetanide |
Provider notes |
| 15.02 |
Bupivacaine |
Approved for post-operative pain management following limb amputation for peripheral arterial disease to reduce post-operative opioid requirement (0.125% infusion via perineural stump catheter) (JFC September 2019).
Provider notes
- NMUH:
- RFL:
- Ampules: No restriction stated
- Heavy: Spinal anaesthesia only
- Surgical Wound Infiltration:
- RFH: Restricted to use in donor nephrectomy patients and in plastic surgery (DIEP flap breast reconstruction only)
- BFH: Not available
- RNOH:
- UCLH:
- WH:
- Inj 0.25% (25mg/10mL); 0.5% (50mg/10mL) only
|
| 15.02 |
Bupivacaine + Adrenaline |
Provider notes |
| 15.02 |
Bupivacaine + Fentanyl epidural |
Provider notes
- NMUH:
- A ready-mixed bag of Fentanyl + Bupivicaine is available from Pharmacy
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 15.02 |
Bupivacaine + Glucose Marcain Heavy® |
Provider notes |
| 04.07.02 |
Buprenorphine patch '35', '52.5','70' |
Provider notes - NMUH:
- RFL:
- Restricted to Pain team initiation
- RNOH:
- UCLH:
- WH:
|
| 04.07.02 |
Buprenorphine patch '5', '10', '15' and '20' |
Buprenorphine patch ‘5’ and ‘10’ patches approved for patients unable to take oral opioids due to swallowing difficulties / short bowel AND requiring a lower dose transdermal opioid dose than the 12 micrograms fentanyl patch (JFC March 2015).
Provider notes
- NMUH:
- See restriction above (5 and 10mcg/hr patches only)
- RFL:
- RNOH:
- See restriction above (5 and 10mcg/hr patches only)
- UCLH:
- WH:
- See restriction above (5 and 10mcg/hr patches only)
|
| 04.07.02 |
Buprenorphine sublingual tablets |
Provider notes |
| 04.10.03 |
Buprenorphine sublingual tablets |
Provider notes
- NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary - see link below
- For continuation ONLY
- RFL:
- In line with ‘Opioid dependence guideline’ on Freenet
- RNOH:
- UCLH:
- WH:
|
| 04.10.02 |
Bupropion |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- CIFT:
- Approved for major depression where NICE recommended options are ineffective or not tolerated (off-label)
- BEHMT approvals:
|
| 06.07.02 |
Buserelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.07.02 |
Buserelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.02 |
Buserelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 04.01.02 |
Buspirone |
Provider notes
- NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- CIFT:
- BEHMT:
|
| 08.01.01 |
Busulfan infusion |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- Approved for conditioning prior to haematopoietic progenitor cell transplantation
- WH:
|
| 08.01.01 |
Busulfan tablets |
Provider notes
- NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 03.04.03 |
C1 Esterase Inhibitor Cinryze® |
Approved for prophylaxis and treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC October 2018).
Provider notes
- NMUH:
- RFL:
- For hereditary angioedema in line with NHSE commissioning policy
- Restricted to immunology
- RNOH:
- UCLH:
- WH:
- For hereditary angioedema in line with NHSE comissioning policy
|
| 03.04.03 |
C1 Esterase Inhibitor Berinert® |
Provider notes
- NMUH:
- RFL:
- For hereditary angioedema in line with NHSE commissioning policy
- Restricted to immunology
- RNOH:
- UCLH:
- WH:
- For hereditary angioedema in line with NHSE comissioning policy
|
| 08.01.05 |
Cabazitaxel |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- As per NICE TA
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 04.09.01 |
Cabergoline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 06.07.01 |
Cabergoline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Restricted to Obs & Gynae Consultant use only
- RFL:
- Restricted to Endocrinology and Gynaecology / Obstetrics
- RNOH:
- UCLH:
- WH:
- Cabergoline is reserved for use by Dr Moult and for suppression of lactation
|
| 08.01.05 |
Cabozantinib caps Cometriq® |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- Non-formulary
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- As per NICE guidance for the treatment of medullary thyroid cancer
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Cabozantinib tabs Cabometyx® |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- As per NICE guidance for the treatment of renal cell carcinoma
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 21.01 |
Cacicol |
Non-healing corneal ulcers/ persistent epithelial defects.
Under evaluation at MEH only (restricted to corneal eye disease service only, April 2017) |
| 13.03 |
Calamine lotion |
Provider notes |
| 13.05.02 |
Calcipotriol 50mcg/g - Topical |
Provider notes
- NMUH:
- RFL:
- Ointment and Scalp solution available
- RNOH:
- UCLH:
- WH:
- Calcipotriol scalp application is restricted to Dermatology use only
|
| 13.05.02 |
Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical |
Provider notes
- NMUH:
- Restricted to consultant Dermatologists ONLY
- RFL:
- Ointment and Gel available
- Restricted to Dermatology ONLY
- RNOH:
- UCLH:
- WH:
- For patients who fail separate topical steroid + vitamin D2 (e.g. calcipotriol)
- Dovobet ointment restricted to Dermatology use ONLY
|
| 13.05.02 |
Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical foam Enstilar® |
Approved after failure of combined topical steroid + vitamin D2 (e.g. Dovobet ointment) (JFC May 2017)
Provider notes
- NMUH:
- For Trunk & Limb psoriasis in patients who fail combined topical steroid + vitamin D2 (e.g. Dovobet ointment)
- Restricted to dermatology use only
- RFL:
- RNOH:
- UCLH:
- WH:
- For patients who fail combined topical steroid + vitamin D2 (e.g. Dovobet ointment)
- Restricted to dermatology use only
|
| 06.06.01 |
Calcitonin (salmon) |
Provider notes - NMUH:
- See link below
- Check MHRA Drug Safety Updates
- RFL:
- RNOH:
- Restricted
- Store in a refrigerator
- Allow to reach room temperature before subcutaneous or intramuscular use.
- UCLH:
- WH:
|
| 13.05.02 |
Calcitriol 3mcg/g - Topical Silkis® |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Calcitriol ointment is restricted to Dermatology use only
|
| 09.05.01.02 |
Calcitriol injection |
Provider notes
- NMUH:
- RFL:
- Approved for percutaneous injection into the parathyroid gland for hyperparathyroidism if intolerant or unresponsive to oral therapy (November 2013)
- RNOH:
- UCLH:
- WH:
|
| 09.06.04 |
Calcitriol oral |
Provider notes |
| 09.05.02.02 |
Calcium acetate + Magnesium carbonate tabs Osvaren® |
Provider notes
- NMUH:
- RFL:
- Restricted to renal patients only
- RNOH:
- UCLH:
- WH:
|
| 09.05.02.02 |
Calcium acetate tabs Phosex® |
Provider notes
- NMUH:
- RFL:
- Restricted to renal patients only
- RNOH:
- UCLH:
- WH:
|
| 09.06.04 |
Calcium and Ergocalciferol |
Provider notes |
| 09.05.01.01 |
Calcium carbonate Cacit® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- For patients requiring effervescent calcium carbonate
- UCLH:
- WH:
|
| 09.05.01.01 |
Calcium carbonate Calcichew® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.05.01.01 |
Calcium Carbonate Adcal® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 09.05.02.02 |
Calcium carbonate Calcichew® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Calcichew is available on the Formulary for the management of hyperphosphotaemia in renal patients
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.05.02.02 |
Calcium carbonate Adcal® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.05.01.01 |
Calcium Chloride injection |
Provider notes |
| 08.01 |
Calcium Folinate |
Provider notes |
| 09.05.01.01 |
Calcium Gluconate 10% injection |
Provider notes |
| 09.05.01.01 |
Calcium Gluconate effervescent tablets |
Provider notes
- NMUH:
- RFL:
- BCF: No restriction (historical)
- RFH: Non-formulary
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
Calmurid® cream Urea 10% |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| A2.04.01.02 |
Calogen |
Not approved for routine treatment of malnutrition however may be prescribed for specific cohorts; see Position Statement for detail (JFC August 2020).
Provider notes
- NMUH:
- Not for discharge. See JFC Position Statement
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.01.02.03 |
Canagliflozin |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- Only on the recommendation of the Diabetes Team.
- Check MHRA Drug Safety Alerts
- RFL:
- Restricted to Endocrinology
- See links below
- RNOH:
- Requires initiation by a Diabetes Specialist
- Check MHRA Drug Safety Updates
- UCLH:
- WH:
- No restriction stated
- Check MHRA Drug Safety Updates
|
| 16.01 |
Canakinumab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- National Amyloidosis Clinic use only
- Approved for
- Cryopyrin-Associated Periodic Syndrome (CAPS)
- Periodic fever syndromes: TRAPS HIDS/MKD and FMF, in line with NHSE Commissioning Policy 200209P
- RNOH:
- UCLH:
- WH:
|
| 02.05.05.02 |
Candesartan |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- 1st choice A2RA/ARB for heart failure
|
| 04.07.04.01 |
Candesartan |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for prophylaxis of chronic and episodic migraine (JFC April 2019)
Provider notes
- NMUH:
- RFL:
- Approved for prophylaxis of chronic and episodic migraine
- RNOH:
- UCLH:
- WH:
|
| 02.09 |
Cangrelor |
Provider notes
- NMUH:
- RFL:
- Primary percutaneous coronary intervention (PPCI) who are intubated and cannot tolerate oral antiplatelets (JFC October 2017)
- RNOH:
- UCLH:
- WH:
|
| 21.02 |
Cannabidiol oral solution (free of charge) Epidiolex® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- Approved for the reduction of seizures in Dravet Syndrome and Lennox-Gastaut syndrome in patients aged two years or more (UCLH and GOSH only; JFC January 2019).
- WH:
|
| 08.01.03 |
Capecitabine |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Check MHRA Drug Safety Update
- RFL:
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- See NICE TA and NHSE Commissioning Policy
- RNOH:
- UCLH:
- WH:
|
| 05.01.09 |
Capreomycin |
Provider notes
- NMUH:
- RFL:
- Microbiology/ ID approval only (TB treatment)
- RNOH:
- UCLH:
- WH:
- Restricted to TB clinic or as per Microbiology advice
|
| 10.03.02 |
Capsaicin cream |
Provider notes
- NMUH:
- 0.025% NON FORMULARY
- 0.075% restricted to pain clinic use ONLY
- RFL:
- 0.075% strength kept for neuropathic pain
- 0.025% is non-formulary
- RNOH:
- 0.025% restricted for use in accordance with the NICE guideline for osteoarthritis
- See link(s) below
- 0.075% NON FORMULARY
- UCLH:
- WH:
- 0.025% restricted to the Rheumatology team. This strength of capsaicin cream is indicated for osteoarthritis only.
- 0.075% restricted to pain clinic ONLY
|
| 10.03.02 |
Capsaicin patch |
JFC approved for neuropathic pain (January 2013)
Provider notes
- NMUH:
- RFL:
- RNOH:
- Restricted to named Consultants within the Chronic Pain team (Dr Roxy Zarnegar and Dr Tacson Fernandez) ONLY in accordance with DTC approval
- UCLH:
- WH:
|
| 02.05.05.01 |
Captopril |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- The use of Captopril is reserved for situations where a short- acting preparation is necessary.
|
| 04.02.03 |
Carbamazepine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
|
| 04.07.03 |
Carbamazepine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- See Trust guideline on intranet for more information
- RFL:
- RNOH:
- Oral liquid available as 100 mg/5mL
- UCLH:
- WH:
|
| 04.08.01 |
Carbamazepine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Prescribe by brand when used for epilepsy. Immediate release and modified release. Provider notes - NMUH:
- RFL:
- RNOH:
- Oral liquid available as 100 mg/5mL
- UCLH:
- WH:
|
| 07.01.01 |
Carbetocin |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Prevention of postpartum haemorrhage due to uterine atony following C-section
|
| 06.02.02 |
Carbimazole |
Provider notes |
| 03.07 |
Carbocisteine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Restricted. Capsules available. Oral syrup available as 250 mg/5mL
- UCLH:
- WH:
- Carbocisteine to be initiated by respiratory team only
- Liquid only available for patients with swallowing difficulties or for enteral feeding tube administration
|
| 11.08.01 |
Carbomer 0.2% eye gel Viscotears®, GelTears® and others |
Provider notes
- NMUH:
- RFL:
- Approved for dry eyes, unstable tear film
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Carboplatin |
Provider notes - NMUH:
- RFL:
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Carboplatin + paclitaxel |
Approved as first-line treatment for advanced squamous cell carcinoma of anus (JFC March 2019).
Note: Carboplatin AUC5 day 1 of 28 day cycles + paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of 28 day cycles. 6 cycles (each cycle 28 days)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Carboplatin + paclitaxel (CROSS) |
Approved as neo-adjuvant treatment before surgery for adenocarcinoma of the oesophagus or the gastro-oesophageal junction (JFC November 2017) Provider notes |
| 07.01.01 |
Carboprost |
Provider notes
- NMUH:
- Restricted to Obs and Gynae only
- RFL:
- Restricted to Obs and Gynae only
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Carfilzomib |
See NICE TA for eligibility criteria Provider notes - NMUH:
- RFL:
- As per NICE TA
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 11.08.01 |
Carmellose + Glycerine eye drops Optive® |
Provider notes
- NMUH:
- RFL:
- Approved for dry eye conditions for artificial eyes
- RNOH:
- UCLH:
- WH:
|
| 12.03.01 |
Carmellose and gelatin oramucosal paste Orabase® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.08.01 |
Carmellose eye drops - single use |
Provider notes
- NMUH:
- Restricted to opthalmology, use as per JFC guidance
- RFL:
- Approved for dry eye conditions (1%)
- RNOH:
- UCLH:
- WH:
- Restricted to Ophthalmology
|
| 01.10 |
Carvedilol |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for primary and secondary prevention of variceal bleeding for patients who do not respond to or cannot tolerate propranolol (August 2015) Provider notes |
| 02.04 |
Carvedilol |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 05.02.04 |
Caspofungin |
Provider notes
- NMUH:
- Microbiology consultant approval only
- RFL:
- See Microguide for agreed indications
- Restricted to Haematology / Oncology as per policy
- Microbiology approval required for all other indications.
- RNOH:
- Microbiology approval only
- Store in a fridge
- UCLH:
- WH:
- Reserved for prescribing by paediatric consultants only
|
| A5.02.05 |
Cavi-Care |
Provider notes |
| 05.01.02.01 |
Cefalexin |
Provider notes
- NMUH:
- RFL:
- See Microguide for approved indications
- Microbiology/ID approval required for all other indications
- RNOH:
- Oral suspension available as 250 mg/5mL
- UCLH:
- WH:
|
| 05.01.02.01 |
Cefazolin solution for inj |
Provider notes
- NMUH:
- RFL:
- Approved for:
- Gram positive infections in haemodialysis patients (RFL only; JFC November 2019).
- Second or third line for gram positive infections in non-dialysis patients where other antimicrobials are not suitable are penicillin-allergic (RFL only; JFC November 2019).
- Surgical prophylaxis in primary implant orthopaedic surgery (RFL only; JFC November 2019).
- Microbiology/ID approval required for all other indications.
- RNOH:
- UCLH:
- WH:
|
| 05.01.02.01 |
Cefixime |
Provider notes
- NMUH:
- Restricted to Consultants in GU Medicine.
- RFL:
- Restricted to GUM
- Microbiology/ID approval required for all other indications
- RNOH:
- UCLH:
- WH:
|
| 05.01.02.01 |
Cefotaxime |
Provider notes
- NMUH:
- Restricted to Microbiology approval only
- RFL:
- See Microguide for approved indications. Approved for Neonatal unit
- Microbiology/ID approval required for all other indications
- RNOH:
- UCLH:
- WH:
- Restricted to Paediatrics and Neonatal use only
|
| 05.01.02.01 |
Ceftazidime |
Provider notes
- NMUH:
- Restricted to Microbiology approval only
- RFL:
- Microbiology/ID approval only
- RNOH:
- UCLH:
- WH:
- For restricted indications as per Trust guidelines or Microbiology advice
|
| 05.01.02.01 |
Ceftazidime + Avibactam |
Approved for the treatment of infections caused by non-MBL carbapenemase-producing aerobic Gram-negative organisms, that have proven susceptibly to ceftazidime-avibactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin, which cannot be used due to resistance or intolerance - Microbiology recommendation only (JFC August 2017)
Provider notes
- NMUH:
- Microbiology approval only
- RFL:
- Consultant Microbiology/ID approval only
- RNOH:
- UCLH:
- WH:
- Restricted antibiotics. Microbiology approval only
|
| 11.03.01 |
Ceftazidime 5% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for Bacterial keratitis/ulcers (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
- Restricted to ophthalmology
|
| 05.01.02.01 |
Ceftolozane + tazobactam |
Approved for multi-resistant Gram-negative organisms that have proven susceptibly to ceftolozane-tazobactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin (JFC September 2016)
Provider notes
- NMUH:
- Microbiology recommendation ONLY
- RFL:
- Consultant Microbiology/ID approval only
- RNOH:
- Consultant Microbiology Approval only
- UCLH:
- WH:
- Restricted antibiotics. Microbiology approval only
|
| 05.01.02.01 |
Ceftriaxone |
Provider notes
- NMUH:
- Restricted to use in paediatrics for sepsis and meningitis
- RFL:
- See Microguide for agreed indications
- Microbiology/ID approval required for all other indications
- RNOH:
- UCLH:
- WH:
- For restricted indications as per Trust guidelines or Microbiology advice
|
| 05.01.02.01 |
Cefuroxime |
Provider notes
- NMUH:
- Restricted to Microbiology approval only
- Injection is formulary
- Tablets are non-formulary
- RFL:
- See Microguide for approved indications
- Microbiology/ID approval required for all other indications
- RNOH:
- UCLH:
- WH:
|
| 11.03.01 |
Cefuroxime 5% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for Bacterial keratitis/ulcers (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
- Restricted to ophthalmology
|
| 11.03.01 |
Cefuroxime intracameral injection Aprokam® |
Approved for prophylaxis post-cataract surgery (June 2013)
Provider notes
- NMUH:
- RFL:
- Approved for prophylaxis in ocular surgery (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
| 10.01.01 |
Celecoxib |
Provider notes - NMUH:
- RFL:
- For Rheumatology use only
- RNOH:
- UCLH:
- WH:
|
| 02.14 |
Celiprolol |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for vascular Ehlers-Danlos syndrome (JFC April 2016) Provider notes |
| 08.01.05 |
Cemiplimab infusion |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- RFL:
- As per TA592
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Ceritinib |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See link below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Certolizumab pegol |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for:
- Rheumatoid arthritis in line with the NCL RA pathway
- Ankylosing Spondylitis (see NICE TAs)
- Psoriatic arthritis (PsA; see NICE TAs)
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines (see links below).
- Restricted to Consultant Rheumatologists
- See MHRA Drug Safety Update.
- See links below.
- RFL:
- Approved for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis in line with NICE guidance.
- RNOH:
- Restricted for Rheumatology Consultants ONLY.
- See links below.
- UCLH:
- WH:
|
| 13.05.03 |
Certolizumab pegol |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 03.04.01 |
Cetirizine |
Provider notes - NMUH:
- RFL:
- No restriction stated
- High doses may be used in dermatology
- RNOH:
- UCLH:
- WH:
|
| 13.02.01.01 |
Cetraben® bath additive |
- NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
- Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Dermatology use ONLY
|
| 13.02.01 |
Cetraben® cream |
Cetraben cream, Enopen cream, ExCetra cream, Exmaben cream and Soffen cream all contain Liquid paraffin light 105 mg/g + White soft paraffin 132 mg/g.
Provider notes
- NMUH:
- Restricted for prescribing in Paediatrics and by Dermatologists
- Preferred preparation is Enopen Cream
- RFL:
- RNOH:
- Use ExCetra as per Hertfordshire Emollients Guideline
- UCLH:
- WH:
|
| 13.09 |
Cetrimide 10% + Undecenoic acid 1% shampoo Ceanel Concentrate® |
Provider notes
- NMUH:
- RFL:
- Restricted to dermatology
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Cetuximab |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Check MHRA Drug Safety Updates
- See links below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 04.01.01 |
Chloral Hydrate |
Provider notes
- NMUH:
- Chloral Mixture, BP 2000, 500mg/5mL (Unlicensed)
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Paediatrics only
- Chloral hydrate suppositories 25mg & 100mg available
- CIFT:
- BEHMT:
|
| 08.01.01 |
Chlorambucil |
Provider notes
- NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 05.01.07 |
Chloramphenicol |
Provider notes - NMUH:
- Chloramphenicol capsules are non-formulary
- To be used as per the Trust guidelines for Management of Acute Bacterial Meningitis
- RFL:
- As per agreed indications on microguide
- RNOH:
- UCLH:
- WH:
- Microbiology approval only
|
| 11.03.01 |
Chloramphenicol 0.5% eye drops - Single use drops |
Provider notes |
| 11.03.01 |
Chloramphenicol 0.5% eye drops, 1% eye ointment |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Eye drops 0.5% preservative free 10mL (Moorfields special) also available
|
| 12.01.01 |
Chloramphenicol 5% ear drops |
Provider notes |
| 04.01.02 |
Chlordiazepoxide |
Provider notes
- NMUH:
- RFL:
- Restricted to in-patient use for alcohol detoxification and anxiety.
- RNOH:
- UCLH:
- WH:
- CIFT:
- Approved for
- Anxiolytic
- Alcohol withdrawal
- Acute phase of mania (off-label)
- BEHMT:
- Approved for
- Anxiolytic
- Alcohol withdrawal
|
| 13.11.02 |
Chlorhexidine + Alcohol wipes Clinell Alcoholic 2% Chlorhexidine Wipes® |
Provider notes - NMUH:
- This product is available as individual sachets of 105x105mm in size and comes in boxes of 200.
- Uses:
- Skin antisepsis prior to insertion of peripheral cannulae, or taking blood cultures.
- Skin antisepsis prior to taking blood cultures.
- Line care: Disinfection of catheter hubs/ports of all IV lines prior to access.
- Post insertion line care (ChloraPrep to be used for skin antisepsis prior to insertion of central line cannulae)
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.11.02 |
Chlorhexidine 0.015% + Cetrimide 0.15% skin cleaner Tisept® |
Provider notes |
| 11.03.01 |
Chlorhexidine 0.02% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for
- Acanthamoeba keratitis (Ophthalmologist use only)
- Antiseptic in povidone-iodine allergy (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
| 12.02.03 |
Chlorhexidine 0.1% + Neomycin 0.5% cream Naseptin® |
Provider notes
- NMUH:
- RFL:
- MRSA decolonisation procedure - see Microguide
- RNOH:
- UCLH:
- WH:
|
| 11.03.02 |
Chlorhexidine 0.2% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for fungal keratitis (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
| 12.03.04 |
Chlorhexidine 0.2% mouthwash |
Provider notes |
| 12.03.04 |
Chlorhexidine 0.2% oral spray |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to community clinic only
|
| 12.03.04 |
Chlorhexidine 1% dental gel |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.04.04 |
Chlorhexidine acetate 0.02% catheter maintenance solution |
Provider notes |
| 13.11.02 |
Chlorhexidine skin cleaners |
Provider notes - NMUH:
- The following products are available:
- ChloraPrep®, Hibiscrub® (see link below for MRSA eradication protocol), Hibitane Obstetric® (restricted to obstetrics), Hydrex®, Unisept®
- RFL:
- The following products are avaialble:
- ChloraPrep®, Hibiscrub®, Hibitane Obstetric®, Hydrex®, Unisept®
- RNOH:
- UCLH:
- WH:
- Available products:
- Chlorhexidine 0.05%CX Antiseptic Dusting Powder®, Hibiscrub®, Hibitane Obstetric®, Hydrex®
|
| 12.01.03 |
Chlorobutanol 5% + Arachis (peanut) oil ear drops Cerumol® |
Provider notes |
| 15.02 |
Chloroprocaine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- For day surgery spinal anaesthesia in adults where the planned surgical procedure is suitable for spinal anaesthesia and is of short duration not exceeding 40 minutes.
|
| 05.04.01 |
Chloroquine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- To be used as per the NMUHT Malaria Guidelines, access via Trust intranet
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Chloroquine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 02.14 |
Chlorothiazide |
Provider notes - NMUH:
- For the treatment of chronic hypoglycaemia, heart failure, hypertension and ascites, in children.
- See the BNF for children for further prescribing information.
- Chlorothiazide suspension 250mg/5ml, available from ‘special-order’ manufacturers or specialist importing companies
- RFL:
- RNOH:
- UCLH:
- WH:
- Chlorothiazide Suspension 250 mg/5 ml (unlicensed product)
|
| 03.04.01 |
Chlorphenamine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Tablets and injection available, Oral syrup available as 2 mg/5mL
- UCLH:
- WH:
|
| 04.02.01 |
Chlorpromazine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team.
- Suppositories are not stocked
- RNOH:
- UCLH:
- WH:
- Tabs 25 mg, 50 mg, 100 mg. Syrup 25 mg/5ml, 100 mg/5 ml. Injection 50 mg/2ml. Only
|
| 04.06 |
Chlorpromazine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Tablets, oral solution and injection: No restriction stated
- Suppository: Non-formulary
- RNOH:
- Oral solution available as 25 mg/5mL
- UCLH:
- WH:
|
| 12.03.01 |
Choline Salicylate 8.7% oral gel Bonjela® Adult, Teejel® |
Provider notes - NMUH:
- RFL:
- RNOH:
- For patients 16 years and above
- UCLH:
- WH:
|
| 06.05.01 |
Chorionic Gonadotrophin Choragon®, Pregnyl® |
Provider notes
- NMUH:
- RFL:
- Restricted to Endocrinology
- Emergency use of Gonasi® (unlicensed) whilst Pregnyl® and Choragon® are unavailable, but new starters must be referred to tertiary care centres
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Ciclesonide inhaler (pMDI) Alvesco® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.05.03 |
Ciclosporin |
NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Ciclosporin is restricted to Consultant Gastroenterologists only
- FBC, LFT & drug level monitoring required
- RNOH:
- UCLH:
- WH:
- Ciclosporin is restricted to Consultant Gastroenterologists only
- FBC, LFT & drug level monitoring required
|
| 08.02.02 |
Ciclosporin Deximune® |
(hospital only prescribing) for renal transplant
for other transplants
NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Liver transplant: Preferred brand for new patients
- Renal transplant: Not for new patients
- Transplant patients must be maintained on the same brand
- RNOH:
- UCLH:
- WH:
|
| 08.02.02 |
Ciclosporin Capsorin® |
(hospital only prescribing) for renal transplant
for other transplants
NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.02.02 |
Ciclosporin Capimune® |
(hospital only prescribing) for renal transplant
for other transplants
NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.02.02 |
Ciclosporin Sandimmun® |
(hospital only prescribing) for renal transplant
for other transplants
NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Liver transplant: Not for new patients
- Renal transplant: Not for new patients
- Transplant patients must be maintained on the same brand
- RNOH:
- UCLH:
- WH:
|
| 08.02.02 |
Ciclosporin Neoral® |
(hospital only prescribing) for renal transplant
for other transplants
NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Restricted to Consultant use only.
- RFL:
- Liver transplant: Not for new patients unless liquid formulation required
- Renal transplant: Preferred brand for renal transplant
- Transplant patients must be maintained on the same brand
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Ciclosporin |
NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Deximune® is the preferred brand
- RNOH:
- Restricted to Rheumatology Consultants ONLY
- See links below
- UCLH:
- WH:
|
| 13.05.03 |
Ciclosporin |
NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications.
Approved for:
- chronic refractory idiopathic urticaria (JFC - January 2015)
- severe atopic dermatitis (DMARD fact sheet)
- severe psoriasis (DMARD fact sheet)
Provider notes
- NMUH:
- RFL:
- Preferred brand is Deximune
- No restriction stated
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
Ciclosporin 0.06% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for severe allergic eyes disease, severe dry eyes, corneal erosions
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
Ciclosporin 0.1% eye drops Ikervis® |
Approved for ocular inflammatory conditions. See NCL fact sheet. Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed Consultant Ophthamologist ONLY
- See links below
- RFL:
- RNOH:
- UCLH:
- For initiation by corneal specialists only
- WH:
- Restricted to ophthalmology
|
| 11.99.99.99 |
Ciclosporin 0.2% eye ointment |
Approved for ocular inflammatory conditions. See NCL fact sheet.
Provider notes
- NMUH:
- RFL:
- Approved for severe allergic eyes disease, severe dry eyes, corneal erosions
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
Ciclosporin 2% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for severe allergic eyes disease, severe dry eyes, corneal erosions
- RNOH:
- UCLH:
- WH:
|
| 13.07 |
Cidofovir in Unguentum M |
Provider notes
- NMUH:
- RFL:
- Restricted to Dermatology and HIV team only for treatment-resistant herpes
- Prior funding approval required before dispensing.
- RNOH:
- UCLH:
- WH:
|
| 05.03.02.02 |
Cidofovir infusion |
Provider notes
- NMUH:
- RFL:
- HIV/Virology approval required
- RNOH:
- UCLH:
- WH:
|
| 01.03.01 |
Cimetidine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Alternative to ranitidine. Tabs 200 mg, 400 mg.
|
| 09.05.01.02 |
Cinacalcet |
Approved for complex primary hyperparathyroidism in adults in line with NHSE clinical commissioning policy (JFC April 2018)
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
- Formulary for treatment of Hypercalcaemia of primary hyperparathyroidism or parathyroid carcinoma - see link below
- RFL:
- Restricted to ‘cinacalcet gatekeeper’ approval only for secondary hyperparathyroidism – see NICE TA.
- Restricted to endocrinology for complex primary hyperparathyroidism – see NHSE commissioning policy
- RNOH:
- WH:
- For primary hyperparathyroidism in line with NHSE policy 16034/P
- For secondary hyperparathyroidism in line with NICE TA 117
|
| 04.06 |
Cinnarizine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.12 |
Ciprofibrate |
Provider notes - NMUH:
- RFL:
- Restricted to Lipid Clinic
- RNOH:
- UCLH:
- WH:
|
| 05.01.12 |
Ciprofloxacin |
Provider notes - NMUH:
- RFL:
- See microguide for agreed indications
- Microbiology approval required for all other indications
- RNOH:
- Oral suspension available as 250 mg/5mL
- UCLH:
- WH:
- For restricted indications as per Trust guidelines or Microbiology advice
|
| 11.03.01 |
Ciprofloxacin 0.3% eye drops/ointment |
Provider notes - NMUH:
- Restricted to Ophthalmology department use ONLY.
- RFL:
- Restricted to Opthalmology
- RNOH:
- UCLH:
- WH:
|
| 15.01.05 |
Cisatracurium |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- The use of cisatracurium is restricted to theatres only.
|
| 08.01.05 |
Cisplatin |
Provider notes - NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 04.03.03 |
Citalopram |
Provider notes
- NMUH:
- Check MHRA Drug Safety Updates
- RFL:
- RNOH:
- Tablets available. Oral drops available as 40 mg/mL
- UCLH:
- WH:
- CIFT:
- Approved for
- Depression
- Generalized Anxiety Disorder (GAD) and panic disorder - 1st/2nd line
- Social Anxiety Disorder (SAD) - 1st/2nd line
- BEHMT:
- Approved for
- Depression
- Panic disorder
|
| 08.01.03 |
Cladribine injection |
Provider notes - NMUH:
- To be prescribed by the Haematology Team ONLY.
- Refer to BCSH Guidelines on Hairy Cell Leukaemia
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 08.02.04 |
Cladribine tablets Mavenclad® |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.01.05 |
Clarithromycin |
Provider notes - NMUH:
- RFL:
- RNOH:
- Microbiologist approval only
- Oral suspension available as 250 mg/5mL
- UCLH:
- WH:
|
| 05.01.06 |
Clindamycin |
Provider notes
- NMUH:
- RFL:
- As per RFL policy on microguide
- Microbiology approval required for all other indications
- Used for prophylaxis and treatment of Mycobacterium avium intracellulare in HIV
- RNOH:
- UCLH:
- WH:
- Microbiology approval only
|
| 13.06.01 |
Clindamycin 1% topical solution Dalacin T® |
Provider notes - NMUH:
- RFL:
- Restricted to Dermatology only
- RNOH:
- UCLH:
- WH:
|
| 07.02.02 |
Clindamycin 2% vaginal cream Dalacin® |
Provider notes |
| 04.08.01 |
Clobazam |
Provider notes - NMUH:
- Clobazam oral suspension is non-formulary
- RFL:
- Blacklist restriction except in epilepsy
- RNOH:
- UCLH:
- WH:
- Should only be commenced on the recommendation of a Neurologist
|
| 13.04 |
Clobetasol propionate 0.05% - Topical |
Provider notes
- NMUH:
- RFL:
- Cream, Ointment and Scalp application (lotion) available
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Clobetasol propionate 0.05% + Neomycin + Nystatin - Topical |
Provider notes
- NMUH:
- RFL:
- Cream and ointment available
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Clobetasol propionate 0.05% shampoo Etrivex® |
Provider notes - NMUH:
- For use SECOND LINE in topical treatment of MODERATE SCALP PSORIASIS in adults who have failed treatment with Dermovate 0.05% Scalp Application.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.14 |
Clobetasol propionate 1 in 4 in White Soft Paraffin |
Provider notes
- NMUH:
- RFL:
- Restricted to dermatology, as per Special BAD list
- RNOH:
- UCLH:
- WH:
- Clobetasol propionate 1 in 4 in White Soft Paraffin 100 g (unlicensed product)
|
| 13.04 |
Clobetasone butyrate 0.05% - Topical Eumovate® |
Provider notes |
| 13.04 |
Clobetasone butyrate 0.05% + Oxytetracyline 3% + Nystatin - Topical Trimovate® |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- Approved for Pruritus ani; Dermatitis - seborrhoeic - infected; Nappy rash; Infected intertrigo; Eczema - infected
- WH:
|
| 05.01.10 |
Clofazimine |
Provider notes - NMUH:
- RFL:
- Microbiology/ID approval only
- RNOH:
- UCLH:
- WH:
- Microbiology approval only
|
| 04.01.01 |
Clomethiazole |
Provider notes
- NMUH:
- RFL:
- No restriction stated (capsules only)
- RNOH:
- UCLH:
- WH:
- CIFT:
- BEHMT:
|
| 06.05.01 |
Clomifene |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
(hospital only prescribing) if used for IVF
for other indications
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.03.01 |
Clomipramine Antidepressant |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- CIFT:
- BEHMT:
|
| 04.02.03 |
Clonazepam |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- CIFT:
- Approved for
- Anxiety (off-label)
- Acute phase of mania (off-label)
- BEHMT:
- Approved for
- Anxiety (off-label)
- Mania (off-label)
|
| 04.07.03 |
Clonazepam |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.08.01 |
Clonazepam |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Suspension 2 mg/5ml. Suspension should not be administered via PEG tubes as it is incompatible with the polystyrene fittings
|
| 02.05.02 |
Clonidine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Only 25 microgram tablets and the injection kept at the RFH
- RNOH:
- UCLH:
- WH:
|
| 04.07.04.02 |
Clonidine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 04.14 |
Clonidine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.09 |
Clopidogrel |
See NICE TA for eligibility Provider notes - NMUH:
- To be prescribed as per NICE guidelines - see links below for further details
- RFL:
- To be prescribed in line with NICE
- See NCL summary for information on preferred choices for specific indications
- RNOH:
- UCLH:
- WH:
|
| 07.02.02 |
Clotrimazole |
Provider notes - NMUH:
- RFL:
- Only 1% cream, 200mg Pessaries and 500mg Pessaries stocked
- RNOH:
- UCLH:
- WH:
- Pessaries available as 200 mg & 500 mg
|
| 13.10.02 |
Clotrimazole 1% - Topical |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Cream 1% 20g, Solution 1% 20mL and Dusting Powder 1% 30g ONLY
|
| 12.01.01 |
Clotrimazole 1% ear drops |
Provider notes |
| 11.03.02 |
Clotrimazole 1% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for fungal infections
- RNOH:
- UCLH:
- WH:
|
| 04.02.01 |
Clozapine Clozaril® |
Provider notes - NMUH:
- Restricted to Consultant Psychiatrist use only
- Monitoring required
- See links below
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- If a patient is admitted on this therapy please ensure that the pharmacy mental health team are aware.
- Patients being treated in the UK will be registered with CPMS (Clozaril Patient Monitoring Service)
- See links below
- RNOH:
- UCLH:
- WH:
- Restricted for initiation by a Consultant Psychiatrist only
|
| 21.01 |
Co‐careldopa |
Rotigotine or co‐careldopa for Hemispatial neglect that is interfering with progress of neurorehabilitation - UCLH only
Approval was subject to Dr Swayne working with Dr Sofat and JFC support to agree the datacollection form and the duration of the pilot study. Duration of audit TBC (November 2016). |
| 13.09 |
Coal tar 1% + Coconut oil 1% + Salicylic acid 0.5% shampoo Capasal® |
Provider notes - NMUH:
- RFL:
- Restricted to dermatology patients only
- RNOH:
- UCLH:
- WH:
|
| 13.05.02 |
Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Sebco® |
Provider notes |
| 13.05.02 |
Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Cocois® |
Provider notes |
| 13.05.02 |
Coal tar and salicylic acid ointment, BP |
Provider notes - NMUH:
- RFL:
- There are non-proprietary preparations available at the Royal Free Hospital but not listed in the eBNF, contact Pharmacy for details.
- RNOH:
- UCLH:
- WH:
|
| 13.09 |
Coal tar extract 5% alcoholic shampoo Alphosyl 2 in 1® |
Provider notes
- NMUH:
- RFL:
- Restricted to Dermatology only
- RNOH:
- UCLH:
- WH:
|
| 13.14 |
Coal tar in Betamethasone ointment |
Provider notes
- NMUH:
- To be prescribed by Consultant Dermatologists for the treatment of Psoriasis.
- Coal Tar 10% in Betamethasone 0.025%; Ointment Coal Tar 5% in Betamethasone 0.025% Ointment
- The above preparations are available from ‘special-order’ manufacturers or specialist importing companies
- RFL:
- Restricted to dermatology. As per specials list.
- 5% coal tar in 0.25% betamethasone ointment
- 10% coal tar in 0.25% betamethasone ointment
- RNOH:
- UCLH:
- WH:
|
| 13.05.02 |
Coal tar lotion 5% Exorex® |
Provider notes
- NMUH:
- RFL:
- Restricted to dermatology
- Lotion (cutaneous emulsion) and Shampoo available
- RNOH:
- UCLH:
- WH:
|
| 02.02.04 |
Co-amilofruse |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.02.04 |
Co-amilozide |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.01.01.03 |
Co-Amoxiclav |
Provider notes - NMUH:
- RFL:
- RNOH:
- Oral suspension available as 125/31.25 mg/5mL and 250/62.5 mg/5mL
- UCLH:
- WH:
|
| 04.09.01 |
Co-Beneldopa immediate release |
Provider notes - NMUH:
- Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.09.01 |
Co-Beneldopa modified release |
Provider notes - NMUH:
- Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.07 |
Cocaine 10% eye drops |
Provider notes
- NMUH:
- RFL:
- Ophthalmology surgery only
- RNOH:
- UCLH:
- WH:
|
| 11.07 |
Cocaine 4% eye drops |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- This is an unlicensed special and restricted to Ophthalmology
- This is a controlled drug
|
| 15.02 |
Cocaine oromucosal solution |
Provider notes
- NMUH:
- RFL:
- 5% and 10% mouthwash available
- RNOH:
- Restricted - 10% available
- UCLH:
- WH:
|
| 04.09.01 |
Co-Careldopa + Entacapone |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.09.01 |
Co-Careldopa immediate release |
Provider notes - NMUH:
- Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.09.01 |
Co-Careldopa intestinal gel Duodopa® |
Approved for Parkinson's disease in line with NHSE clinical commissioning policy D04/P/e (JFC November 2019).
Provider notes
- NMUH:
- RFL:
- Restricted to neurology only; prior funding approval required
- RNOH:
- UCLH:
- WH:
|
| 04.09.01 |
Co-Careldopa modified release |
Provider notes - NMUH:
- Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.07.01 |
Co-codamol 30/500 Paracetamol + Codeine |
Provider notes |
| 04.07.01 |
Co-codamol 8/500 Paracetamol + Codeine |
Provider notes |
| 13.06.02 |
Co-Cyprindiol 2000/35 (cyproterone 2mg / ethinylestradiol 35micrograms) Dianette® |
Provider notes - NMUH:
- Check MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.06.02 |
Co-danthramer |
Provider notes - NMUH:
- Restricted to terminally ill patients only
- RFL:
- Restricted to oncologist and geriatricians
- RNOH:
- UCLH:
- WH:
- Because of a potential carcinogenic risk, danthron containing laxatives are indicated only for constipation in the terminally ill. Co-danthramer may cause irritation and excoriation in incontinent patients and may colour the urine red. Please note: Capsules not available. Suspension only.
|
| 01.06.02 |
Co-danthrusate |
Provider notes - NMUH:
- Restricted to terminally ill patients only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.04.02 |
Codeine |
NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. Provider notes |
| 04.07.02 |
Codeine |
NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Check MHRA Drug Safety Updates
- RFL:
- RNOH:
- Initiation restricted to patient review by the Acute Pain Service
- Oral solution available as 15 mg/5mL
- UCLH:
- WH:
|
| 03.09.01 |
Codeine Linctus BP |
NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- Check for MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.07.01 |
Co-dydramol 10/500 Paracetamol + Dihydrocodeine |
Provider notes |
| 10.01.04 |
Colchicine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Access Trust guideline via intranet
- RFL:
- No restriction stated (including pericarditis)
- RNOH:
- UCLH:
- WH:
|
| 12.04 |
Colchicine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for oral mucosal inflammatory disease in particular ‘Recurrent apthous stomatitis (RAS)’ and ‘Oral ulceration in Behcet’s disease’ (JFC April 2018).
Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Monitoring requirements are FBC, U&E and LFTs at 3 months, 6 months and then annually, CK only if myalgia.
Provider notes
- NMUH:
- As above. Unlicensed form must be completed prior to use.
- RFL:
- Approved for Behcet's (see Bart's protocol)
- RNOH:
- UCLH:
- WH:
|
| 09.06.04 |
Colecalciferol + Calcium carbonate Adcal-D3® |
Provider notes |
| 09.06.04 |
Colecalciferol caps/liquid |
Provider notes - NMUH:
- RFL:
- RNOH:
- Oral liquid available as 3000 units/mL
- UCLH:
- WH:
|
| 02.12 |
Colesevelam Cholestagel® |
Provider notes
- NMUH:
- RFL:
- Non-formulary for hypercholesterolaemia
- Available for partial biliary obstruction, primary biliary cirrhosis and diarrhoea if colestyramine and colestipol is unavailable (off-label)
- RNOH:
- UCLH:
- WH:
|
| 02.12 |
Colestipol Colestid® |
Provider notes
- NMUH:
- RFL:
- Restricted to Lipid clinic for hypercholesterolaemia
- Restricted to Hepatology / Gastroenterology for partial biliary obstruction, primary biliary cirrhosis and diarrhoea if colestyramine is unavailable (off-label)
- RNOH:
- UCLH:
- WH:
|
| 01.09.02 |
Colestyramine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Sugar-free formulations preferred
- Current shortage - colestipol is the recommended alternative
- RNOH:
- UCLH:
- WH:
|
| 02.12 |
Colestyramine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Sugar-free formulation preferred
- Restricted to Lipid Clinid for hypercholesterolaemia
- Current shortage - colestipol is the recommended alternative
- RNOH:
- UCLH:
- WH:
|
| 05.01.07 |
Colistimethate for nebulisation |
Provider notes
- NMUH:
- Microbiology recommendation only
- RFL:
- Consultant Microbiology/ID approval only
- RNOH:
- Microbiologist approval only
- UCLH:
- WH:
|
| 05.01.07 |
Colistimethate injection |
Provider notes
- NMUH:
- Microbiology recommendation only
- RFL:
- Consultant Microbiology/ID approval only
- RNOH:
- Microbiologist approval only
- UCLH:
- WH:
|
| 13.10.05 |
Collodion Flexible BP |
Provider notes |
| 01.01.01 |
Co-magaldrox |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Suspension (Maalox) containing magnesium hydroxide 195mg, dried aluminium hydroxide 220mg/5ml. Na+ content 0.24mmol/5ml
|
| 09.02.02.01 |
Compound Sodium Lactate (Hartmann's) Intravenous Infusion |
Provider notes |
| 03.04.03 |
Conestat Alfa |
Approved for prophylaxis and treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC October 2018) Provider notes - NMUH:
- RFL:
- For hereditary angioedema in line with NHSE comissioning policy
- Restricted to immunology
- RNOH:
- UCLH:
- WH:
|
| 06.04.01.01 |
Conjugated oestrogen Premarin® |
Provider notes
- NMUH:
- RFL:
- No restriction stated (0.625mg and 1.25mg only)
- RNOH:
- UCLH:
- WH:
|
| 06.04.01.01 |
Conjugated oestrogen with Medroxyprogesterone Premique® |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Tabs containing conjugated oestrogens 625 micrograms and medroxyprogesterone acetate 5 mg ONLY
|
| 01.04.02 |
Co-Phenotrope |
Provider notes |
| 02.04 |
Co-tenidone |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.01.08 |
Co-trimoxazole |
Provider notes
- NMUH:
- RFL:
- See Microguide for agreed indications
- Approved for treatment and prevention of PCP infection; see Chemotherapy protocols
- Microbiology or ID approval required for other indications
- RNOH:
- Oral suspension available as 40/200 mg/5mL and 80/400 mg/5mL
- UCLH:
- WH:
- Microbiology approval only
|
| A2.03.01 |
Cow and Gate Pepti-Junior |
Provider notes - NMUH:
- Suitable for infants from birth for:
- protracted diarrhoea
- food intolerance
- short bowel
- cystic fibrosis
- inflammatory bowel disease
- malnutrition
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Crisantaspase |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Crizotinib |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- Check MHRA drug safety alerts
- See London Cancer Guidelines for the Treatment of Lung Cancer
- RFL:
- As per NICE TA
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additonally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- In line with NICE TA's
- In line with Cancer Drug Fund
- WH:
|
| 13.03 |
Crotamiton 10% cream Eurax® |
Provider notes |
| 09.01.02 |
Cyanocobalamin |
Provider notes |
| 04.06 |
Cyclizine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- Tablets approved for:
- Nausea
- Vomiting
- Labyrinthine disorders
- Motion sickness
- Vertigo
- Prevention/treatment of post-operative nausea and vomiting
- Nausea or vomiting associated with radiotherapy
- Nausea and vomiting associated with narcotic analgesics
- Injection approved for:
- Nausea
- Vomiting
- Labyrinthine disorders
- Motion sickness
- Vertigo
- Prevention/treatment of post-operative nausea and vomiting
- Pre-op. emergency surgery: Reduce regurgitation/aspiration gastric contents
- Nausea or vomiting associated with radiotherapy
- Nausea and vomiting associated with narcotic analgesics
- WH:
|
| 11.05 |
Cyclopentolate eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for mydriasis and cycloplegia (0.5% & 1%)
- RNOH:
- UCLH:
- WH:
|
| 11.05 |
Cyclopentolate eye drops - preservative free |
Provider notes
- NMUH:
- No restriction stated (single-use drops)
- RFL:
- Mydriasis and cycloplegia (0.5% + 1% single-use drops & 1% bottles)
- RNOH:
- UCLH:
- WH:
- No restriction stated (single-use drops)
|
| 08.01.01 |
Cyclophosphamide |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- For immune system disorders refer to local protocols
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Cyclophosphamide |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Approved for use in Scleroderma (lung fibrosis), Vasculitis, SLE and Sarcoid
- RNOH:
- UCLH:
- WH:
|
| 05.01.09 |
Cycloserine |
Provider notes - NMUH:
- Restricted for the use in combination with other drugs for Tuberculosis resistant to first line drugs only
- RFL:
- Microbiology/ ID approval only
- RNOH:
- UCLH:
- WH:
- Restricted to TB clinic or as per Microbiology advice
|
| 03.04.01 |
Cyproheptadine |
Provider notes
- NMUH:
- Stocked in the Emergency Drug Cupboard ONLY as an antidote for serotonin syndrome.
- RFL:
- No restriction stated
- Approved for cold urticaria - Dermatology use only
- Approved for carcinoid (NET) diarrhoea
- RNOH:
- UCLH:
- WH:
|
| 06.04.02 |
Cyproterone |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Restricted to Endocrinology
- RNOH:
- UCLH:
- WH:
- In view of hepatotoxicity associated with long-term daily doses of 300 mg daily, the CSM recommend the use of cyproterone in prostatic cancer should be restricted to:
- Short courses to cover testosterone flare associated with LHRH agonists.
- Treatment of hot flushes after orchidectomy or LHRH agonists.
- Patients who do not respond to, or are intolerant of other treatments.
- Tabs 50 mg, 100 mg
|
| 08.03.04.02 |
Cyproterone |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.03 |
Cytarabine |
Provider notes - NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 02.08.02 |
Dabigatran caps |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
See NICE TA for eligibity criteria
Not preferred treatment for VTE (JFC February 2020; see Position Statement below).
Provider notes
- NMUH:
- As per NICE TA157, TA249, TA327 (not preferred)
- Follow NCL DOAC prescribing guide
- RFL:
- As per NICE guidance
- Follow NCL DOAC prescribing guide
- RNOH:
- Follow NCL DOAC prescribing guide
- UCLH:
- WH:
- Restricted for use as thromboprophylaxis after elective hip and knee surgery
|
| 08.01.05 |
Dabrafenib caps |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Dacarbazine |
Provider notes - NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Dacomitinib tabs |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- RFL:
- As per TA595
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 08.01.02 |
Dactinomycin |
Not approved for Relapsed/refractory acute myeloid leukaemia (AML) (JFC October 2016) Provider notes |
| 05.01.07 |
Dalbavancin infusion |
Approved if recommended by Microbiology for skin and soft tissue infections in patients only if (JFC April 2017):
- unable to receive oral therapy and
- available treatment pathways for repeated IV antibiotics are unsuitable e.g. chaotic lifestyle, immobility, poor venous access
Provider notes
- NMUH:
- On microbiology recommendation only
- RFL:
- Restricted to Microbiology Consultant only
- RNOH:
- UCLH:
- WH:
- As above (restricted to Microbiology)
|
| 02.08.01 |
Danaparoid |
Provider notes
- NMUH:
- RFL:
- As per local protocol only
- RNOH:
- UCLH:
- WH:
|
| 03.04.03 |
Danazol |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for prophylaxis of C1 esterase inhibitor deficiency and other bradykinin-mediated angioedema (JFC October 2018).
Provider notes
- NMUH:
- RFL:
- As per JFC recommendations. Restricted to immunology
- RNOH:
- UCLH:
- WH:
|
| 06.07.02 |
Danazol |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 10.02.02 |
Dantrolene sodium |
Provider notes - NMUH:
- Check MHRA Drug Safety Update
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 15.01.08 |
Dantrolene sodium injection |
Provider notes - NMUH:
- Check MHRA Drug Safety Update
- RFL:
- Stock kept in theatres on Malignant Hyperthermia trolley
- RNOH:
- UCLH:
- WH:
- Dantrolene Injection is kept in the following locations: Main Theatres, Obstetrics Theatre
|
| 06.01.02.03 |
Dapagliflozin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- Only on the recommendation of the Diabetes Team.
- Check MHRA Drug Safety Alerts
- RFL:
- Restricted to Endocrinology
- See links below
- RNOH:
- Requires initiation by a Diabetes Specialist
- Check MHRA Drug Safety Updates
- UCLH:
- WH:
- No restriction stated
- Check MHRA Drug Safety Updates
|
| 06.01.02.03 |
Dapagliflozin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.01.10 |
Dapsone |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Microbiology/ID approval only
- RNOH:
- UCLH:
- WH:
|
| 12.04 |
Dapsone |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for oral mucosal inflammatory conditions: mucous membrane pemphigoid (MMP), recurrent aphthous stomatitis (RAS) and linear IgA bullous dermatosis (JFC April 2018)
Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Initially monitor FBC, LFTs and reticulocytes weekly for four weeks, monthly for 3 months then every 3 months thereafter. After a dose increase monitor FBC, LFTs and reticulocytes at weeks 2, 4 and 8.
Provider notes
- NMUH:
- RFL:
- Approved for Behcet's (see Bart's protocol)
- RNOH:
- UCLH:
- WH:
|
| 05.01.07 |
Daptomycin |
Store in a refrigerator
Provider notes
- NMUH:
- Consultant Microbiologist approval only
- RFL:
- Microbiology/ID approval only
- RNOH:
- Microbiology approval only
- UCLH:
- WH:
- Microbiology approval only
|
| 08.02.04 |
Daratumumab inj |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- As per NICE TA510, TA573
- RFL:
- As per NICE TA510, TA573
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 09.01.03 |
Darbepoetin alfa Aranesp® |
Provider notes
- NMUH:
- For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
- RFL:
- Restricted to Renal team – preferred brand of erythropoietin
- Restricted to Haematology for MDS
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Darunavir |
Provider notes
- NMUH:
- To be prescribed as per BHIVA Guidelines by the HIV team only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Darunavir + Cobicistat Rezolsta® |
Provider notes
- NMUH:
- To be initiated by Consultants in HIV Medicine only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Darunavir + Cobicistat + Emtricitabine + Tenofovir alafenamide Symtuza® |
Approved for HIV infection in line with NHSE commissioning policy F03/P/b (JFC January 2019)
Provider notes
- NMUH:
- To be prescribed by the HIV team only, as per the clinical commissioning policy - see link below.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.03.02 |
Dasabuvir |
Provider notes
- NMUH:
- To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth only for Hepatitis C
- Check MHRA Drug Safety Updates
- RFL:
- For use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Dasatinib |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patient this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 08.01.02 |
Daunorubicin |
Provider notes - NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 08.01.02 |
Daunorubicin liposomal DaunoXome® |
Provider notes - NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 09.01.03 |
Deferasirox |
Provider notes
- NMUH:
- RFL:
- Commissioned as per NHS England policy for haemoglobinopathies.
- Confirm with the commissioning team regarding other indications.
- RNOH:
- UCLH:
- WH:
|
| 09.01.03 |
Deferiprone |
Provider notes
- NMUH:
- To be prescribed by the Haematology Team ONLY.
- See links below
- RFL:
- Commissioned as per NHS England policy for haemoglobinopathies.
- Confirm with the commissioning team regarding other indications.
- RNOH:
- UCLH:
- WH:
|
| 06.03.02 |
Deflazacort |
Provider notes - NMUH:
- RFL:
- Restricted to Rheumatology and Endocrinology only.
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.02 |
Degarelix |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- See link below
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.01.09 |
Delamanid |
Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017) Provider notes - NMUH:
- RFL:
- As per NHSE policy for XDR-TB and MDR-TB
- RNOH:
- UCLH:
- Pulmonary multidrug-resistant tuberculosis
- WH:
|
| 05.01.03 |
Demeclocycline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Microbiology approval only
|
| 06.05.02 |
Demeclocycline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- Treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable. Initially 0.9–1.2 g is given daily in divided doses, reduced to 600–900 mg daily for maintenance.
- UCLH:
- WH:
|
| 06.06.02 |
Denosumab XGEVA® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for hypercalcaemia of malignancy who are either refractory to bisphosphonates or have creatinine clearance <30mL/min in whom bisphosphonates are contraindicated (JFC August 2018).
Only on the advice of oncology or palliative care consultants.
Provider notes
- NMUH:
- As per above agreed indication
- RFL:
- As per above agreed indication
- RNOH:
- UCLH:
- WH:
|
| 06.06.02 |
Denosumab XGEVA® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for preventing skeletal related events for oncology patients subject to service redevelopment (November 2015)
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- To be prescribed by the Oncology team ONLY.
- Check MHRA Drugs Safety Updates
- RFL:
- As per NICE TA265.
- This drug must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- Giant cell tumour of bone
- UCLH:
- WH:
|
| 06.06.02 |
Denosumab Prolia® |
(hospital only prescribing) for osteoporotic men or women with renal impairment
for osteoporotic women when used in line with NICE TA
Approved for osteoporosis in women (see NICE TA) and men unable to take oral bisphosphonates (either due to intolerance or unable to comply with administration instructions) and unable to receive IV zoledronic acid due to renal dysfunction (JFC October 2017)
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- To be prescribed by Rheumatology and Care of the Elderly Consultants ONLY.
- Check MHRA Drugs Safety Updates
- RFL:
- Approved for osteoporosis treatment in line with NICE TA by Endocrinology and Rheumatology
- See links below
- RNOH:
- See links below for Transfer of Care Guideline and Template Letter with Hertfordshire
- UCLH:
- WH:
- Also approved for osteoporosis in men unable to take oral bisphosphonates and unable to receive IV zoledronic acid due to renal dysfunction (November 2017)
|
| 07.02.02 |
Dequalinium chloride vaginal tablets |
Approved for bacterial vaginosis as a second-line alternative to clindamycin 2% intravaginal cream in patients who have not tolerated or failed metronidazole treatment (JFC August 2018). Provider notes - NMUH:
- Restricted to GU medicine ONLY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.02.02 |
Derma-S® barrier preparation |
Provider notes |
| 13.02.01 |
Dermatonics Once Heel Balm® Urea 25% |
JFC approved for primary and secondary care for treatment of anhidrotic, fissured, calloused and hard foot skin in diabetic patients at high risk of ulceration (March 2018) Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- See indication above.
- Restricted to podiatry use ONLY
|
| 13.02.01 |
Dermol® 500 lotion |
Provider notes
- NMUH:
- Restricted to the Dermatology team
- RFL:
- RNOH:
- Short-term use for infected skin
- UCLH:
- WH:
- Restricted to the Dermatology team
|
| 13.02.01.01 |
Dermol® bath/shower additive |
Provider notes
- NMUH:
- RFL:
- Dermol 200 shower gel and 600 bath emollient available
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
Dermol® cream |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.01.03 |
Desferrioxamine Mesilate |
Provider notes
- NMUH:
- To be prescribed by the Haematology Team ONLY.
- See links below
- RFL:
- Commissioned as per NHS England policy for haemoglobinopathies.
- Confirm with the commissioning team regarding other indications.
- RNOH:
- UCLH:
- WH:
|
| 18 |
Desferrioxamine Mesilate |
Provider notes |
| 15.01.02 |
Desflurane |
Provider notes |
| 03.04.01 |
Desloratadine |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- The use of desloratadine is reserved for consultant ENT surgeons only
- Tabs 5mg ONLY
|
| 06.05.02 |
Desmopressin |
Provider notes - NMUH:
- DDAVP: On formulary
- DesmoMelt: Formulary for use as a first line agent in the treatment of primary nocturnal enuresis
- RFL:
- DDAVP: Restricted to child health; sublingual tablets available (120micrograms and 240micrograms)
- Desmotabs: Restricted to child health
- Desmospray: On formulary
- Octim: On formulary
- Injection: 4micrograms in 1mL available
- RNOH:
- Tablets, Injection, Nasal spray (for continuation of treatment), Oral lyophilisates (for continuation of treatment)
- UCLH:
- WH:
- DDAVP: Intranasal solution 100 micrograms/1 ml & Inj 4 micrograms/1 ml ONLY
- DesmoMelt: The use of Desmomelt tablets is restricted to Paediatrics only
- Desmotabs: The use of desmopressin tablets is restricted to Dr Rossi only
- Desmospray: On Formulary
|
| 07.03.02.01 |
Desogestrel 75mcg pill generic, Cerazette®, Cerelle®, other brands available |
Provider notes
- NMUH:
- Preferred brand = generic
- Restricted to Consultants in GU Medicine ONLY
- RFL:
- Preferred brand = generic
- Approved for Sexual Health and Family
- Approved for Gynaecology
- RNOH:
- UCLH:
- WH:
|
| 10.01.02.02 |
Dexamethasone |
Provider notes |
| 11.04.01 |
Dexamethasone + Framycetin + Gramicidin drops Sofradex® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 12.01.01 |
Dexamethasone + Framycetin + Gramicidin drops Sofradex® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 12.01.01 |
Dexamethasone + Neomycin + Glacial Acetic Acid ear spray Otomize® |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to ENT department use only
|
| 11.04.01 |
Dexamethasone + Neomycin + Polymyxin B drops/ointment Maxitrol® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 12.01.01 |
Dexamethasone 0.1% + Ciprofloxacin 0.3% ear drops Cilodex® |
Approved for treatment of acute otitis externa with perforated/damaged tympanic membrane (JFC March 2018) Provider notes |
| 11.04.01 |
Dexamethasone 0.1% eye drops |
Provider notes |
| 11.04.01 |
Dexamethasone 0.1% eye drops - preservative free |
Provider notes
- NMUH:
- RFL:
- No restriction stated (single-use drops & preservative-free bottles)
- RNOH:
- UCLH:
- WH:
- Dexamethasone eye drops 0.1% preservative-free (Moorfields)
|
| 11.04.01 |
Dexamethasone intravitreal implant Ozurdex® |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
- See links below
- RFL:
- Approved for macular oedema following RVO in line with NICE TA (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
| 06.03.02 |
Dexamethasone oral and systemic injection |
Provider notes
- NMUH:
- See MHRA Drugs Safety Updates
- RFL:
- RNOH:
- Oral solution available as 2 mg/5mL
- UCLH:
- WH:
- Also available for COVID-19 treatment
- The use of dexamethasone inj 24mg/ml is restricted to theatres only
|
| 04.04 |
Dexamfetamine |
Provider notes
- NMUH:
- RFL:
- Restricted to the Sleep Clinic for narcolepsy
- Restricted to CAMS for ADHD in children and adolescents
- RNOH:
- UCLH:
- WH:
- CIFT
- Approved for adults with ADHD (off-label) - 3rd line after methylphenidate and lisdexamphetamine
- BEHMT
- Approved for adults with ADHD (off-label)
|
| 15.01.04.04 |
Dexmedetomidine injection |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for light sedation (RASS 0 to -3) in mechanically ventilated adult patients with CAM ICU positive agitated delirium where agitation precludes weaning and extubation only after standard sedative agents (including propofol, clonidine or a benzodiazepine) had been trialled for 48 hours. (JFC January 2019).
Provider notes
- NMUH:
- RFL:
- see above indication
- Refer to local protocol for use
- RNOH: As per indication above
- UCLH:
- WH:
|
| 04.07.02 |
Diamorphine |
Provider notes |
| 04.01.02 |
Diazepam |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
- Oral solution available as 2 mg/5mL
- UCLH:
- WH:
- Tablets 2 mg, 5 mg, 10 mg.
- Oral solution 2 mg/5 ml, 5mg/5 ml
- Injection (emulsion) 10 mg/2 ml - Diazemuls
- CIFT:
- Approved for
- Anxiolytic
- Alcohol withdrawal
- Acute phase of mania (off-label)
- Benzodiazepine dependence (off-label)
- BEHMT:
- Approved for
- Anxiolytic
- Alcohol withdrawal
- Acute phase of mania (off-label)
- Benzodiazepine dependence (off-label)
|
| 04.08.02 |
Diazepam |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Only diazepam injection (emulsion) and rectal solution stocked
- RNOH:
- Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
- Oral solution available as 2 mg/5mL
- UCLH:
- WH:
- ‘Diazemuls’ are preferred to plain diazepam injection as they are less likely to cause thrombophlebitis
|
| 10.02.02 |
Diazepam |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- RNOH:
- Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
- Oral solution available as 2 mg/5mL
- UCLH:
- WH:
|
| 15.01.04.01 |
Diazepam |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 06.01.04 |
Diazoxide |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to children < 1year
|
| 06.06.02 |
Dibotermin Alfa, rhBMP-2 Inductos® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Complex spinal fusion surgeries in line with NHSE commissioning policy
- This product is currently unavailable in the UK
- UCLH:
- WH:
|
| 11.03.01 |
Dibromopropamidine 0.15% eye ointment |
Provider notes
- NMUH:
- RFL:
- Approved for acanthamoeba keratitis (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
| 04.14 |
Dichlorphenamide |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- Approved for
- Periodic paralysis – second line for patients who have not responded to acetazolamide (UCLH only; JFC February 2019)
- WH:
|
| 13.08.01 |
Diclofenac 3% gel Solaraze® |
Provider notes - NMUH:
- RFL:
- Restricted to Dermatologists
- RNOH:
- UCLH:
- WH:
|
| 10.01.01 |
Diclofenac sodium |
Provider notes
- NMUH:
- See MHRA Drug Safety Update
- RFL:
- Restricted to Rheumatology, Obstetricians / Gynaecology and Paediatrics (suppositories or injection)
- Injection, Suppositories 12.5mg/25mg/100mg, EC tablets 25mg/50mg
- RNOH:
- Restricted: Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking).
- UCLH:
- WH:
- See MHRA Drug Safety Update
|
| 10.01.01 |
Diclofenac sodium + Misoprostol |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Must not be given to women of child-bearing potential
|
| 11.08.02 |
Diclofenac sodium 0.1% eye drops - single use |
Provider notes
- NMUH:
- RFL:
- Approved for
- Cataract surgery (Ophthalmologist use only)
- Post-op inflammation (Ophthalmologist use only)
- Ocular symptoms in allergic conjunctivitis (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
| 10.01.01 |
Diclofenac sodium modified release |
Provider notes
- NMUH:
- Non-formulary
- Check MHRA Drug Safety Updates
- RFL:
- Restricted to only Rheumatology and Obs / Gynae
- M/R tablets 75mg and 100mg available
- RNOH:
- UCLH:
- WH:
- See MHRA Drug Safety Update
|
| 18 |
Dicobalt edetate |
Provider notes |
| 01.02 |
Dicycloverine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.03.01 |
Diethylstilbestrol |
Provider notes |
| 13.04 |
Diflucortolone valerat 0.3% - Topical Nerisone Forte® |
Provider notes - NMUH:
- RFL:
- Oily cream and ointment available
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Diflucortolone valerate 0.1% - Topical Nerisone® |
Provider notes - NMUH:
- RFL:
- Cream, oily cream and ointment are available
- RNOH:
- UCLH:
- WH:
|
| 16.01 |
Diflunisal |
Provider notes
- NMUH:
- RFL:
- National Amyloidosis Clinic use only
- Approved for polyneuropathy progression in the hereditary ATTR subtype (ATTRm)
- RNOH:
- UCLH:
- WH:
|
| 02.01.01 |
Digoxin |
Provider notes - NMUH:
- NB. The Digoxin 100 micrograms/mL (Paediatric) is unlicensed and NON-FORMULARY.
- RFL:
- RNOH:
- Tablets available. Oral elixir available as 50 micrograms/mL
- UCLH:
- WH:
|
| 02.01.01 |
Digoxin specific antibody fragments Digifab® |
Provider notes |
| 04.07.02 |
Dihydrocodeine |
Provider notes - NMUH:
- RFL:
- RNOH:
- Oral elixir available as 10 mg/5mL
- UCLH:
- WH:
|
| 04.07.02 |
Dihydrocodeine modified release |
Provider notes |
| 04.07.04.03 |
Dihydroergotamine inj |
Provider notes
- NMUH:
- RFL:
- Restricted to neurology for migraine and cluster headache
- RNOH:
- UCLH:
- WH:
|
| 05.04.02 |
Diloxanide |
Provider notes
- NMUH:
- RFL:
- Microbiology/ID consultant approval only
- RNOH:
- UCLH:
- WH:
|
| 21.01 |
Diltiazem cream |
Diltiazem cream for transrectal ultrasound guided prostate biopsy
Twelve-month evaluation at UCLH site only (March 2015) |
| 01.07.04 |
Diltiazem Cream 2% |
Provider notes
- NMUH:
- RFL:
- For anal fissures only - restricted to Colorectal team
- RNOH:
- UCLH:
- WH:
|
| 02.06.02 |
Diltiazem immediate release |
Provider notes |
| 02.06.02 |
Diltiazem modified release |
Prescribe by brand name: modified-release preparations have different release characteristics and are not interchangeable. Provider notes - NMUH:
- Adizem-SR, Adizem-XL, Tildiem LA, Tildiem Retard available
- RFL:
- Tildiem LA, Tildiem Retard and Slozem and the preferred brands
- RNOH:
- UCLH:
- WH:
- Tildiem LA, Tildiem Retard available
|
| 08.02.04 |
Dimethyl fumarate Tecfidera® |
DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- Check MHRA Drugs Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.05.03 |
Dimethyl fumarate Skilarence® |
DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.10.04 |
Dimeticone 4% lotion Hedrin® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.01.01 |
Dinoprostone Prostin E2® |
Provider notes
- NMUH:
- RFL:
- See ‘Induction of Labour’ policy on Freenet
- RNOH:
- UCLH:
- WH:
- Vaginal gel 1 mg/2.5 ml (Prostin E2), Vaginal gel 2 mg/2.5 ml (Prostin E2) Inj 5 mg/0.5 ml extra amniotic
|
| 07.01.01 |
Dinoprostone Propess® |
Provider notes
- NMUH:
- Restricted to Obstetrics and Gynaecology Consultants only for induction and Augmentation of Labour
- RFL:
- See ‘Induction of Labour’ policy on Freenet
- RNOH:
- UCLH:
- WH:
|
| 14.04 |
Diphtheria antitoxin |
Provider notes |
| 13.02.01 |
Diprobase® cream |
Provider notes
- NMUH:
- Restricted to Dermatology team
- RFL:
- RNOH:
- Use Epimax as per Hertfordshire Emollients Guideline
- UCLH:
- WH:
|
| 02.09 |
Dipyridamole |
See NICE TA for eligibility Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- RFL:
- See NCL JFC summary of antiplatelet options in cardiovascular disease for advice on specific indications
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
Disodium edetate 0.37% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for collagenase inhibitor
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
Disodium edetate 0.37% solution |
Provider notes
- NMUH:
- RFL:
- Approved as chelating agent, aid to calcified corneal plaque removal
- RNOH:
- UCLH:
- WH:
|
| 02.03.02 |
Disopyramide immediate release |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.03.02 |
Disopyramide modified release |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.10.01 |
Disulfiram |
Provider notes |
| 13.05.02 |
Dithranol cream Dithrocream® |
Provider notes - NMUH:
- Dithrocream 0.25% and Dithrocream 0.5% are FORMULARY, for irritation on trunk and limbs.
- Dithrocream 0.1%, Dithrocream 1% and Dithrocream 2% are NON-FORMULARY.
- RFL:
- Dithrocream 0.1%, 0.25%, 0.5%, 1% and 2% available
- RNOH:
- UCLH:
- WH:
|
| 13.05.02 |
Dithranol Paste, BP |
Provider notes - NMUH:
- RFL:
- There are non-proprietary preparations available at the Royal Free Hospital but not listed in the eBNF, contact Pharmacy for details.
- RNOH:
- UCLH:
- WH:
|
| 02.07.01 |
Dobutamine |
Provider notes |
| 08.01.05 |
Docetaxel |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- RFL:
- No restrictions stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Docetaxel + oxaliplatin + disodium folinate + fluorouracil (FLOT) |
Approved gastric or gastro-oesophageal junction adenocarcinoma (JFC November 2017) Provider notes |
| 01.06.02 |
Docusate sodium |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Caps 100mg. Oral solution 50 mg/5 ml. Paediatric oral solution 12.5 mg/5 ml
- UCLH:
- WH:
- Caps 100 mg. Oral solution 50 mg/5 ml. Paediatric oral solution 12.5 mg/5 ml
|
| 05.03.01 |
Dolutegravir |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Dolutegravir + Abacavir + Lamivudine Triumeq® |
Approved for HIV in line with NHSE Commissioning Policy B06/P/a.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Dolutegravir + Rilpivirine Juluca® |
Approved for HIV in line with NHSE Commissioning Policy 200210P.
Provider notes
- NMUH:
- Restricted to HIV team ONLY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.02 |
Domperidone |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- Tablets availabe. Oral suspension available as 1 mg/mL.
- UCLH:
- WH:
|
| 04.06 |
Domperidone |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Check MHRA Safety Drug Updates
- RFL:
- RNOH:
- Oral suspension available as 1 mg/mL
- UCLH:
- WH:
- Risk of cardiac side effects - to be used at the lowest effective dose for the shortest period of time
|
| 04.11 |
Donepezil |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- See link below
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Care of the Elderly consultants only
- Tabs 5mg only
|
| 02.07.01 |
Dopamine |
Provider notes |
| 05.03.01 |
Doravirine + Lamivudine + Tenofovir disoproxil Delstrigo® |
Provider notes
- NMUH:
- As per NHSE commissioning policy 190137P
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Doravirine tabs Pifeltro® |
Provider notes
- NMUH:
- As per NHSE Commissioning Policy 190137P
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Dorzolamide 2% + Timolol 0.5% eye drops Cosopt® |
Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for ppen-angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Dorzolamide 2% + Timolol 0.5% eye drops - unit dose Cosopt® |
Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open-angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
- Restricted to Ophthalmology
|
| 11.06 |
Dorzolamide 2% eye drops |
See NCL guideline for place in therapy.
Provider notes
- NMUH:
- RFL:
- Approved for open-angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
- Not to be used as first-line treatment - see link below
|
| 11.06 |
Dorzolamide 2% eye drops - unit dose |
Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy.
Provider notes
- NMUH:
- See NCL Glaucoma guideline
- RFL:
- Approved for open-angle glaucoma and ocular hypertension
- RNOH:
- UCLH:
- WH:
|
| 04.03.01 |
Dosulepin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Not approved for any indication in line with NHS England 'Items which should not routinely be prescribed in primary care' guidance (JFC January 2020)
Provider notes
- NMUH:
- For continuation ONLY
- Non-formulary for initiation in all indications
- RFL:
- RNOH:
- UCLH:
- WH:
- CIFT:
- BEHMT:
|
| 04.07.04.02 |
Dosulepin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Not approved for any indication in line with NHS England 'Items which should not routinely be prescribed in primary care' guidance (JFC January 2020)
Provider notes
- NMUH:
- For contiuation of treatment ONLY
- Non-formulary for iniation in all indications
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
Doublebase® gel |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Use Isomol Gel as per Hertfordshire Emollients Guideline
- UCLH:
- WH:
|
| 03.05.01 |
Doxapram |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 15.01.07 |
Doxapram |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.05.04 |
Doxazosin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Immediate release preparations only
- RNOH:
- UCLH:
- WH:
- Immediate release preparations only.
- Prolonged release preparations not recommended for routine use by NHSE (Dec 2017)
|
| 07.04.01 |
Doxazosin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- Modified release preparations are non-formulary
- RFL:
- Modified release preparations are non-formulary
- RNOH:
- UCLH:
- WH:
- Modified release praparations are non-formulary
|
| 08.01.02 |
Doxorubicin |
Provider notes - NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 08.01.02 |
Doxorubicin pegylated liposomal Caelyx® |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 05.01.03 |
Doxycycline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Oral: See Microguide for approved indications
- IV: Seek Microbiology, ID or Pharmacy advice before prescribing
- RNOH:
- UCLH:
- WH:
|
| 05.04.01 |
Doxycycline |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- See Trust guideline on intranet for further information
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.03.02 |
Dronedarone |
Provider notes
- NMUH:
- NOT 1ST LINE DRUG - REQUIRES CARDIOLOGIST APPROVAL.
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- RFL:
- Cardiology initiation only – use as per NICE TA
- RNOH:
- Requires CARDIOLOGIST approval
- UCLH:
- WH:
- For use in the treatment of Non‐Permanent Atrial Fibrillation (AF) where it is not the first‐line option; this is use is limited to an SpR or a Consultant cardiologist who has seen the patient.
|
| 06.01.02.03 |
Dulaglutide |
Semaglutide is the preferred GLP-1 receptor agonist for type 2 diabetes, when used in line with the NCL Fact sheet (JFC August 2019).
Dulaglutide should only be initiated for patients (JFC August 2019):
- who are needle-phobic and cannot use the semaglutide pen device.
- with impaired manual dexterity (e.g. due to severe arthritis) and cannot use the semaglutide pen device.
- with learning difficulty or mental health issues and require GLP-1 receptor agonist administration by a third-party as the dulaglutide device minimises the risk of needle-stick injury
Provider notes
- NMUH:
- Non-formulary but see link below
- RFL:
- Restricted to initiation by endocrinology only for Type 2 diabetes
- See above for detailed eligibility criteria
- RNOH:
- Requires initiation by a Diabetes Specialist
- UCLH:
- WH:
- As above
- Initiation restricted to endocrinology
|
| 04.03.04 |
Duloxetine Cymbalta® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 04.07.03 |
Duloxetine Cymbalta® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for neuropathic pain in patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin (JFC November 2013).
Provider notes
- NMUH:
- Restricted for patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin
- RFL:
- Restricted for patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin
- RNOH:
- Restricted for patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin
- UCLH:
- WH:
- Restricted for patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin
|
| 07.04.02 |
Duloxetine Yentreve® |
Provider notes
- NMUH:
- Duloxetine (Yentreve) is FORMULARY for use in women with moderate to severe urinary stress incontinence. Duloxetine (Yentreve) should be used as a second line option for urinary stress incontinence, as an alternative to surgical treatment, as per NICE guidance.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| A5.02.04 |
DuoDERM Extra Thin |
Provider notes |
| 13.05.01 |
Dupilumab injection |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- RFL:
- For the treatment of Atopic Dermatitis in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
| A5.01.02 |
Durafiber |
Absorbent Cellulose dressing with gel matrix Provider notes |
| A5.03.03 |
Durafiber Ag |
Provider notes - NMUH:
- To be used on the recommendation of the Tissue Viability Nurse only.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Durvalumab |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- Non-formulary
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- As per NICE/CDF criteria
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 13.14 |
Dutasteride |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Approved for use by Dermatology for frontal fibrosing alopecia (third line drug. Off label use)
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
E45® cream |
Provider notes
- NMUH:
- E45 cream is NON-FORMULARY.
- Cetomacrogel A cream (500g) is used at NMUHT.
- RFL:
- RNOH:
- Use ZeroCream or ExoCream as per Hertfordshire Emollients Guideline
- UCLH:
- WH:
|
| A5.02.03 |
Eclypse Adherent |
Provider notes |
| 11.03.02 |
Econazole 1% eye drops |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- This is an unlicensed special and restricted to Ophthalmology
|
| 09.01.03 |
Eculizumab infusion |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.09 |
Eculizumab infusion |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for 2nd line management of Delayed Haemolytic Transfusion Reactions [DHTRs] hyperhaemolysis in adult Sickle Cell and β-thalassaemia patients who have not responded to IVIG and steroids (pending internal funding approval; JFC July 2019)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- Restricted to haematology. UMC to be informed of each patient. Funding agreed for 1 patient per annum.
- WH:
|
| 02.08.02 |
Edoxaban tabs |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
See NICE TA for eligibility criteria
Not preferred treatment for VTE (JFC February 2020; see Position Statement below).
Provider notes
- NMUH:
- As per NICE TA354 (not preferred) and TA355
- Follow NCL DOAC prescribing guide
- RFL:
- As per NICE guidance
- Follow NCL DOAC prescribing guide
- RNOH:
- UCLH:
- WH:
- Not to be used for initiation of therapy.
|
| 05.03.01 |
Efavirenz |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.09 |
Eflornithine 11.5% cream Vaniqa® |
Provider notes
- NMUH:
- RFL:
- Restricted to dermatology and endocrinology only
- Initiate in secondary care only and transfer to primary care after 4 months if effective
- RNOH:
- UCLH:
- WH:
|
| 05.03.03.02 |
Elbasvir + Grazoprevir |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
- RFL:
- Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
| A2.01.01.02 |
Elemental 028 ® Extra |
Provider notes |
| 09.08.01 |
Eliglustat |
See NICE HST for eligibility criteria
Provider notes
- NMUH:
- RFL:
- Gaucher disease in line with NICE HST
- RNOH:
- UCLH:
- Gaucher disease in line with NICE HST
- WH:
|
| 09.08.01 |
Elosulfase alfa |
See NICE HST for eligibility criteria
Provider notes
- NMUH:
- RFL:
- Morquio A Syndrome in line with NICE HST
- RNOH:
- UCLH:
- WH:
|
| 09.01.04 |
Eltrombopag |
Provider notes
- NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines see link below.
- RFL:
- As per NICE guidance and CCG policy
- RNOH:
- UCLH:
- WH:
|
| 01.04.02 |
Eluxadoline |
Provider notes - NMUH:
- This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Emicizumab |
Provider notes - NMUH:
- RFL:
- Approved for congenital haemophilia A with factor VIII inhibitors in line with NHSE clinical commissioning policy 170067/P (RFL only; JFC November 2018)
- RNOH:
- UCLH:
- WH:
|
| 06.01.02.03 |
Empagliflozin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- Only on the recommendation of the Diabetes Team.
- Check MHRA Drug Safety Alerts
- RFL:
- Restricted to Endocrinology
- See links below
- RNOH:
- Requires initiation by a Diabetes Specialist
- Check MHRA Drug Safety Updates
- UCLH:
- WH:
- No restriction stated
- Check MHRA Drug Safety Updates
|
| 21.01 |
Empagliflozin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Empagliflozin for symptomatic neutropenia secondary to glycogen storage disease type 1b (GSD1b) or glucose 6 phosphatase catalytic subunit 3 (G6PC3) deficiencies
Approved under evaluation at UCLH only. |
| 05.03.01 |
Emtricitabine |
Provider notes
- NMUH:
- To be prescribed as per BHIVA Guidelines by the HIV team only
- Patients currently benefiting from FTC in their combination therapy, who either accessed FTC in studies or move to London with FTC as part of their existing regimen, should continue to receive FTC without interruption
- For patients who have previously not received 3TC, the decision to prescribe 3TC or FTC to be made by the clinician and patient after discussion and consideration of relevant factors
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Emtricitabine + Rilpivirine + Tenofovir disoproxil Eviplera® |
Provider notes - NMUH:
- NHSE approval required
- Initiation restricted to Consultants HIV Medicine
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Emtricitabine + Tenofovir alafenamide Descovy® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.02.01.01 |
Emulsiderm® liquid emulsion |
Provider notes - NMUH:
- Restricted to Dermatology team
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
Emulsifying Ointment, BP |
Provider notes - NMUH:
- Stock 500g tub
- Emulsifying ointment can be used as a soap substitute
- Check MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.05.05.01 |
Enalapril |
Provider notes |
| 08.01.05 |
Encorafenib caps |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- Non-formulary
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- As per NICE TA
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Enfuvirtide |
Provider notes
- NMUH:
- To be used in accordance with the London HIV consortium BHIVA guidelines
- For HIV team only
- Patients currently benefiting from enfuvirtide in their combination therapy should continue to receive enfuvirtide without interruption. Current benefit is defined as patients whose viral load is either undetectable or remaining below their pre-enfuvirtide baseline level. Patients whose current viral load has substantially rebounded or returned to their baseline level when their first used enfuvirtide and who have a strong CD4 count, are likely to have developed or be developing resistance to enfuvirtide. Enfuvirtide is also unlikely to be having antiretroviral activity, and these patients should consider stopping the enfuvirtide in their combination, with close monitoring BHIVA Guidelines - Treatment of HIV-1 infected adults with antiretroviral therapy
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 14.04 |
Engerix B® Hepatitis B vaccine Single Component |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.08.01 |
Enoxaparin |
(hospital only prescribing) for defined course thromboprophylaxis and patients requiring treatment doses in line with NCL guidance (see Section 3.1)
for long-term thromboprophylaxis and patients requiring treatment doses in line with NCL guidance (see Section 3.3)
Provider notes
- NMUH:
- RFL:
- Prophylaxis - only whilst tinzaparin shortage
- Treatment - haemophilia recommendation only
- RNOH:
- UCLH:
- WH:
|
| 02.01.02 |
Enoximone |
Provider notes |
| A2.04.01.02 |
Enshake |
Provider notes |
| A2.02.02.03 |
Ensure Compact |
- Bottle (125mL)
- Vanilla, banana, strawberry, café latte
- Contains lactose
- Gluten free
- Halal certified (except strawberry)
- Banana and vanilla flavours Kosher certified
- Suitable for vegetarian diet (except strawberry)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
Primary care notes
Second-choice product - for patients who did not tolerate first-line choices and lower volume is indicated or fluid restricted - see Primary Care Guidance |
| A2.02.02.01 |
Ensure Plus Fibre |
Provider notes |
| A2.02.01.02 |
Ensure Plus Juce |
- Bottle (220mL)
- Apple, orange, fruit punch, peach, lemon and lime, strawberry
- Clinically lactose and gluten-free
- Halal certified (except lemon and lime)
- Kosher certified (except strawberry)
- Suitable for vegetarian diets (except strawberry)
Provider notes
- NMUH:
- Taste aberrations/aversions to milky supplements, fat intolerance/steatorrhoea, Cancer cachexia, poor wound healing, anorexia, Disease-related malnutrition, short bowel syndrome, Intractable malabsorption, pre-operative preparation for those who are malnourished. Proven inflammatory bowel disease, total gastrectomy, bowel fistulae, dysphagia Non-milk tasting. For patients who dislike milk. Used to meet nutritional requirements in addition to oral intake
- RFL:
- RNOH:
- UCLH:
- WH:
Primary care notes
Second-choice product - for patients who did not tolerate first-line choices and cannot tolerate milk-based supplements- see Primary Care Guidance |
| A2.02.02.01 |
Ensure Plus Milkshake style |
- Bottle (200mL)
- Vanilla, strawberry, chocolate, coffee, fruits of the forest, neutral, orange, peach, raspberry and banana
- Clinically lactose and gluten free Halal certified (except vanilla)
- Kosher certified and suitable for vegetarian diet (except strawberry, fruits of the forest, peach, raspberry)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
Primary care notes
Second-choice product - for patients who did not tolerate first-line choices - see Primary Care Guidance |
| A2.02.02.01 |
Ensure Plus Yoghurt style |
Provider notes |
| A2.01.02.03 |
Ensure Twocal |
Provider notes |
| 04.09.01 |
Entacapone |
Provider notes
- NMUH:
- Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see link)
- RFL:
- RNOH:
- UCLH:
- Parkinson's disease - adjunct to levodopa + dopa-decarboxylase inhibitor
- WH:
- Entacapone is available for use by Care of the Elderly and Neurology Consultants only
|
| 05.03.03.01 |
Entecavir |
Provider notes
- NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See link below
- RFL:
- See NICE TA for eligibility criteria
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Entrectinib caps |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.02 |
Enzalutamide |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and Local Trust Guidelines.
- See links below
- RFL:
- As per NICE TAs
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 14.04 |
Enzira® Influenza vaccine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
Epaderm® cream/ointment |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Use Epimax as per Hertfordshire Emollients Guideline
- UCLH:
- WH:
- Epaderm ointment only - restricted to paediatric trial of emollients
|
| 02.07.02 |
Ephedrine |
Provider notes
- NMUH:
- Restricted for use in Theatres only.
- RFL:
- RNOH:
- In idiopathic orthostatic hypotension in spinally injured patients
- UCLH:
- WH:
- Ephedrine inj is available for use by anaesthetists only.
|
| 12.02.02 |
Ephedrine 0.5% nasal drops |
Provider notes |
| 07.06 |
Ephedrine tablets |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Approved for use for priapism (unlicensed use).
- See Trust Sickle Cell guidelines via intranet
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.02 |
Epirubicin |
Provider notes - NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 02.02.03 |
Eplerenone |
Approved for heart failure in patients unable to tolerate spironolactone due to gynaecomastia (JFC April 2017)
Provider notes
- NMUH:
- Check for MHRA Drug Safety Updates
- Restricted for patients who are unable to tolerate spironolactone due to gynaecomastia
- RFL:
- Restricted to cardiology for:
- Heart failure in patients unable to tolerate spironolactone due to gynaecomastia
- Ejection Fraction <40% post STEMI
- RNOH:
- Requires CARDIOLOGIST approval
- UCLH:
- WH:
- Eplerenone is reserved for the use of Consultant Cardiologists only for those who develop gynecomastia with spironolactone
|
| 09.01.03 |
Epoetin alfa Eprex® |
Provider notes
- NMUH:
- For anaemia associated with chronic renal failure only.
- Restricted to renal consultants signature and Dr. Tindall signature only.
- Please note that the CSM has advised that the subcutaneous route is contraindicated in chronic renal failure. Please use the IV route instead. The dialysis unit has changed over to NeoRecormon which is an IV preparation.
- RFL:
- Restricted to Renal team - for patients who cannot tolerate darbepoetin or established patients only
- RNOH:
- UCLH:
- WH:
- Epoetin is available for treatment anaemia of renal disease only
|
| 09.01.03 |
Epoetin beta NeoRecormon® |
Provider notes
- NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Restricted to Renal and Haematology Consultants.
- See MHRA drug safety updates
- RFL:
- Restricted to Renal team - for patients who cannot tolerate darbepoetin or established patients only
- Restricted to Haematology for MDS
- RNOH:
- UCLH:
- WH:
- Epoetin is available for treatment anaemia of renal disease only
- Pre-filled syringe 2,000 units, 3,000 units, 4,000 units, 6,000 units, 10,000 units ONLY
|
| 02.08.01 |
Epoprostenol |
Approved for
Provider notes
- NMUH:
- Restricted for ICU use only.
- Check MHRA for Drug Safety Updates
- RFL:
- Restricted to ITU and pulmonary hypertension
- RNOH:
- UCLH:
- Approved for primary pulmonary hypertension: functional grades III + IV
- Approved for Inhibition of platelet aggregation during renal dialysis
- WH approvals:
|
| 02.09 |
Eptifibatide Integrilin® |
Provider notes |
| 09.06.04 |
Ergocalciferol |
Provider notes
- NMUH:
- RFL:
- 300,000 units intramuscular injection only
- RNOH:
- UCLH:
- WH:
- Inj 7.5 mg (300,000 units)/1 ml only
|
| 07.01.01 |
Ergometrine maleate |
Provider notes
- NMUH:
- Restricted to Obstetrics Only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.01.01 |
Ergometrine maleate + Oxytocin Syntometrine® |
Provider notes
- NMUH:
- Restricted to Obstetrics ONLY
- RFL:
- See Maternity Unit Guideline on Massive Obstetric Haemorrhage
- RNOH:
- UCLH:
- WH:
|
| 04.07.04.01 |
Ergotamine Tartrate |
Provider notes |
| 08.01.05 |
Eribulin |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Erlotinib tab |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when use in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by the Oncology team ONLY.
- As per NICE guidance TA258, TA374.
- RFL:
- As per NICE guidance TA258, TA374.
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 05.01.02.02 |
Ertapenem |
Provider notes
- NMUH:
- Microbiology approval only
- RFL:
- Microbiology approval only (except ITU, microbiology approval required within 48 hours)
- RNOH:
- Microbiologist approval only
- UCLH:
- WH:
- Restricted antibiotic - Microbiology approval only
|
| 06.01.02.03 |
Ertugliflozin tabs |
Provider notes
- NMUH:
- Not stocked at NMUH - use alternative SGLT2 inhibitor
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.02 |
Erythromycin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 05.01.05 |
Erythromycin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- Injection is reserved for the use of Paediatrics only
- RFL:
- RNOH:
- Oral suspension available as 125 mg/5mL and 250 mg/5mL
- UCLH:
- WH:
- Restricted to Maternity use or as prokinetic
|
| 11.03.01 |
Erythromycin 0.5% eye ointment |
Provider notes
- NMUH:
- RFL:
- Approved for
- Chlamydial conjunctivits & trachomatis
- Chlamydial rosacea
- RNOH:
- UCLH:
- WH:
- This is unlicensed special and restricted to Ophthalmology
|
| 13.06.01 |
Erythromycin 40mg + Zinc acetate 12mg/mL topical solution Zineryt® |
Provider notes
- NMUH:
- RFL:
- Restricted to Dermatology
- RNOH:
- UCLH:
- WH:
|
| 04.03.03 |
Escitalopram |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- CIFT approvals:
- Social Anxiety Disorder - if other SSRIs are not appropriate
- Depression
- BEHMT approvals:
|
| 02.04 |
Esmolol |
Provider notes - NMUH:
- Only 100mg/10ml vials are kept at NMUHT.
- RFL:
- Restricted to ITU, cardiology and theatres only.
- RNOH:
- UCLH:
- WH:
|
| 01.03.05 |
Esomeprazole |
Provider notes
- NMUH:
- RFL:
- RFH: Non-formulary
- BCF: No restriction stated (historical use)
- RNOH:
- UCLH:
- WH:
|
| 06.04.01.01 |
Estradiol Zumenon® |
Provider notes |
| 06.04.01.01 |
Estradiol Elleste-Solo® |
Provider notes |
| 07.02.01 |
Estradiol 10mcg vaginal tablet Vagifem® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Severe vulvar and vaginal atrophy in patients with a history of breast cancer
|
| 07.02.01 |
Estradiol 7.5mcg /24hrs 7.5 microgram/24 hours vaginal delivery system Estring® |
Provider notes |
| 06.04.01.01 |
Estradiol gel Oestrogel® |
Approved as hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women (JFC September 2018). Provider notes - NMUH:
- RFL:
- Restricted to the menopause clinic only
- RNOH:
- UCLH:
- WH:
|
| 06.04.01.01 |
Estradiol patch Evorel®, FemSeven®, Estradot®, Estraderm MX®, Progynova TS® |
Provider notes
- NMUH:
- RFL:
- Evorel available, use other brands if shortage of Evorel
- RNOH:
- UCLH:
- WH:
- Evorel 50 micrograms/24 hours,100 micrograms/24 hours ONLY. For patients requiring 25 micrograms of estradiol per day, the Evorel 50 micrograms patch may be cut in half.
|
| 06.04.01.01 |
Estradiol with Dydrogesterone Femoston-Conti® |
Provider notes
- NMUH:
- RFL:
- Femoston-Conti 1/5 available
- RNOH:
- UCLH:
- WH:
|
| 06.04.01.01 |
Estradiol with Dydrogesterone Femoston® |
Provider notes
- NMUH:
- RFL:
- Femoston 1/10 and 2/10 available
- RNOH:
- UCLH:
- WH:
- Femoston 1/10 tablets available
|
| 06.04.01.01 |
Estradiol with Levonorgestrel patch FemSeven® Conti |
Provider notes |
| 06.04.01.01 |
Estradiol with Levonorgestrel patch FemSeven® Sequi |
Provider notes |
| 06.04.01.01 |
Estradiol with Norethisterone Climesse® |
Provider notes |
| 06.04.01.01 |
Estradiol with Norethisterone Kliofem® |
Provider notes |
| 06.04.01.01 |
Estradiol with Norethisterone Kliovance® |
Provider notes |
| 06.04.01.01 |
Estradiol with Norethisterone patch Evorel® Sequi |
Provider notes |
| 06.04.01.01 |
Estradiol with Norethisterone patch Evorel® Conti |
Provider notes |
| 07.02.01 |
Estriol 0.01% vaginal cream |
Provider notes
- NMUH:
- RFL:
- For Gynae (HRT) and Paediatrics (labial adhesions) only
- RNOH:
- UCLH:
- WH:
|
| 07.02.01 |
Estriol 1mg/1g vaginal cream Ovestin® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Etanercept |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
JFC approved Benepali as the brand of choice.
Approved for:
- Rheumatoid arthritis in line with the NCL RA pathway
- Juvenile Idiopathic Arthritis (JIA; see NICE TAs below)
- Ankylosing spondylitis (see NICE TAs below)
- Psoriatic Arthritis (PsA; see NICE TAs below)
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- Restricted to Consultant Rheumatologists
- See MHRA Drug Safety Update
- See links below
- RFL:
- Approved for use in Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis in line with NICE guidance
- RNOH:
- Rheumatology Consultants ONLY
- Please prescribe by brand name Benepali or Enbrel - patients requiring 50 mg should be prescribed Benepali and patients requiring 25 mg should be prescribed Enbrel
- See links below
- UCLH:
- WH:
|
| 13.05.03 |
Etanercept |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
JFC approved Benepali as the brand of choice.
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Restricted to Consultant Dermatologists
- Check MHRA safety updates.
- See links below.
- RFL:
- Approved for use in the treatment of Psoriasis in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
| 16.01 |
Etanercept |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
JFC approved Benepali as the brand of choice.
Provider notes
- NMUH:
- RFL:
- National Amyloidosis Clinic use only
- Approved for:
- TRAPS, HIDS
- For use in other amyloidosis indications, contact pharmacy.
- RNOH:
- UCLH:
- WH:
|
| 09.05.01.02 |
Etelcalcetide |
Provider notes
- NMUH:
- RFL:
- Restricted to ‘etelcalcetide gatekeeper’ approval only for secondary hyperparathyroidism – see NICE TA
- RNOH:
- UCLH:
- WH:
|
| 05.01.09 |
Ethambutol |
Provider notes
- NMUH:
- No restriction stated (suspension 400mg/5ml [unlicensed] is available for the treatment of tuberculosis in children)
- RFL:
- For treatment of tuberculosis only
- RNOH:
- Microbiologist approval only
- UCLH:
- WH:
|
| 06.04.01.01 |
Ethinylestradiol |
Provider notes |
| 08.03.01 |
Ethinylestradiol |
Provider notes |
| 07.03.01 |
Ethinylestradiol / levonorgestrel phased pill 21-days TriRegol®, Logynon® |
Provider notes - NMUH:
- Preferred brand = Logynon
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.01 |
Ethinylestradiol / levonorgestrel phased pill 28-days Logynon ED® |
Provider notes |
| 07.03.01 |
Ethinylestradiol 20 mcg / norethisterone 1mg pill 21-days Loestrin 20® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.01 |
Ethinylestradiol 20mcg / desogestrel 150mcg pill 21-days Bimizza®, Gedarel 20/150®, Mercilon®, Munalea 20/150® |
Provider notes
- NMUH:
- Restricted to Consultants in GU Medicine ONLY = Gedarel 20/150
- Preferred brand for Obs & Gynae = Mercilon
- RFL:
- Preferred brand = Munalea
- RNOH:
- UCLH:
- WH:
- Preferred brand = Mercilon
- The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
|
| 07.03.01 |
Ethinylestradiol 20mcg / gestodene 75 mcg pill 21-days Aidulan 20/75®, Femodette®, Millinette 20/75®, Sunya® |
Provider notes
- NMUH:
- Preferred brand = Millinette 20/75
- Millinette 20/75 is restricted to Consultants in GU Medicine ONLY
- RFL:
- Preferred brand = Aidulan
- RNOH:
- UCLH:
- WH:
|
| 07.03.01 |
Ethinylestradiol 30 mcg / drospirenone 3 mg pill 21-days Lucette®, Yasmin®, Yiznell®, other brands available |
Not approved for oral contraception (JFC, February 2016)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.01 |
Ethinylestradiol 30 mcg / norethisterone 1.5mg pill 21-days Loestrin 30® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.01 |
Ethinylestradiol 30mcg / desogestrel 150mcg pill 21-days Gedarel 30/150®, Marvelon®, Munalea 30/150®, other brands available |
Provider notes
- NMUH:
- Restricted to Consultants in GU Medicine ONLY = Gedarel 30/150
- Preferred brand for Obs & Gynae = Marvelon
- RFL:
- RNOH:
- UCLH:
- WH:
- Preferred brand = Marvelon
- The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
|
| 07.03.01 |
Ethinylestradiol 30mcg / gestodene 75 mcg pill 21-days Aidulan 30/75®, Femodene®, Katya®, other brands available |
Provider notes
- NMUH:
- Restricted to Consultants in GU Medicine ONLY = Millinette 30/75
- Preferred brand for Obs & Gynae = Femodene
- RFL:
- Preferred brand = Aidulan
- RNOH:
- UCLH:
- WH:
- Preferred brands = Femodene
- Millinette 30/75= for Community Clinics ONLY
- The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
|
| 07.03.01 |
Ethinylestradiol 30mcg / levonorgestrel 150mcg pill 21-days Microgynon 30®, Rigevidon®, Maexeni®, other brands available |
Provider notes
- NMUH:
- Restricted to GU Medicine ONLY = Rigevidon
- For Obs & Gynae = Microgynon 30
- RFL:
- Preferred brands = Maexeni, Rigevidon, Microgynon 30
- RNOH:
- UCLH:
- WH:
- Preferred brand = Microgynon 30
- Rigevidon= Formulary item for Community Trust
|
| 07.03.01 |
Ethinylestradiol 30mcg / levonorgestrel 150mcg pill 28-days Microgynon 30 ED® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.01 |
Ethinylestradiol 35 mcg / norgestimate 250 mcg pill 21-day Cilique®, Cilest®, Lizinna® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- There is insufficient information to know if there is an increased risk associated with norgestimate.
|
| 04.08.01 |
Ethosuximide |
Provider notes |
| 15.02 |
Ethyl Chloride Cryogesic® Spray |
econdary care notes |
| 07.06 |
Etilefrine |
Provider notes - NMUH:
- For treatment of priapism in patients with sickle cell disease
- Etilefrine 25mg Tablets, available from ‘special-order’ manufacturers or specialist importing companies
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 10.01.01 |
Etodolac |
Provider notes - NMUH:
- Restricted to use by Rheumatology Consultants only
- RFL:
- Restricted to use by Rheumatology only
- RNOH:
- UCLH:
- WH:
- Restricted to Rheumatology only
|
| 10.01.01 |
Etodolac modified release |
Provider notes
- NMUH:
- Restricted to use by Rheumatology Consultants only
- RFL:
- Restricted to use by Rheumatology only
- RNOH:
- UCLH:
- WH:
- Restricted to Rheumatology only
|
| 15.01.01 |
Etomidate Etomidate-Lipuro® |
Provider notes |
| 15.01.01 |
Etomidate Hypnomidate® |
Provider notes |
| 07.03.02.02 |
Etonogestrel 68mg subdermal implant Nexplanon® |
Second-choice parenteral progestogen-only contraceptive (JFC July 2019)
Provider notes
- NMUH:
- Restricted to Consultants in GU Medicine ONLY.
- Check for MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.04 |
Etoposide |
Provider notes - NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 10.01.01 |
Etoricoxib |
Provider notes
- NMUH:
- Non-formulary
- Check MHRA Drug Safety Updates
- RFL:
- Restricted to use by Rheumatology only
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Etravirine |
Provider notes
- NMUH:
- To be prescribed as per BHIVA Guidelines by the HIV team only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
Eucerin ® Intensive cream/lotion Urea 10% |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Everolimus Votubia® |
DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS.
Approved for:
- renal angiomyoplipomas who are at risk of complications but who do not require immediate surgery, and is reserved for patients with multiple AMLs in one or both kidneys and one or more lesions of >3cm in diameter. Restricted to renal consultants in renal genetics specialist clinic only (JFC July 2013)
- refractory focal onset seizures associated with tuberous sclerosis complex (TSC) in line with NHS England Commissioning Policy (JFC June 2019)
Provider notes
- NMUH:
- RFL:
- Approved for renal angiomyoplipomas (see above and NHSE Commissioning Policy)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Everolimus Afinitor® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS See NICE TA for eligibility criteriaProvider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
- TA432, 449 and 498 do not apply at NMUH as services not offered.
- See links below
- RFL:
- As per NICE guidance (see below)
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 02.12 |
Evolocumab |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed on the recommendation of Consultant Cardiologists and Endocrinologists ONLY
- See links below
- RFL:
- As per NICE guidance
- Restricted to Lipid Clinic
- Prescriptions are supplied monthly for first 4 months then 3 monthly. Homecare service also available
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.01 |
Exemestane |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- RFL:
- RNOH:
- UCLH:
- WH:
- Exemestane is indicated for 3rd line treatment (after tamoxifen and anastrazole) in post-menopausal women with metastatic breast cancer
|
| 02.12 |
Ezetimibe |
Primary hypercholesterolaemia where a statin is contraindicated, not tolerated (consider referral to lipid specialist) or as an adjunct where high-intensity statins have failed to sufficiently reduce cholesterol levels
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- See indication above and NICE TA
- RNOH:
- UCLH:
- WH:
- The use of ezetimibe is reserved as a 3rd line agent where treatment with simvastatin, and then atorvastatin has failed, and for patients for whom the use of a statin is contraindicated, or who are statin intolerant, in accordance with the NICE guidance.
|
| 02.11 |
Factor IX |
Provider notes - NMUH:
- RFL:
- Available from the haemophilia centre
- Alphanine®, Alprolix® (eftrenonacog alfa), Benefix® (nonacog alfa), Idelvion® (albutrepenonacog alfa), Refixia® (nonacog beta pegol)
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Factor VIIa, recombinant Novo 7® |
Provider notes
- NMUH:
- RFL:
- Available from the haemophilia centre
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Factor VIII |
Provider notes - NMUH:
- PbR (Payment by Results) excluded drug
- RFL:
- Available from the Haemophilia centre
- Advate® (octocog alfa), Elocta® (efmoroctocog alfa), Fanhdi®, Fibrogammin®, Helixate Nexgen® (octocog alfa), Kogenate® (octocog alfa), Novoeight®, Optivate®, Refacto AF® (moroctocog alfa)
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Factor VIII + von Willebrand factor |
Provider notes - NMUH:
- RFL:
- Available through the haemophilia centre
- Voncento®, Wilate®, Haemate P®
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Factor VIII Inhibitor Bypassing Fraction |
Provider notes - NMUH:
- RFL:
- Available through the haemophilia centre
- Feiba®
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Factor VIII, recombinant Susoctocog alfa; Obizur® |
Provider notes
- NMUH:
- RFL:
- Approved for acquired haemophilia A in line with NHSE clinical commissioning policy 170061P (RFL only; JFC November 2018)
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Factor X Coagadex® |
Provider notes - NMUH:
- RFL:
- Available from the haemphilia centre
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Factor XI Hemoleven® |
Provider notes - NMUH:
- RFL:
- Available from the Haemphilia centre
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Factor XIII Fraction, Dried |
Provider notes
- NMUH:
- RFL:
- Available from the haemophilia centre
- RNOH:
- UCLH:
- WH:
|
| 05.03.02.01 |
Famciclovir |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- For Microbiology use only
|
| 10.01.04 |
Febuxostat |
Provider notes
- NMUH:
- This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Restricted to Consultant Rheumatologists or under the direction of a Consultant Rheumatologist.
- Access Trust guideline via intranet
- RFL:
- Restricted to Consultant Rheumatologists in line with NICE TA
- RNOH:
- UCLH:
- WH:
|
| 10.03.02 |
Felbinac 3% gel |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to the Rheumatology team ONLY
- Available over the counter without a prescription
|
| 02.06.02 |
Felodipine |
Provider notes |
| 14.04 |
Fendrix® Hepatitis B vaccine Single Component |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.12 |
Fenofibrate |
Provider notes - NMUH:
- RFL:
- Restricted to Lipid Clinic
- RNOH:
- UCLH:
- WH:
|
| 15.01.04.03 |
Fentanyl |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Restricted Only on the recommendation of the Pain Team for patients intolerant to or with contraindications to morphine and oxycodone
- UCLH:
- WH:
|
| 04.07.02 |
Fentanyl buccal tablets Effentora® |
Provider notes
- NMUH:
- RFL:
- Approved for the pallative care and pain management team only
- RNOH:
- Only on the recommendation of the Pain Team for inpatients intolerant to or with contraindications to morphine and oxycodone. Not to be prescribed on discharge.
- UCLH:
- WH:
|
| 04.07.02 |
Fentanyl patch |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 21.01 |
Fentanyl patch |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Fentanyl patch for acute post-operative pain in primary knee replacement surgery
30 patient evaluation at RNOH site only. Evaluation to be reviewed at JFC (April 2015) |
| 04.07.02 |
Fentanyl sublingual tablets Abstral® |
Approved for the treatment of breakthrough, chronic, cancer pain in palliative patients taking opioid agonists, who are unable to obtain relief from, or are intolerant to, oral morphine and oxycodone immediate release. Pain or Palliative Care recommendation only (JFC September 2018).
Provider notes
- NMUH:
- Restricted to haematology and palliative care teams only
- RFL:
- Approved for the palliative care and pain management team only
- RNOH:
- UCLH:
- WH:
|
| 09.01.01.02 |
Ferric Carboxymaltose Ferinject® |
See local guidance for iron replacement
Approved for:
- Iron deficient anaemia in Obstetrics (January 2017)
- Iron deficient anaemia in adult outpatients only, not in patients in first trimester of pregnancy or for patient on haemodialysis (March 2017)
Provider notes
- NMUH:
- To be used for day case patients and out patients ONLY
- See link below for parenteral irons prescribing guideline.
- Ferinject must be prescribed on the specific Daycase Ferinject prescription form; see link below
- Note: Parenteral iron is contraindicated in the first trimester of pregnancy. For dose of Ferinject in patients with haemodialysis dependent chronic kidney disease, refer to the summary of prouct characteristics.
- Check MHRA Drug Safety updates
- RFL:
- Approved for use in private patients at RFL
- Approved for use in renal and liver patients at RFH
- RNOH:
- For the optimisation of pre-operative anaemia in patients aged 14 to 17 years.
- UCLH:
- Restricted to outpatients / daycase / facilitate inpatient discharge
- WH:
- Parenteral iron should only be considered if oral therapy has failed due to lack of patient co-operation, severe gastrointestinal side effects, continuing severe blood loss or malabsorption. Provided oral therapy is taken reliably and is absorbed, then the haemoglobin response is not significantly faster with the parenteral route.
|
| 09.01.01.02 |
Ferric derisomaltose (previously iron isomaltoside) Monofer® |
See local guidance for iron replacement
Provider notes
- NMUH:
- Check MHRA Drug Safety update
- RFL:
- First-choice of fast infusion product (excluding renal)
- Available to all patient groups at BH and CFH.
- Restricted to specific patient groups at RFH:
- For patients who would otherwise require multiple iron infusions, and there is a documented reason why multiple infusions would impact on patient’s quality of life
- For patients on 2NA in whom a shorter duration iron infusion is indicated, and there is documented reason why a longer infusion would impact on patient’s quality of life
- For patients in whom there is an URGENT need for IV iron e.g. patients planned for Theatre, or for pregnancy
- For patients on a cancer pathway to enable cancer treatment to proceed
- For patients with disabling anaemia who require urgent correction of Hb levels, based on clinical symptoms/clinical need (patient-specific need)
- For patients who have experienced serious / life-threatening allergies or adverse events to other IV iron products
- RNOH:
- For the optimisation of pre-operative anaemia in accordance with local guideline. Oral iron must be used where surgery is not urgent
- UCLH:
- WH:
|
| 17 |
Ferric subsulphate solution Monsels |
Approved as a haemostatic agent in colposcopy (JFC January 2019)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.01.01.01 |
Ferrous fumarate |
Provider notes - NMUH:
- No restriction stated (not Galfer)
- RFL:
- RNOH:
- Oral syrup available as 140 mg/5mL
- UCLH:
- WH:
- Oral syrup available as 140 mg/5mL (ONLY formulation available)
|
| 09.01.01.01 |
Ferrous fumarate + Folic acid Pregaday® |
Provider notes |
| 09.01.01.01 |
Ferrous gluconate |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Ferrous gluconate contains a lower content of elemental iron and therefore may be better tolerated than ferrous sulphate.
|
| 09.01.01.01 |
Ferrous sulphate |
Provider notes - NMUH:
- RFL:
- RNOH:
- First choice for iron-deficiency anaemia
- UCLH:
- WH:
|
| 09.01.01.01 |
Ferrous sulphate modified release Ferrograd® |
Provider notes |
| 03.04.01 |
Fexofenadine |
Additionally approved for the treatment of chronic spontaneous urticaria at a 'high dose' for patients who do not respond to 'high dose' cetirizine (JFC November 2018). Notes: initiate at 180mg daily and increase according to response to a maximum of 360mg twice-daily (720mg daily).
Provider notes
- NMUH:
- As per indication stated above
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 17.01 |
Fibrin Sealant Evicel® |
Approved for Dura matter closure (July 2015)
Provider notes
- RNOH:
- Restricted for soft tissue sarcoma surgery, primary bone tumour surgery, complex revision hip and knee surgery and dura mater closure
- RFL:
|
| 17.01 |
Fibrin Sealant Tisseel® Ready to Use |
Provider notes
- NMUH:
- RFL:
- For use in Vascular / Opthalmology surgery
- RNOH:
- UCLH:
- WH:
- MEH approvals:
- Approved for conjunctival surgery in preference to sutures for pterygium surgery (January 2013)
|
| 05.01.07 |
Fidaxomicin |
Consultant microbiologist approval only for multiple recurrent Clostridium difficile infections (at least three). Fidaxomicin could also be used in patients in extremis when all other drugs had failed (October 2012)
Provider notes
- NMUH:
- Microbiology approval only
- RFL:
- Consultant microbiologist approval only
- RNOH:
- Microbiology approval only
- UCLH:
- WH:
- Microbiology approval only
|
| 09.01.06 |
Filgrastim |
Provider notes
- NMUH:
- Zarzio® is the preferred brand
- Check MHRA Drugs Safety Alerts
- See link below
- RFL:
- Accofil® is the preferred brand (from June 2019)
- RNOH:
- Requires HAEMATOLOGIST approval
- Store in a refrigerator
- UCLH:
- WH:
|
| 06.04.02 |
Finasteride |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- Restricted to Urology use only
- RFL:
- RNOH:
- UCLH:
- WH:
- Finasteride should be initiated by urology only for the treatment of patients with BPH in whom alpha-blockers have failed.
|
| 08.02.04 |
Fingolimod |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- Check MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.03.02 |
Flecainide |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 04.07.03 |
Flecainide |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 21.01 |
Florbetapir F 18 injection |
Amyvid (florbetapir) for Alzheimer's disease
10 patient evaluation at RFL site only. Evaluation to be reviewed at JFC (JFC September 2014 and February 2015) |
| 17.01 |
Flowable haemostatic agent with thrombin Surgiflo® |
Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016) |
| 17.01 |
Flowable haemostatic agent with thrombin Floseal® |
Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016)
Provider notes
|
| 13.04 |
Flucinolone Acetonide 0.0025% - Topical Synalar 1 in 10 Dilution® |
Provider notes |
| 05.01.01.02 |
Flucloxacillin |
Provider notes |
| 05.02 |
Fluconazole |
Provider notes - NMUH:
- Infusion restricted to Microbiology Consultants use only
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted antifungal. Microbiology approval only
|
| 05.02 |
Flucytosine infusion |
Provider notes
- NMUH:
- Restricted to Microbiology Consultants use only
- RFL:
- Microbiology / ID approval required
- RNOH:
- UCLH:
- WH:
- Microbiology approval only
|
| 05.02 |
Flucytosine tablets |
Provider notes
- NMUH:
- RFL:
- Microbiology / ID approval required
- RNOH:
- UCLH:
- WH:
|
| 08.01.03 |
Fludarabine |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- RFL:
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 06.03.01 |
Fludrocortisone |
Provider notes |
| 13.04 |
Fludroxycortide - topical Haelan® |
Provider notes - NMUH:
- Haelan tape is FORMULARY, for use on keloid scars only.
- Haelan cream and Haelan ointment are NON-FORMULARY.
- RFL:
- Restricted to Dermatologists only
- RNOH:
- UCLH:
- WH:
|
| 15.01.07 |
Flumazenil |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Flumazenil is used to reverse the sedative effects of benzodiazepines in anaesthetic, intensive care and diagnostic procedures. It should not be used for routine benzodiazepine reversal. It has a shorter half-life than diazepam and midazolam and care is required to avoid the risk of resedation.
|
| 12.01.01 |
Flumetasone 0.02% + Clioquinol 1% ear drops Locorten-Vioform® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Fluocinolone acetonide 0.00625% - Topical Synalar 1 in 4 Dilution® |
Provider notes |
| 13.04 |
Fluocinolone acetonide 0.025% - Topical Synalar® |
Provider notes - NMUH:
- RFL:
- Cream, ointment and gel available
- RNOH:
- UCLH:
- WH:
- Gel 0.025% (Synalar) 30g ONLY
|
| 13.04 |
Fluocinolone acetonide 0.025% + Clioquinol 3%- Topical Synalar C® |
Provider notes - NMUH:
- RFL:
- Cream and Ointment available
- RNOH:
- UCLH:
- WH:
|
| 11.04.01 |
Fluocinolone acetonide intravitreal implant Iluvien® |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
- See links below
- RFL:
- Approved for diabetic macular oedema in line with NICE TA (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
- For Diabetic macular oedema after an inadequate response to prior therapy (Nov 2013 TA301)
|
| 13.04 |
Fluocinonide 0.05% - Topical Metosyn® |
Provider notes - NMUH:
- RFL:
- cream and ointment available
- RNOH:
- UCLH:
- WH:
|
| 11.08.02 |
Fluorescein eye drops - unit dose |
Provider notes
- NMUH:
- RFL:
- Approved for diagnostic examinations (2% single-use drops)
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
FluorEscein injection |
Provider notes
- NMUH:
- RFL:
- Approve for ophthalmic angiography, e.g. examination of fundus and iris vasculature, sclera and episclera (10% & 20% available)
- RNOH:
- UCLH:
- WH:
|
| 11.08.02 |
Fluorescein paper strips 1mg |
Provider notes |
| 09.05.03 |
Fluorides En-De-Kay® Tablet |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- For Islington Community Only - direct ward delivery
|
| 09.05.03 |
Fluorides En-De-Kay® Oral Drops |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- For Islington community only
|
| 09.05.03 |
Fluorides Duraphat® Toothpaste |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- 0.619% toothpaste available for Simmons House and Islington community clinics only
|
| 17.02 |
Fluorocholine-18F |
Provider notes - RFL:
- PETC/CT imaging for staging of prostate cancer (RFL only, September 2013)
|
| 11.04.01 |
Fluorometholone 0.1% eye drops FML® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.08.01 |
Fluorouracil 0.5% + Salicylic acid 10% solution Actikerall® |
Provider notes
- NMUH:
- RFL:
- Restricted to dermatology
- RNOH:
- UCLH:
- WH:
|
| 11.99.99.99 |
Fluorouracil 10mg in 0.2mL injection |
Provider notes
- NMUH:
- RFL:
- Approved for glaucoma surgery, post-trabeculectomy, reduce scarring post-op (specialist use only)
- RNOH:
- UCLH:
- WH:
|
| 13.08.01 |
Fluorouracil 5% cream Efudix® |
Provider notes
- NMUH:
- RFL:
- Restricted to Dermatology only
- RNOH:
- UCLH:
- WH:
|
| 08.01.03 |
Fluorouracil injection |
Provider notes - NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 04.03.03 |
Fluoxetine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Caps 20mg. Liquid 20mg/5ml. Only
- CIFT:
- Approved for
- Depression
- Generalized Anxiety Disorder (GAD) and panic disorder - 1st/2nd line
- Social Anxiety Disorder (SAD) - 1st/2nd line
- BEHMT:
- Approved for
- Depression
- Obsessive-compulsive disorder
- Bulimia nervosa
|
| 04.02.02 |
Flupentixol decanoate depot injection Depixol® Conc. |
Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- Restricted for initiation by a Consultant Psychiatrist only
|
| 04.02.02 |
Flupentixol decanoate depot injection Depixol® Low Volume |
Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- Restricted for initiation by a Consultant Psychiatrist only
|
| 04.02.02 |
Flupentixol decanoate depot injection Depixol® |
Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- Restricted for initiation by a Consultant Psychiatrist only
|
| 04.02.01 |
Flupentixol tab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
|
| 04.03.04 |
Flupentixol tab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- CIFT:
- BEHMT approvals:
|
| 04.02.02 |
Fluphenazine decanoate depot injection Modecate® |
Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- Restricted for initiation by a Consultant Psychiatrist only
|
| 04.02.02 |
Fluphenazine decanoate depot injection Modecate Concentrate® |
Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- Restricted for initiation by a Consultant Psychiatrist only
|
| 08.03.04.02 |
Flutamide |
Provider notes - NMUH:
- Restricted to Consultant Oncologist and Urologist use only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Fluticasone furoate + Umeclidinium + Vilanterol inhaler (DPI) Trelegy® |
Approved for COPD when ICS + LAMA + LABA inhalation therapy is indicated, as per NICE guidance (JFC September 2019)
Provider notes
- NMUH:
- As per recommendations above
- RFL:
- As per NICE & NCL JFC recommendations
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Fluticasone furoate + Vilanterol inhaler (DPI) Relvar Ellipta® |
Approved for:
- COPD (JFC February 2017)
- Asthma (JFC May 2017)
- Adolescent asthma; age 12-19 (JFC May 2019)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 12.02.01 |
Fluticasone furoate 27.5mcg/spray nasal spray |
Provider notes - NMUH:
- Restricted for use in paediatric patients ONLY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.10 |
Fluticasone inhaler (DPI) |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved as first-line choice (before budesonide nasules) for eosinophilic oesophagitis in adults. Fluticasone Accuhaler (dry powder inhaler) '250' should be sucked 1-2 doses twice daily and down titrate dose for maintenance dosing (JFC February 2018)
Provider notes
- NMUH:
- RFL:
- See local policy for information on use
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Fluticasone inhaler (pMDI + DPI) Flixotide® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Restricted to Paediatric Consultants use only.
- RFL:
- pMDI and Accuhaler available
- RNOH:
- For continuation of therapy
- UCLH:
- WH:
- Turbohalers, Accu-halers and Autohalers are reserved for unable to tolerate an MDI with a spacing device.
- 50 micrograms, 125 micrograms, 250 micrograms/metered inhalation CFC-Free (Flixotide Evohaler) & Accu- haler 500 micrograms/ metered inhalation ONLY
|
| 13.04 |
Fluticasone propionate - Topical Cutivate® |
Provider notes - NMUH:
- RFL:
- Restricted to paediatrics only.
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Fluticasone propionate + Formoterol inhaler (pMDI) Flutiform® |
Approved for asthma requiring a combined ICS/LABA (May 2013)
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Fluticasone propionate + Salmeterol inhaler (DPI) AirFluSal Forspiro® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 03.02 |
Fluticasone propionate + Salmeterol inhaler (pMDI + DPI) Sirdupla®, Seretide® |
Provider notes - NMUH:
- See links below
- Seretide 125 & 250 Evohalers and are NON-FORMULARY, except in paediatric patients.
- Seretide 500 is non-formulary. AirFlusal Fospiro 50/500 should be used instead. See link below for further information.
- RFL:
- RNOH:
- UCLH:
- WH:
- Approved for prescribing by Respiratory Team only. All pharmacists must ensure inpatients have been reviewed by Respiratory Nurse Specialist before supplying prior to prescribing.
|
| 12.02.01 |
Fluticasone propionate 400mcg/unit nasal drops |
Provider notes |
| 12.02.01 |
Fluticasone propionate 50mcg/spray nasal spray |
Provider notes |
| 12.04 |
Fluticasone propionate nasules / nasal spray |
Approved for Oral lichen planus after failure of betamethasone (JFC June 2017)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Indicated for oral linchen planus (OLP) only
|
| 04.03.03 |
Fluvoxamine maleate |
Provider notes
- NMUH:
- RFL:
- BCF: No restriction stated
- RFH: Non-formulary
- RNOH:
- UCLH:
- WH:
- CIFT:
- BEHMT
|
| 09.01.02 |
Folic Acid |
Provider notes
- NMUH:
- RFL:
- No restriction stated
- When used in combination with oral methotrexate various regimens are used from once-weekly, twice-weekly to daily use (except on day of methotrexate)
- RNOH:
- UCLH:
- WH:
- Folic acid is indicated in confirmed folate deficiency due to dietary lack, gastrointestinal disease, pregnancy, chronic haemolytic states, myeloproliferative disorders, haemodialysis, and parenteral nutrition, intensive care of the very sick patient or in premature infants. Folic acid can be used to correct serious haematological changes caused by dihydrofolate reductase inhibitors (DFRIs), after the DFRI has been discontinued. Examples of DFRIs include trimethoprim and co-trimoxazole.
- Before treating megaloblastic anaemia with folic acid alone, vitamin B12 deficiency MUST be excluded. Folic acid may relieve the haematological features of vitamin B12 deficiency and allow neuropathy to develop undetected. If treatment must be started immediately, both folic acid and hydroxocobalamin should be given.
|
| 08.01.05 |
Folinic acid + fluorouracil + irinotecan (FOLFIRI) |
Approved for: - 2nd / 3rd line treatment of inoperable gasto-oesophageal adenocarcinoma (May 2015)
- 2nd line for high grade neuroendocrine tumour (March 2016)
Provider notes |
| 08.01.05 |
Folinic acid + fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) |
Approved for 1st line treatment of unresectable metastatic colorectal cancer (May 2015) Provider notes |
| 08.01.05 |
Folinic acid + fluorouracil + oxaliplatin + irinotecan (mFOLFIRINOX) |
Approved adjuvant treatment of pancreatic cancer (JFC September 2018)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.08.01 |
Fondaparinux |
Provider notes
- NMUH:
- Restricted to use for patients with Unstable Angina / NSTEMI.
- See Trust Guideline on use
- RFL:
- Restricted to use for patients with Unstable Angina / NSTEMI
- RNOH:
- UCLH:
- WH:
- Restricted for use in unstable angina and NSTMEI
|
| A2.02.02.03 |
Foodlink Complete Powder |
- Sachets - requires a patient to be able to mix with full-fat milk
- Chocolate, strawberry, banana, natural
- Gluten-free
- Suitable for vegetarians
- May not be appropriate in the following patients
- Patients requiring complete nutrition e.g. reliant entirely on supplements, patients requiring enteral feeding
- Renal patients (CKD stage 4 and 5)
- Vegans and patients with lactose intolerance
Provider notes
Non-formulary
Primary care notes
First-choice product - see Primary Care Guidance |
| 03.01.01.01 |
Formoterol fumarate inhaler (DPI) Oxis® Turbohaler |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Turbohalers, Accuhalers and Autohalers are reserved for patients unable to tolerate an MDI with spacing device.
|
| A2.02.02.03 |
Forticreme Complete |
Provider notes - NMUH:
- Stroke, Dysphagia, fluid restrictions, CAPD, HD, Disease related malnutrition, short bowel syndrome, Intractable malabsorption, pre-operative preparation for those who are malnourished, inflammatory bowel disease, total gastrectomy, bowel fistulae, dysphagiaSemi-solid. High in protein. For dysphagia or requiring a soft diet, tolerating low volume of food
- RFL:
- RNOH:
- UCLH:
- WH:
|
| A2.02.02.03 |
Fortisip Compact Protein |
Provider notes |
| 05.03.01 |
Fosamprenavir |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.10.03 |
Foscarnet sodium 2% cream |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.03.02.02 |
Foscarnet sodium IV |
Provider notes - NMUH:
- Restricted for HIV patients use only.
- RFL:
- Restricted to HIV; Transplant patients; Haematology; Oncology
- Virology approval required for all other indications
- RNOH:
- UCLH:
- WH:
|
| 05.01.07 |
Fosfomycin intravenous |
Microbiology approval only for treatment of infections, or suspected infections, caused by multi-drug resistant Gram-negative organisms, including ESBLs (JFC August 2016)
Provider notes
- NMUH:
- Should only be prescribed following advice from a Consultant Microbiologist
- RFL:
- Consultant Microbiology/ID approval only
- RNOH:
- UCLH:
- WH:
- Microbiology approval only
|
| 05.01.07 |
Fosfomycin oral sachets |
Approved for prescribing in primary and secondary care for symptomatic UTI sensitive to fosfomycin, where patients are unable to receive, or the organism is resistant to, first-line antibiotics (July 2015)
Provider notes
- NMUH:
- Consultant Microbiology approval only
- RFL:
- See Microguide for approved indications
- Microbiology/ID approval required for all other indications
- RNOH:
- Microbiology approval only
- UCLH:
- WH:
- Microbiology approval only
|
| 08.03.04.01 |
Fulvestrant |
Approved as third-line therapy for locally advanced or metastatic HER2-, ER+ breast cancer in postmenopausal women without symptomatic visceral disease, that has recurred or progressed after a non-steroidal aromatase inhibitor and tamoxifen (JFC February 2016).
Provider notes
- NMUH:
- To be prescribed by Oncology Consultants ONLY
- See indication above and NICE TA593
- RFL:
- Approved as per above
- Approved as per NICE TA593 in combination with ribociclib
- Approved as per NICE TA579 in combination with abemaciclib
- RNOH:
- UCLH:
- WH:
|
| 02.02.02 |
Furosemide |
Provider notes |
| 11.03.01 |
Fusidic Acid 1% gel |
Provider notes
- NMUH:
- RFL:
- Approved for Staph aureus eye infections
- RNOH:
- UCLH:
- WH:
- Restricted to Paediatrics and Ophthalmology out-patients
|
| 04.07.03 |
Gabapentin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Second choice agent for neuropathic pain after first-line amitriptyline.
Provider notes
- NMUH:
- See Trust guideline via intranet for more information
- RFL:
- RNOH:
- Second choice agent for neuropathic pain
- UCLH:
- WH:
- Second choice agent for neuropathic pain; also for orthopaedics - post surgery
|
| 04.08.01 |
Gabapentin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Neurology initiation and continuation only
- RNOH:
- UCLH:
- WH:
- Should only be commenced on the recommendation of a Neurologist
- Neurontin available as 100mg and 300mg capsules
|
| 04.11 |
Galantamine |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- See link below
- Supply only to be made for CONTINUATION OF THERAPY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.11 |
Galantamine modified release |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- See link below
- Supply only to be made for CONTINUATION OF THERAPY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.08.01 |
Galsulfase |
Provider notes
- NMUH:
- RFL:
- Restricted to the lysosomal storage disorders unit
- RNOH:
- UCLH:
- WH:
|
| 11.03.03 |
Ganciclovir 0.15% ophthalmic gel |
Provider notes
- NMUH:
- RFL:
- Approved for herpes simplex keratitis (2nd line, after aciclovir)
- RNOH:
- UCLH:
- WH:
|
| 11.03.03 |
Ganciclovir 4mg/0.08mL intravitreal injection |
Provider notes
- NMUH:
- RFL:
- Approved for CMV retinitis (Ophthalmologist use only; prepared in Pharmacy CIVAS)
- RNOH:
- UCLH:
- WH:
- This is an unlicensed special and restricted to Ophthalmology
|
| 05.03.02.02 |
Ganciclovir IV |
Provider notes
- NMUH:
- RFL:
- Restricted to HIV; Transplants; Other immunosuppressed patients
- Virology approval required for all other indications
- RNOH:
- UCLH:
- WH:
|
| 05.03.02.02 |
Ganciclovir oral |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Microbiology
|
| 14.04 |
Gardasil® Human papilloma virus vaccine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
(hospital only prescribing) for PHE HPV vaccination programme for men who have sex with men (MSM)
for PHE HPV vaccination programme for adolescents in school year 8 (age 12-13 years)
Approved for HPV vaccination for MSM (men who have sex with men) in line with Public Health England national immunisation schedule. Restricted to GUM and HIV clinics (JFC September 2018).
Provider notes
- NMUH:
- Restricted to GUM and HIV clinics in line with PHE recommendations
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 21.01 |
Gardasil® Human papillomavirus vaccine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Recalcitrant warts
5 patient evaluation at RFL site only (JFC March 2013) |
| 01.01.02 |
Gastrocote® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.01.02 |
Gaviscon Advance® suspension |
Provider notes - NMUH:
- Gaviscon Advance Tablets are non-formulary and will not be stocked
- Gaviscon Advance suspension is formulary
- RFL:
- RNOH:
- UCLH:
- WH:
- Suspension only available
|
| 01.01.02 |
Gaviscon Infant® |
Provider notes |
| 08.01.05 |
Gefitinib |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by the Oncology Team ONLY.
- See links below
- RFL:
- Approved for non-small cell lung cancer in line with NICE
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
- Restricted to the treatment of NSCLC with EGFR mutation.
|
| 09.02.02.02 |
Gelatin intravenous infusion Gelaspan® |
Provider notes
- NMUH:
- RFL:
- BCF: No restriction stated
- RFH: Non-formulary
- RNOH:
- UCLH:
- WH:
|
| 09.02.02.02 |
Gelatin intravenous infusion Geloplasma® |
Provider notes |
| 09.02.02.02 |
Gelatin intravenous infusion Gelofusine® |
Provider notes
- NMUH:
- RFL:
- BCF: Non-formulary
- RFH: No restriction stated
- RNOH:
- UCLH:
- WH:
|
| 09.02.02.02 |
Gelatin intravenous infusion Volplex® |
Provider notes |
| 08.01.03 |
Gemcitabine |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- TA389 NOT APPLICABLE TO TRUST AS SERVICE IS NOT PROVIDED
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 11.03.01 |
Gentamicin 0.3% drops Ophthalmic |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Approved for bacterial keratitis (with preservative & preservative-free)
- Renal use - see PD antibiotic policies
- RNOH:
- UCLH:
- WH:
|
| 12.01.01 |
Gentamicin 0.3% drops Ear |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 11.03.01 |
Gentamicin Forte 1.5% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for bacterial keratitis (Ophthalmologist use only; with preservative & preservative-free)
- RNOH:
- UCLH:
- WH:
- Gentamicin Forte 1.5 % Eye Drops 10 ml Bottle and Gentamicin Forte WITHOUT PRESERVATIVE available
- These are unlicensed specials and restricted to Ophthalmology.
|
| 05.01.04 |
Gentamicin injection |
Provider notes
- NMUH:
- RFL:
- Refer to gentamicin prescribing guidelines in Microguide
- RNOH:
- Different brands of gentamicin 80mg in 2mL vials are stocked at RNOH
- The Amdipharm, Hospira and Sanofi brands are licensed for administration intramuscularly (IM) and intravenously (IV) and will be kept as stock in all ward areas.
- The Wockhardt brand is licensed for intravenous route (IV) only and will be stocked in Theatres only. This formulation must not be administered intramuscularly.
- UCLH:
- WH:
|
| 12.03.05 |
Glandosane® oral spray |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Glandosane may be prescribed by an accredited Speech and Language Therapist.
|
| 08.02.04 |
Glatiramer acetate |
Approve for relapsing-remitting multiple sclerosis in line with NHS England Commissioning (JFC Feb 2016).
Brabio® is the preferred brand.
Provider notes
- NMUH:
- RFL:
- Restricted to Neurology for MS in line with NICE TA
- RNOH:
- UCLH:
- WH:
- For relapsing-remitting multiple sclerosis, see above
|
| 05.03.03.02 |
Glecaprevir + Pibrentasvir |
Provider notes - NMUH:
- This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
- RFL:
- Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
| 06.01.02.01 |
Glibenclamide |
Withdrawn from the UK market (November 2019).
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Glibenclamide can cause profound hypoglycaemia, especially in the elderly
|
| 06.01.02.01 |
Gliclazide |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Gliclazide has been reported to cause less weight gain than other Sulphonylureas.
- Tolbutamide and Gliclazide are the drugs of choice in renal impairment.
- Tolbutamide is short acting. Gliclazide is longer acting and is principally metabolised and inactivated in the liver.
|
| 06.01.02.01 |
Glimepiride |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Glimepiride is available for supply on consultant signature only, for the treatment of overweight Type II diabetics, or those with compliance problems.
|
| 06.01.02.01 |
Glipizide |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.01.04 |
Glucagon GlucaGen® HypoKit |
Provider notes - NMUH:
- RFL:
- RNOH:
- For use in accordance with the RNOH Hypoglycaemia Emergency Protocol (see link below)
- UCLH:
- WH:
|
| A2.07 |
Glucose |
Provider notes |
| 06.01.04 |
Glucose gel 40% GlucoGel®, Glucoboost®, Dextrogel® |
Provider notes
- NMUH:
- Glucoboost is stocked at NMUH
- RFL:
- RNOH:
- For use in accordance with the RNOH Hypoglycaemia Emergency Protocol (see link below)
- UCLH:
- WH:
|
| 09.02.02.01 |
Glucose Intravenous |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Glucose 5% (100 mL, 250 mL, 500 mL and 1000 mL)
- Glucose 10% (500 mL)
- Glucose 20% (500 mL)
- Glucose 50% (50 mL)
- Glucose 1% in compound sodium lactate (Hartmann's) (1000 mL)
- UCLH:
- WH:
|
| 06.01.06 |
Glucose urine test strip Diastix® |
Provider notes |
| 13.07 |
Glutaraldehyde 10% solution Glutarol® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.06.02 |
Glycerol (Glycerin) |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Suppositories 1 g, 2 g, 4 g
|
| 11.99.99.99 |
Glycerol eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for clearing corneal oedema (50% drops available)
- RNOH:
- UCLH:
- WH:
- This is unlicensed and restricted to Ophthalmology
|
| 02.06.01 |
Glyceryl trinitrate parenteral |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.07.04 |
Glyceryl Trinitrate rectal ointment |
Provider notes
- NMUH:
- RFL:
- Rectogesic brand - restricted to Colorectal team
- RNOH:
- UCLH:
- WH:
- Rectogesic brand is first choice for anal fissures (4mg/g)
|
| 02.06.01 |
Glyceryl trinitrate short-acting (tablets and sprays) |
Provider notes
- NMUH:
- Nitrolingual Pumpspray and 500mcg sublingual tablets available
- RFL:
- Only 500 microgram tablets and 400 microgram spray kept at the RFH.
- RNOH:
- UCLH:
- WH:
- Sublingual tablets 500 micrograms and 400 microgram spray available at WH
|
| 02.06.01 |
Glyceryl trinitrate transdermal |
Provider notes
- NMUH:
- Restricted to venous cannulation use only.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.04.04 |
Glycine 1.5% Irrigation Solution |
Provider notes - NMUH:
- RFL:
- RNOH:
- Available as 3000 mL bags
- UCLH:
- WH:
|
| 15.01.03 |
Glycopyrronium injection |
Provider notes |
| 13.12 |
Glycopyrronium powder Robinul® |
Provider notes
- NMUH:
- RFL:
- Approved for use in dermatology and Vascular Hyperhidrosis clinic for the treatment of hyperhidrosis
- RNOH:
- UCLH:
- WH:
|
| 13.12 |
Glycopyrronium solution for iontophoresis |
Provider notes
- NMUH:
- RFL:
- Approved for use by Dermatology - paediatric use
- RNOH:
- UCLH:
- WH:
|
| 01.02 |
Glycopyrronium tablets |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Unlicensed 1mg and 2mg tablets available
- RNOH:
- UCLH:
- WH:
|
| 13.12 |
Glycopyrronium tablets |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Unlicensed - 1mg and 2mg tablets available
- RNOH:
- UCLH:
- WH:
|
| 01.05.03 |
Golimumab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
See NCL treatment pathway for place in therapy (note: biosimilar adalimumab and biosimilar infliximab are preferred anti-TNFs; JFC April 2019).
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Restricted to Consultant Gastroenterologists for NICE approved indications.
- Check MHRA Drug Safety Update.
- See links below.
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Consultant Gastroenterologists
- NICE TA329 applies
|
| 10.01.03 |
Golimumab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for:
- Rheumatoid arthritis in line with the NCL RA pathway
- Ankylosing Spondylitis (see NICE TAs)
- Psoriatic Arthritis (PsA; see NICE TAs)
Provider notes
- NMUH:
- This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- Restricted to Consultant Rheumatologists
- See links below
- Check MHRA Drug Safety Updates
- RFL:
- Restricted to Rheumatology
- Approved for use in Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis in line with NICE guidance
- RNOH:
- Rheumatology Consultants ONLY.
- UCLH:
- WH
|
| 06.05.01 |
Gonadorelin |
Provider notes |
| 06.07.02 |
Goserelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Approved to preserve fertility when using cyclophosphamide
- RNOH:
- UCLH:
- WH:
|
| 06.07.02 |
Goserelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.07.02 |
Goserelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.02 |
Goserelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Preferred product is leuprorelin
- RNOH:
- UCLH:
- WH:
- Goserelin is reserved for the treatment of breast cancer only
|
| A5.02.04 |
Granuflex |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Hydrocolloid dressing 10 cm * 10 cm (10), 20 cm * 20 cm (5) & Border dressing 10 cm * 13 cm (5), 15 cm * 15 cm (5) only
|
| A5.02.01 |
GranuGel |
Provider notes |
| 03.04.02 |
Grasses + Rye and Trees Pollen Extract Pollinex® |
Approved for grass/tree-pollen seasonal allergic rhinitis requiring treatment with subcutaneous immunotherapy for patients over 6 years old (JFC October 2019).
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- Approved for:
- Seasonal allergic rhinitis - treatment when anti-allergy drugs ineffective. Restricted to RLHIM/RNTNE and UCLH paediatric allergy clinics for tree and grass pollen allergies (UMC Oct 2018)
- WH:
|
| 05.02 |
Griseofulvin |
Provider notes |
| 13.10.02 |
Griseofulvin 400mcg/spray Grisol AF® |
Provider notes |
| 02.05.03 |
Guanethidine monosulfate |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.05.03 |
Guselkumab |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.08.02 |
Haem Arginate Normosang® |
Provider notes |
| 14.07 |
Haemophilus influenzae type B Combined Vaccine Menitorix® |
Approved as Test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017) Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- Test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (UMC March 2017)
- WH:
|
| 01.07.01 |
Haemorrhoid relief ointment |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Generic 'Haemorrhoid relief ointment'
- UCLH:
- WH:
|
| 04.02.01 |
Haloperidol |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- CIFT:
- BEHMT approvals:
|
| 04.14 |
Haloperidol |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.02.02 |
Haloperidol depot injection Haldol Decanoate® |
Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- Restricted for initiation by a Consultant Psychiatrist only
|
| 14.04 |
Havrix Monodose® Hepatitis A vaccine Single Component |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 14.04 |
HBvaxPRO® Hepatitis B vaccine Single Component |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.03 |
Helicobacter Test INFAI |
Provider notes |
| 02.08.01 |
Heparin calcium |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.08.01 |
Heparin sodium |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.08.01 |
Heparin sodium |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.13 |
Heparinoid 0.3% Hirudoid® |
Provider notes - NMUH:
- Cream is formualry and gel is non-formulary
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 14.05.02 |
Hepatitis B immunoglobulin for intramuscular use |
Provider notes - NMUH:
- Available from Health Protection Agency
- RFL:
- RNOH:
- UCLH:
- WH:
- Available from Microbiology (Ext 5084)
|
| 14.05.02 |
Hepatitis B immunoglobulin for intravenous use Hepatect® CP |
Provider notes
- NMUH:
- RFL:
- Restricted to liver and renal transplants
- See liver transplant protocol for more information
- RNOH:
- UCLH:
- WH:
|
| 14.04 |
Hepatyrix® Hepatitis A vaccine with typhoid vaccine |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.03.01 |
Hexamidine 0.1% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for acanthamoeba keratitis (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
| 13.10.05 |
Histoacryl® |
Provider notes
- NMUH:
- Restricted for use by Gastroenterology Consultants.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.05 |
Homatropine 1% eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for mydriasis and cycloplegia
- RNOH:
- UCLH:
- WH:
|
| 11.05 |
Homatropine 1% eye drops - preservative free |
Provider notes
- NMUH:
- RFL:
- Approved for mydriasis and cycloplegia
- RNOH:
- UCLH:
- WH:
- Preservative free Eye-drops Eye-drops 1% (Moorfields’ special)
|
| 11.99.99.99 |
HPMC 2% in balanced salt solution injection |
Provider notes
- NMUH:
- RFL:
- Approved to protect ocular structures and maintain anterior chamber depth during cataract and intraocular surgery
- RNOH:
- UCLH:
- WH:
|
| 02.11 |
Human fibrinogen Riastap® |
Provider notes - NMUH:
- RFL:
- Available through the haemophilia centre
- RNOH:
- UCLH:
- WH:
|
| 06.05.01 |
Human Menopausal Gonadotrophins Menogon® |
Provider notes |
| 21.01 |
Hyaluronic acid injection Ostenil Plus® |
Hyaluronic acid injection (Ostenil Plus) to prevent surgery
Approved under evaluation at RNOH only (July 2014) RNOH: Restricted for use in accordance with the evaluation protocol by consultants in the Shoulder and Elbow Unit |
| 10.03.01 |
Hyaluronidase |
JFC approved for epidurolysis (epidural lysis of adhesions, adhesiolysis) for the treatment of chronic pain in patients presenting with radicular pain (JFC October 2016) Provider notes |
| 02.05.01 |
Hydralazine |
Hydralazine injection is for hospital prescribing only
Hydralazine tablets have no restriction for primary care
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| A5.02.04 |
Hydrocoll Border |
Provider notes |
| 13.04 |
Hydrocortisone - Topical |
Provider notes - NMUH:
- Hydrocortisone 2.5% Ointment is FORMULARY.
- Hydrocortisone 2.5% cream is NON-FORMULARY.
- All other strength are available as both cream and ointment.
- RFL:
- 2.5% cream available
- 0.5% and 1% available in both cream and ointment
- RNOH:
- UCLH:
- WH:
|
| 06.03.02 |
Hydrocortisone sodium phosphate Efcortesol® |
Provider notes |
| 06.03.02 |
Hydrocortisone sodium succinate Solu-Cortef® |
Provider notes |
| 13.04 |
Hydrocortisone 0.25% + Crotamiton 10% - Topical Eurax-Hydrocortisone® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Hydrocortisone 0.5% + Nystatin + Benzalkonium + Dimeticone - Topical Timodine® |
Provider notes - NMUH:
- RFL:
- RNOH:
- Non-formulary
- Store in a refrigerator
- UCLH:
- WH:
|
| 13.04 |
Hydrocortisone 1% + Clotrimazole 1% - Topical Canesten HC® |
Provider notes |
| 13.04 |
Hydrocortisone 1% + Miconazole 2% - Topical Daktacort® |
Provider notes - NMUH:
- Datkacort Cream is FORMULARY
- Daktacort Ointment is NON-FORMULARY
- RFL:
- Both cream and ointment available
- RNOH:
- Store Daktacort cream in the refrigerator
- UCLH:
- WH:
|
| 13.04 |
Hydrocortisone 1% + Nystatin + Chlorhexidine - Topical Nystaform-HC® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Hydrocortisone 1% + Urea 10% - Topical Alphaderm® |
Provider notes |
| 10.01.02.02 |
Hydrocortisone acetate |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.04 |
Hydrocortisone Acetate 1% + Fusidic Acid 2% - Topical Fucidin H® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.05.02 |
Hydrocortisone acetate rectal foam Colifoam® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 12.03.01 |
Hydrocortisone buccal tablets |
Provider notes |
| 13.04 |
Hydrocortisone butyrate - Topical Locoid® |
Provider notes - NMUH:
- RFL:
- cream, lipocream, ointment and scalp lotion available
- RNOH:
- UCLH:
- WH:
- Cream 0.1% 30g, Ointment 0.1% 30g, Lotion 0.1% 30ml ONLY
|
| 11.04.01 |
Hydrocortisone sodium phosphate 3.35 mg/ml drops Softacort® |
Approved for mild non-infectious allergic or inflammatory ocular surface diseases (JFC September 2019)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.03.02 |
Hydrocortisone tablets |
Provider notes |
| 13.11.06 |
Hydrogen peroxide 1% cream |
Approved for non-bullous impetigo (JFC September 2020).
Provider notes
- NMUH:
- Approved for non-bullous impetigo
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 12.03.04 |
Hydrogen peroxide 6% mouthwash BP |
Provider notes - NMUH:
- Check for MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.11.06 |
Hydrogen peroxide solution |
Provider notes
- NMUH:
- 3% solution stocked at NMUH
- Check MHRA drug safety updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.02.01.01 |
Hydromol® bath and shower emollient |
- NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
- Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)
Provider notes
- NMUH:
- RFL:
- Approved for ichthyosis and epidermolysis bullosa
- RNOH:
- UCLH:
- WH:
|
| 13.02.01 |
Hydromol® cream/ointment |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted for the use by Consultant Dermatologists ONLY
- Ointment 125g, 500g available
|
| 04.07.02 |
Hydromorphone injection |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- Relief of severe pain in cancer
- WH:
|
| 04.07.02 |
Hydromorphone modified release Palladone® SR |
Provider notes - NMUH:
- Restricted to Consultant Haematologists and Consultant Oncologists use only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.01.02 |
Hydroxocobalamin |
Provider notes |
| 18 |
Hydroxocobalamin |
Provider notes |
| 08.01.05 |
Hydroxycarbamide |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 09.01.03 |
Hydroxycarbamide |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Hydroxycarbamide Suspension 50mg/5ml (100 ml) unlicensed preparation is also available
- RFL:
- Restricted to Haematology
- Not prescribed on Chemocare for this indication
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Hydroxychloroquine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- Restricted to Rheumatology Consultants Only
- See links below
- UCLH:
- WH:
|
| 13.05.03 |
Hydroxychloroquine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for symptomatic erosive oral lichen planus refractory to topical treatment (corticosteroids or tacrolimus) (JFC June 2018).
DMARD fact sheet also specifies approval for "Dermatological conditions caused or aggravated by sunlight".
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 03.04.01 |
Hydroxyzine |
Provider notes - NMUH:
- Check for MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
- Ucerax brand for syrup only
|
| 01.02 |
Hyoscine butylbromide |
Provider notes - NMUH:
- Check MHRA Drug Safety alerts
- RFL:
- RNOH:
- UCLH:
- WH:
- Check MHRA drug safety alerts
|
| 15.01.03 |
Hyoscine Hydrobromide |
Provider notes |
| 04.06 |
Hyoscine hydrobromide patches |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.06 |
Hyoscine hydrobromide tablets |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 03.07 |
Hypertonic sodium chloride 3% nebuliser solution MucoClear® 3% |
Provider notes
- NMUH:
- RFL:
- RNOH:
- Restricted for the management of altered respiratory secretions in the spinal injured patient. Requires approval from a member of the Tracheostomy team or an ITU consultant
- UCLH:
- WH:
|
| 03.07 |
Hypertonic sodium chloride 7% nebuliser solution Nebusal® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.08.01 |
Hypromellose 0.3% + Dextran 70 0.1% eye drops Tears naturale® |
Provider notes
- NMUH:
- RFL:
- Approved for tear deficiency
- RNOH:
- UCLH:
- WH:
|
| 11.08.01 |
Hypromellose eye drops |
Provider notes
- NMUH:
- RFL:
- Approved for tear deficiency (0.3%)
- RNOH:
- UCLH:
- WH:
|
| 11.08.01 |
Hypromellose eye drops - preservative free |
Provider notes
- NMUH:
- RFL:
- Approved for tear deficiency (bottle)
- RNOH:
- UCLH:
- WH:
- Restricted to ophthalmology (unit-dose drops)
|
| 06.06.02 |
Ibandronic Acid 150mg tablets |
Provider notes |
| 06.06.02 |
Ibandronic Acid 50mg tablets |
Approved as second-line adjuvant therapy for post-menopausal (including those for whom it is chemically induced) women with breast cancer to prevent bone recurrence and cancer mortality, for patients without IV access/zolendronic acid toxicity (JFC February 2019). Provider notes - NMUH:
- 1st line bisphosphonate for the Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.06.02 |
Ibandronic Acid IV injection |
Provider notes |
| 08.01.05 |
Ibrutinib |
Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotheray prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 10.03.02 |
Ibuprofen 5 % gel |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 10.01.01 |
Ibuprofen immediate release |
Provider notes - NMUH:
- See MHRA Drug Safety Update
- RFL:
- RNOH:
- UCLH:
- WH:
- Intravenous injection restricted to Consultant level
|
| 07.01.01.01 |
Ibuprofen IV injection Pedea® |
- NMUH:
- RFL:
- Restricted to neonatal unit
- RNOH:
- UCLH:
- WH:
|
| 03.04.03 |
Icatibant |
Approved for treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC June 2018)
Provider notes
- NMUH:
- RFL:
- For the treatment of hereditary angioedema in line with NHSE comissioning policies
- Restricted to Immunology only
- RNOH:
- UCLH:
- WH:
- For hereditary angioedema in line with NHSE comissioning policy
|
| 08.01.02 |
Idarubicin |
Provider notes
- NMUH:
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 02.08 |
Idarucizumab |
For dabigatran reversal. Restricted to patients with who have life/limb threatening bleeding, uncontrolled bleeding, or require emergency surgery (February 2016)
Provider notes
- NMUH:
- See Trust intranet for guideline
- RFL:
- As above
- Haemophilia recommendation only
- RNOH:
- UCLH:
- Kept in blood transfusion lab and restricted to thrombosis haematology consultants only
- WH:
|
| 08.01.05 |
Idelalisib tabs |
Idelalisib should not be initiated as a first-line treatment in chronic lymphocytic leukaemia (CLL) patients with 17p deletion or TP53 mutation - see 'Direct Communication' below.
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 09.08.01 |
Idursulfase |
Provider notes
- NMUH:
- RFL:
- Restricted to the lysosomal storage disorders unit
- RNOH:
- UCLH:
- WH:
|
| 08.01.01 |
Ifosfamide |
Provider notes - NMUH:
- RFL:
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 02.05.01 |
Iloprost injection |
Provider notes - NMUH:
- RFL:
- Approved for use in pulmonary hypertension, scleroderma and peripheral vascular disease - see local protocols
- Also approved for use on ITU
- RNOH:
- UCLH:
- WH:
- Available on named patient basis only. Contact pharmacy for further information
|
| 02.05.01 |
Iloprost nebules Ventavis® |
Approved for COVID-19 associated ARDS with refractory hypoxaemia, in line with COVID-19 Speciality guide for critical care (see JFC Position Statement).
Provider notes
- NMUH:
- Non-formulary (use epoprostenol for COVID-19 associated ARDS)
- RFL:
- RFH: Restricted to critical care and used in ARDS with refractory hypoxaemia only
- BCH: Non-formulary
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Imatinib tabs |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Gilvec for GIST only. Generic for all other indications. Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by the Haematology Team ONLY.
- See links below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 09.08.01 |
Imiglucerase |
Provider notes
- NMUH:
- RFL:
- Restricted to the lysosomal storage disorders unit
- RNOH:
- UCLH:
- WH:
|
| 05.01.02.02 |
Imipenem + Cilastatin |
Provider notes - NMUH:
- RFL:
- Microbiology approval only
- RNOH:
- UCLH:
- WH:
|
| 04.03.01 |
Imipramine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- CIFT:
- BEHMT:
|
| 13.07 |
Imiquimod 3.75% cream Zyclara® |
Approve for actinic keratosis (AK) and basal cell carcinoma (BCC) (JFC March 2013) Provider notes - NMUH:
- Aldara and Zyclara have been approved for actinic keratosis, by JFC, as second line options (following treatment with fluorouracil): Zyclara for surface area >25cm2, Aldara for surface area <25cm2
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.07 |
Imiquimod 5% cream Aldara® |
Provider notes
- NMUH:
- Restricted to Dermatology and GU Consultants
- Approved for treatment of Superficial basal cell carcinoma, as a second line option, where fluorouracil treatment is contraindicated or has not been tolerated.
- Aldara and Zyclara have been approved for actinic keratosis, by JFC, as second-line options (following treatment with fluorouracil): Aldara for surface area <25cm2, Zyclara for surface area >25cm2
- RFL:
- Restricted to Dermatology only
- RNOH:
- UCLH:
- WH:
|
| 14.04 |
Inactivated Influenza Vaccine (Split Virion) |
Provider notes |
| A5.03.02 |
Inadine (Povidone-iodine) |
Provider notes - NMUH:
- 9.5 x 9.5 cm is stocked at NMUH
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.02.01 |
Indapamide |
Provider notes |
| 02.02.01 |
Indapamide modified release |
Provider notes |
| 11.08.02 |
Indocyanine green injection ICG |
Provider notes
- NMUH:
- RFL:
- Approved for ophthalmic angiography of choroidal vasculature
- RNOH:
- UCLH:
- WH:
|
| 10.01.01 |
Indometacin immediate release caps |
Provider notes
- NMUH:
- Access Trust guideline via intranet
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 10.01.01 |
Indometacin modified release caps |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Rheumatology only
|
| 07.06 |
Indometacin suppositories |
Approved for tocolytic therapy during pre-natal repair of myelomeningocele, a serious form of spina bifida (UCLH only; JFC February 2018)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- As tocolytic therapy during pre-natal repair of myelomeningocele (fetal spina bifida) (UMC Dec 2017)
- WH:
|
| 07.04.01 |
Indoramin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Restricted to Urology use only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.11.01 |
Industrial Methylated Spirit BP |
Provider notes |
| 14.04 |
Infanrix Hexa® Diphtheria, tetanus, pertussis, poliomyelitis (inactivated), hepatitis b (rDNA) and Hib |
Provider notes |
| 14.04 |
Infanrix-IPV+Hib® Diphtheria, Tetanus, Pertussis [Acellular, Component], Poliomyelitis [Inactivated] and Haemophilus T |
Provider notes |
| A2.01.03.02 |
Infatrini |
Provider notes - NMUH:
- Infatrini (Nutricia Clinical) Liquid (sip or tube feed) per 100mL
- For ages 0-12 months to increase calorie intake to meet requirements and for growth.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.05.03 |
Infliximab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Zessly is the preferred brand (JFC October 2019).
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
- Red List Medicine – Hospital Only Prescribing PbR (Payment by Results) excluded drug.
- Restricted to Consultant Gastroenterologists for NICE approved indications.
- Check MHRA Drug Safety Update
- RFL:
- Restricted to Consultant Gastroenterologists for NICE approved indications
- RNOH:
- UCLH:
- WH:
- Restricted to Consultant Gastroenterologists
- NICE TA163, TA187 and TA329 applies
|
| 01.10 |
Infliximab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Zessly is the preferred brand (JFC October 2019).
Provider notes
- NMUH:
- RFL:
- Approved for steroid-refractory ipilimumab-induced colitis (RFL only; JFC August 2016).
- RNOH:
- UCLH:
- WH:
|
| 04.14 |
Infliximab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Zessly is the preferred brand (JFC October 2019).
Provider notes
- NMUH:
- RFL:
- Approved for use in neurosarcoid (Dr Kidd only)
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Infliximab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Zessly is the preferred brand (JFC October 2019).
Approved for:
- Rheumatoid arthritis in line with the NCL RA pathway
- Ankylosing Spondylitis (see NICE TAs)
- Psoriatic Arthritis (PsA; see NICE TAs)
Provider notes
- NMUH:
- This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Restricted to Consultant Rheumatologists
- See links below.
- Check MHRA Drug Safety Updates.
- RFL:
- Approved for use in Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis in line with NICE guidance
- Approved for sarcoid (seek pharmacy advice)
- Approved for Bechets disease (see pharmacy advice)
- RNOH:
- Restricted for Rheumatology Consultants ONLY.
- UCLH:
- WH:
|
| 13.05.03 |
Infliximab |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Zessly is the preferred brand (JFC October 2019).
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- Restricted to Consultant Dermatologists
- See MHRA Drug Safety Updates
- RFL:
- Approved for treatment of Psoriasis and Hydradenitis Suppurativa (NHSE)
- Approved for Pyoderma gangrenosum – prior funding approval required
- RNOH:
- UCLH:
- WH:
|
| 06.01.01.03 |
Injection Devices Autopen® |
Provider notes |
| 06.01.01.03 |
Injection Devices HumaPen® Luxura |
Provider notes |
| 16.01 |
Inotersen injection |
See NICE HST for eligibility criteria
Provider notes
- NMUH:
- RFL:
- National Amyloidosis Clinic use only
- Approved for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis, in line with NICE HST
- RNOH:
- UCLH:
- WH:
|
| 06.01.01.01 |
Insulin Humulin® S |
Provider notes |
| 06.01.01.01 |
Insulin Actrapid® |
Provider notes |
| 06.01.01.01 |
Insulin Aspart NovoRapid® |
Provider notes
- NMUH:
- RFL:
- RNOH:
- For use in accordance with RNOH Hyperglycaemia Protocol for Type 1 Diabetes Mellitus (see link below)
- UCLH:
- WH:
|
| 06.01.01.02 |
Insulin degludec Tresiba® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for patients with Type 1 diabetes who had
(i) intermittent adherence to basal insulin leading to recurrent DKA or HbA1c ≥9.5% despite regular intervention from MDT or
(ii) problematic hypoglycaemia and were not eligible for an insulin pump (JFC November 2017)
Provider notes
- NMUH:
- To be prescribed as per the indication stated above and Trust guidance (see link below)
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.01.01.02 |
Insulin Detemir Levemir® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Initiation as per Diabetes team advice
|
| 06.01.01.02 |
Insulin Glargine 100units/mL Lantus® |
For continuation only (new starters to use Abasaglar)
Provider notes
- NMUH:
- Check MHRA Safety Alerts
- See link below
- RFL:
- For continuation only (patients newly initiating glargine should use Abasaglar)
- See link below
- RNOH:
- UCLH:
- WH:
|
| 06.01.01.02 |
Insulin Glargine 100units/mL Abasaglar® |
Approved for:
- Type 2 diabetes: First choice analogue basal insulin. See NCL guideline for insulin in Type 2 diabetes guideline
- Type 1 diabetes
Provider notes
- NMUH:
- Check MHRA Safety Alerts
- See link below for use in Type 2 diabetes
- RFL:
- Initiation of therapy under the recommendation of the diabetic team only
- See link below for use in Type 2 diabetes
- RNOH:
- See link below for use in Type 2 diabetes
- UCLH:
- WH:
- Initiation as per Diabetes team advice
|
| 06.01.01.01 |
Insulin Glulisine Apidra® |
Provider notes
- NMUH:
- RFL:
- BCF: Not in use
- RFH: Restricted to endocrinology
- RNOH:
- UCLH:
- WH:
|
| 06.01.01.01 |
Insulin Lispro 100 units/mL Humalog® |
Provider notes
- NMUH:
- Check MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.02.04 |
Interferon Alfa IntronA® |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Consultant Haematologists and Gastroenterologists only
|
| 08.02.04 |
Interferon Alfa Roferon-A® |
Provider notes - NMUH:
- RFL:
- Preferred brand for haematology
- RNOH:
- UCLH:
- WH:
|
| 08.02.04 |
Interferon beta-1a Avonex® |
Provider notes
- NMUH:
- RFL:
- Restricted to Neurology for MS in line with NICE TA
- RNOH:
- UCLH:
- WH:
|
| 08.02.04 |
Interferon beta-1a Rebif® |
Provider notes
- NMUH:
- RFL:
- Restricted to Neurology for MS in line with NICE TA
- RNOH:
- UCLH:
- WH:
|
| 08.02.04 |
Interferon beta-1b Betaferon® |
Provider notes
- NMUH:
- RFL:
- Restricted to Neurology for MS in line with NICE TA
- RNOH:
- UCLH:
- WH:
|
| 08.02.04 |
Interferon gamma-1b Immukin® |
Provider notes
- NMUH:
- RFL:
- Restricted to immunology use only
- RNOH:
- UCLH:
- WH:
|
| A5.02.01 |
Intrasite Gel |
Provider notes |
| 07.03.04 |
Intra-uterine Contraceptive Devices TT 380® Slimline |
Provider notes - NMUH:
- Restricted to Consultants in GU Medicine ONLY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.04 |
Intra-uterine Contraceptive Devices Mini TT 380 Slimline® |
Provider notes - NMUH:
- Restricted to Consultants in GU Medicine ONLY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.04 |
Intra-uterine Contraceptive Devices Nova-T® 380 |
Provider notes |
| 07.03.04 |
Intra-uterine Contraceptive Devices T-Safe® 380A QuickLoad |
Provider notes - NMUH:
- Restricted to Obs & Gynae and GU Consultants ONLY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.02.03 |
Intra-uterine levonorgestrel system Kyleena® |
Approved as first-line intra-uterine device for contraception (February 2019)
Provider notes
- NMUH:
- To be used as above
- Restricted to sexual health clinics
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.02.03 |
Intra-uterine levonorgestrel system Levosert® |
Approved as first-line intra-uterine device for (JFC March 2018):
- heavy menstrual bleeding
- contraception
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.02.03 |
Intra-uterine levonorgestrel system Jaydess® |
Sexual-health clinic use only as second-line intra-uterine device for contraception, Kyleena preferred (April 2019).
Provider notes
- NMUH:
- Sexual-health clinic use only as second-line intra-uterine device for contraception, Kyleena preferred
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.02.03 |
Intra-uterine levonorgestrel system Mirena® |
Provider notes
- NMUH:
- Restricted to Consultants in GU Medicine ONLY
- Check MHRA Drug Safety Updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.02.02 |
Iodine and Iodide |
Provider notes - NMUH:
- RFL:
- 5% oral solution available
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Ipilimumab |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
- RFL:
- As per NICE TA
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 12.02.02 |
Ipratropium bromide 21 mcg/spray [0.03%] nasal spray |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 03.01.02 |
Ipratropium inhaler (pMDI) and nebuliser solution |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- CFC-free inhaler 20 micrograms/metered inhalation ONLY
|
| 02.05.05.02 |
Irbesartan |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- 1st choice for hypertension / diabetes
|
| 08.01.05 |
Irinotecan Hydrochloride |
See NICE TA for eligibility criteria Provider notes - NMUH:
- To be prescribed by the Oncology team only.
- See links below
- RFL:
- No restriction stated
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
- RNOH:
- UCLH:
- WH:
|
| 09.01.01.02 |
Iron Dextran CosmoFer® |
See local guidance for iron replacement
Provider notes
- NMUH:
- See link below to access the Trust guidelines on use of parenteral irons for iron deficiency anaemia
- Check MHRA Drug Safety updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.01.01.02 |
Iron Sucrose Venofer® |
See local guidance for iron replacement
Provider notes
- NMUH:
- See Trust guidelines on use of parenteral irons for iron deficiency anaemia; link below
- Check MHRA Drug Safety updates
- RFL:
- Renal anaemia only - Venofer and Cosmofer are preferred choices
- RNOH:
- Preferred parenteral iron preparation for inpatients
- UCLH:
- WH:
|
| 05.02 |
Isavuconazole capsules/infusion |
Approved for treatment of proven or probable invasive aspergilosis or mucomycosis where other antifungals are not appropriate (JFC August 2020)
Provider notes
- NMUH:
- As per JFC decision above
- On microbiology recommendation ONLY
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 04.03.02 |
Isocarboxazid |
Provider notes
- NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
- BEHMT:
- CIFT:
|
| 15.01.02 |
Isoflurane |
Provider notes |
| 05.01.09 |
Isoniazid |
Provider notes
- NMUH:
- No restriction stated (Isoniazid elixir 50mg/5mL [unlicensed] available for the treatment of tuberculosis in children)
- RFL:
- For treatment and prophylaxis of tuberculosis only
- Microbiology or ID approval required for other indications
- RNOH:
- Microbiologist approval only
- UCLH:
- WH:
|
| 06.01.01.02 |
Isophane Insulin Insulatard® |
Provider notes - NMUH:
- The fomulary choices are vial, 3ml cartridge and Innolet.
- RFL:
- RNOH:
- First line for patients on a feed or patients that are on high doses of steroids, and require insulin. Available in the EDC Fridge
- UCLH:
- WH:
|
| 06.01.01.02 |
Isophane Insulin Humulin® I |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Initiation as per Diabetes team advice
|
| 02.07.01 |
Isoprenaline |
Provider notes
- NMUH:
- For refractory bradycardia. Isoprenaline 2.25mg in 2ml injection, available from ‘special-order’ manufacturers or specialist importing companies
- RFL:
- Unlicensed product
- Adhere to local protocols
- RNOH:
- Unlicensed product
- Store in a refrigerator
- UCLH:
- WH:
- Refractory bradycardia
- Unlicensed product
|
| 02.06.01 |
Isosorbide dinitrate immediate released |
Provider notes |
| 02.06.01 |
Isosorbide dinitrate parenteral |
Provider notes - NMUH:
- RFL:
- Restricted to cardiac cath lab use only.
- RNOH:
- UCLH:
- WH:
- 0.1% infusion available only
|
| 02.06.01 |
Isosorbide mononitrate |
Provider notes - NMUH:
- 60mg modified release and immediate release 10mg and 20mg tablets available
- RFL:
- RNOH:
- UCLH:
- WH:
- 60mg modified release and immediate release 10mg and 20mg tablets available
|
| 13.06.01 |
Isotretinoin 0.05% + Erythromycin 2% gel Isotrexin® |
Provider notes
- NMUH:
- RFL:
- Restricted to Dermatology
- RNOH:
- UCLH:
- WH:
- Isotrexin gel is restricted to Dermatology
|
| 13.06.02 |
Isotretinoin capsules |
Provider notes - NMUH:
- Restricted to Dermatology
- Check MHRA Drug Safety Updates
- RFL:
- Restricted to Dermatology
- Follow prescribing advice and important safety information including pregnancy prevention programme (PPP) for females of childbearing potential. Maximum 30 days treatment at a time
- Patients who do not qualify for the pregnancy prevention programme (PPP) may be supplied more than one month at a time
- RNOH:
- UCLH:
- WH:
- Isotretinoin capsules are restricted to Dermatology prescribing only and are not available in the community unless by special arrangement, for details see data sheet.
|
| 01.06.01 |
Ispaghula Husk |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 05.02 |
Itraconazole |
Provider notes
- NMUH:
- RFL:
- Oral: Restricted to Dermatology; HIV; Haematology. ID/Microbiology approval for all other indications.
- Intravenous: Microbiology/ID approval
- RNOH:
- Microbiology approval only
- UCLH:
- WH:
- For restricted indications as per Trust guidelines or Microbiology advice
|
| 02.06.03 |
Ivabradine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
See NICE TA for eligibility criteria
Secondary care notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information.
- RFL:
- Restricted to cardiology approval only - as per NICE TA
- RNOH:
- Requires CARDIOLOGIST approval
- UCLH:
- WH:
- Available for prescribing to consultant cardiologists only
- NICE TA267 applies
|
| 13.06 |
Ivermectin 10 mg/g cream |
Approve for papulopustular rosacea. Suitable for primary and secondary care initiation (JFC July 2016)
Provider notes
- NMUH:
- To be prescribed by dermatology ONLY for papulopustular rosacea
- RFL:
- To be prescribed by dermatology ONLY for papulopustular rosacea
- RNOH:
- UCLH:
- WH:
|
| 05.05.07 |
Ivermectin tablets |
Provider notes - NMUH:
- 3mg tablets available from 'special order'
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Ixazomib |
See NICE TA for eligibility criteria Provider notes - NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See link below
- RFL:
- As per NICE guidance
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Ixekizumab injection |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. See NICE TA for eligibility criteria Provider notes - NMUH:
- RFL:
- As per NICE guidance for the treatment of Psoriatic Arthritis
- RNOH:
- UCLH:
- WH:
|
| 13.05.03 |
Ixekizumab injection |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See link below
- RFL:
- For Psoriasis in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
| A2.01.01.01 |
Jevity |
Provider notes - NMUH:
- For patients who require a fibre feed, such as those requiring long-term nutrition support.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| A2.01.02.01 |
Jevity 1.5 kcal |
Provider notes - NMUH:
- For patients requiring higher energy intake or fluid restriction or a shorter feeding period who also need a fibre feed.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| A2.01.02.02 |
Jevity Plus |
Provider notes |
| A2.01.02.02 |
Jevity Plus HP |
Provider notes - NMUH:
- For patients with high protein requirements who need a fibre feed, including those on long-term nutritional support.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| A5.02.06 |
Kaltostat |
Provider notes - NMUH:
- We stock the following in Pharmacy:Kaltostat 7.5x12cm and 5x5cm, Kaltostat Cavity 2g.
- Kaltostat cavity should only be used when haemostatis is involved. Otherwise Aquacel ribbon (2x45cm) should be used.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 10.03.02 |
Kaolin Poultice |
Provider notes |
| 15.01.01 |
Ketamine injection |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 21.01 |
Ketamine oral solution |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
RFL Restricted: Acute pain unresponsive to opiates (inpatient use only; initiation by Pain team consultant or consultant Anaesthetist), for the following indications:
- Neuropathic pain and persistent post‐surgical pain, including phantom limb pain
- In a patient with a history of high opioid consumption preceding injury/surgery
- In pain with poor opioid responsiveness
- In hyperalgesic states, with or without allodynia
Evaluation for RFL only (approved by DTC in July-17, updated and approved by DTC November 2020 & ratified by JFC in August-17)
|
| 07.02.02 |
Ketoconazole 2% cream |
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 13.10.02 |
Ketoconazole 2% cream |
Provider notes
- NMUH:
- RFL:
- Restricted to Dermatology only
- RNOH:
- UCLH:
- WH:
|
| 13.09 |
Ketoconazole 2% shampoo |
Provider notes
- NMUH:
- RFL:
- Restricted to Dermatology only
- RNOH:
- UCLH:
- WH:
|
| 06.07 |
Ketoconazole tablets Ketoconazole HRA® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Approved as first line in pre-treatment prior to surgery (4-6 weeks prior to surgery) or second line post-surgery in patients with persistent Cushing syndrome (long term treatment)
- RNOH:
- UCLH:
- WH:
|
| 06.01.06 |
Ketone urine test strips Ketostix® |
Provider notes |
| 15.01.04.02 |
Ketorolac |
Provider notes
- NMUH:
- RFL:
- Restricted to anaesthetics
- RNOH:
- UCLH:
- WH:
- Ketorolac tablets are not available
|
| 11.08.02 |
Ketorolac 0.5% eye drops |
Approved for:
- Treatment of inflammation post cataract surgery in patients unable to tolerate topical corticosteroids
- Prophylaxis of cystoid macular oedema (CMO) in high-risk patients
Provider notes
- NMUH:
- Restricted to Consultant Ophthalmologist use only.
- RFL:
- Approved for inflammation in anterior segment (Consultant Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
- Restricted to ophthalmology
|
| 11.04.02 |
Ketotifen 250mcg/mL eye drops |
Provider notes |
| 11.04.02 |
Ketotifen 250mcg/mL eye drops - preservative free |
Approved for seasonal allergic conjunctivitis who have an allergy to preservatives within either sodium cromoglicate or olopatadine (JFC July 2019)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.04 |
Labetalol |
Provider notes
- NMUH:
- RFL:
- Tablets – no restriction
- Infusion – following local protocol
- RNOH:
- UCLH:
- WH:
|
| 04.08.01 |
Lacosamide |
For patients refractory to standard AEDs (JFC March 2013)
Provider notes
- NMUH:
- Restricted for neurology patients with refractory epilepsy to standard antiepileptic drugs
- RFL:
- RNOH:
- UCLH:
- WH:
- Should only be commenced on the recommendation of a Neurologist only for refractory epilepsy (adjunctive Tx of partial-onset seizures in adults and adolescents)
|
| 01.06.04 |
Lactulose |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 01.06.04 |
Lactulose |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- No restriction stated.
- May be used at doses up to 30mL QDS
- RNOH:
- UCLH:
- WH:
|
| 05.03.01 |
Lamivudine |
Provider notes
- NMUH:
- Epivir brand only approved for HIV patients
- Zeffix brand approved for HIV and Hepatitis B patients
- RFL:
- 150mg & 300mg approved for HIV patients
- 100mg approved for Hepatitis B patients
- RNOH:
- UCLH:
- WH:
- Epivir brand on formulary
|
| 04.02.03 |
Lamotrigine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Psychiatry recommendation only
- RNOH:
- UCLH:
- WH:
- CIFT:
- BEHMT:
|
| 04.08.01 |
Lamotrigine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- Restricted to Neurology department use only
- RFL:
- RNOH:
- UCLH:
- WH:
- Tabs 25 mg, 50 mg, 200 mg. Dispersible tabs 5 mg, 25 mg, 100 mg. Only
|
| 03.04.03 |
Lanadelumab injection |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- Non-formulary
- TA606 does not apply at NMUH as service is not offered
- RFL:
- For hereditary angioedema in line with NICE TA
- Restricted to immunology
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.03 |
Lanreotide Somatuline® LA |
Provider notes
- NMUH:
- RFL:
- Restricted to endocrine and neuroendocrine team
- RNOH:
- UCLH:
- WH:
- Restricted to endocrinology team
|
| 08.03.04.03 |
Lanreotide Somatuline Autogel® |
Provider notes
- NMUH:
- RFL:
- Restricted to endocrine and neuroendocrine team
- RNOH:
- UCLH:
- WH:
- Restricted to endocrinology team
|
| 01.03.05 |
Lansoprazole |
Provider notes - NMUH:
- See links below
- Check MHRA Drug Safety Alerts
- The use of orodispersible tablets is restricted to patients with difficulty in swallowing capsules
- RFL:
- Orodispersible tablets restricted to patients with feeding tubes/ difficulty in swallowing tablets
- RNOH:
- UCLH:
- WH:
|
| 09.05.02.02 |
Lanthanum Fosrenol ® |
Provider notes - NMUH:
- RFL:
- Restricted to renal patients only
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Lapatinib |
Provider notes - NMUH:
- Special Funding Approval required - seek advice from Oncology Pharmacist
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 09.08.01 |
Laronidase |
Provider notes
- NMUH:
- RFL:
- Restricted to the lysosomal storage disorders unit
- RNOH:
- UCLH:
- WH:
|
| 15.02 |
LAT gel (Lidocaine 4% + Adrenaline 0.1% + Tetracaine 0.5%) |
Approved for second-line management of pain in children requiring sutures/debridement (JFC February 2018)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Latanoprost 0.005% + Timolol 0.5% Xalacom® |
Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. Provider notes - NMUH:
- Combination therapies to be used when compliance / cost issues arise
- See link below
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Latanoprost 0.005% eye drops |
See NCL guideline for place in therapy. Provider notes - NMUH:
- RFL:
- For ophthalmologists only
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Latanoprost 0.005% eye drops - preservative free |
Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes
Provider notes
- NMUH:
- Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes
- See link below
- RFL:
- Restricted to second-line use only
- RNOH:
- UCLH:
- WH:
|
| 05.03.03.02 |
Ledipasvir + Sofosbuvir |
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
- Check MHRA Drug Safety Updates
- RFL:
- Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
- RNOH:
- UCLH:
- WH:
|
| 10.01.03 |
Leflunomide |
Provider notes
- NMUH:
- Restricted to Rheumatology Consultants ONLY
- RFL:
- RNOH:
- Restricted to Rheumatology Consultants ONLY
- See links below
- UCLH:
- WH:
- Restricted to Rheumatology Consultants ONLY
|
| 08.02.04 |
Lenalidomide caps |
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- All prescriptions must be accompanied by a prescription authorisation form
- As per NICE TA171, TA322, TA505, TA586, TA587, TA627
- Check MHRA Drug Safety Update
- RFL:
- As per NICE TA171, TA322, TA505, TA586 and TA587.
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
- Patient, prescriber and supplying pharmacy must comply with a pregnancy prevention programme
- RNOH:
- UCLH:
- WH:
|
| 09.01.06 |
Lenograstim Granocyte® |
Provider notes
- NMUH:
- Restricted for use in paediatric patients ONLY. For Adult patients, use filgrastim (Zarzio) first line.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Lenvatinib caps Kisplyx® |
DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS See NICE TA for eligibility criteria Provider notes - NMUH:
- RFL:
- As per NICE guidance for renal cell carcinoma
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 08.01.05 |
Lenvatinib caps Lenvima® |
DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- See links below
- TA551 does not apply at NMUH as service is not offered
- RFL:
- As per NICE guidance for thyroid cancer and hepatocellular carcinoma
- This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
- RNOH:
- UCLH:
- WH:
|
| 08.03.04.01 |
Letrozole |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- Restricted to Oncology department use only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.05.01 |
Letrozole tabs |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved for ovulation induction in women with WHO group II infertility (JFC February 2020).
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- 2nd line (off-label) after the failure of clomifene citrate for ovulation induction in women with WHO Group II anovulation
- WH:
|
| 06.07.02 |
Leuprorelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 06.07.02 |
Leuprorelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 06.07.02 |
Leuprorelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 08.03.04.02 |
Leuprorelin |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Approved as first-choice for breast cancer (JFC February 2020).
Provider notes
- NMUH:
- RFL:
- Preferred product for use in prostate, maintenance of fertility and breast cancer women.
- RNOH:
- UCLH:
- WH:
|
| 04.08.01 |
Levetiracetam |
Provider notes - NMUH:
- Restricted to Consultant Neurologists only
- To be used as second line adjunctive treatment of partial seizures with or without secondary generalisation
- RFL:
- RNOH:
- UCLH:
- WH:
- Should only be commenced on the recommendation of a Neurologist
- Tabs 250 mg, 500 mg, 1 g. Oral solution 100 mg/ 1 ml only
- Intravenous infusion also available
- The infusion is available in the emergency drugs cupboard
|
| 11.06 |
Levobunolol 0.5% eye drops |
See NCL guideline for place in therapy. Provider notes - NMUH:
- See link below
- Check MHRA Drug Safety Update
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 11.06 |
Levobunolol 0.5% eye drops - unit dose |
See NCL guideline for place in therapy. Provider notes - NMUH:
- See link below
- Check MHRA Drug Safety Update
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Ophthalmology
|
| 15.02 |
Levobupivacaine |
Provider notes
- NMUH:
- RFL:
- BCF: Restricted to obstetrics, theatres and critical care
- RFH: Non-formulary
- RNOH:
- UCLH:
- WH:
|
| 15.02 |
Levobupivacaine + Fentanyl epidural |
Provider notes
- NMUH:
- RFL:
- BCF: 100ml Restricted to Obstetrics, 500ml Restricted to Theatres Acute Pain Team only
- RFH: Non-formulary
- RNOH:
- UCLH:
- WH:
|
| 09.08.01 |
Levocarnitine |
Provider notes
- NMUH:
- RFL:
- Non-formulary for paediatrics (GOSH specialist service)
- For peritoneal dialysis patients (levocarnitine deficiency)
- RNOH:
- UCLH:
- WH:
|
| 05.01.12 |
Levofloxacin |
Approved for treatment of TB, if moxifloxacin is unavailable or patient has liver impairment (JFC August 2020).
Provider notes
- NMUH:
- Restricted to Consultant Microbiologist or Consultant Gastroenterologist recommendation
- RFL:
- Follow RFL microbiology guidelines for agreed indications
- Microbiology approval required for all other indications
- RNOH:
- UCLH:
- WH:
- For restricted indications as per Trust guidelines or Microbiology advice
|
| 11.03.01 |
Levofloxacin 5mg/ml (0.5%) eye drops - preservative free |
- NMUH:
- RFL:
- Approved for
- Bacterial conjunctivitis
- Keratitis
- Post-intravitreal injections
- Corneal abrasions
- RNOH:
- UCLH:
- WH:
|
| 13.03 |
Levomenthol in aqueous cream |
Provider notes
- NMUH:
- RFL:
- 0.5%, 1% and 2% available
- RNOH:
- UCLH:
- WH:
|
| 04.02.01 |
Levomepromazine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Restricted for initiation until after a discussion with liaison psychiatry team
- RNOH:
- UCLH:
- WH:
|
| 04.06 |
Levomepromazine |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 07.03.05 |
Levonorgestrel 1.5mg tablet |
Provider notes
- NMUH:
- Restricted to Consultants in GU Medicine ONLY
- Check MHRA drug safety updates
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 02.14 |
Levosimendan infusion |
Approved for patients not responding to, or intolerant of, conventional inotropes if they have a reasonable expectation of survival and one of the below:
- Acute decompensation of severe chronic heart failure [NYHA III/IV].
- Low cardiac output syndrome.
- Takotsubo cardiomyopathy (JFC August 2020).
Provider notes
- NMUH:
- Restricted to ITU only for indications above. Follow local guidance.
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 06.02.01 |
Levothyroxine |
Provider notes
- NMUH:
- RFL:
- No restriction stated
- (hospital only prescribing) for levothyroxine oral solution (Tirosint®) - restricted to ITU only
- RNOH:
- UCLH:
- WH:
- Oral solution 100 mcg/5ml (adults only) and 50 mcg/5ml available
|
| 15.02 |
Lidocaine + Adrenaline injection Xylocaine® |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- For emergency caesarean section
|
| 12.03.01 |
Lidocaine 10% spray Xylocaine® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 15.02 |
Lidocaine 10% spray Xylocaine® |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes |
| 15.02 |
Lidocaine 2% + Chlorhexidine 0.25% gel Instillagel® |
Provider notes |
| 15.02 |
Lidocaine 2.5% + Prilocaine 2.5% cream EMLA® |
Provider notes |
| 11.07 |
Lidocaine 4% + Fluorescein 0.25% eye drops - unit dose |
Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- For diagnostic or surgical use only. Not to be given for home use
|
| 15.02 |
Lidocaine 4% cream LMX4® |
Approved for topical anaesthetic of first-choice prior to venous cannulation or venepuncture for paediatrics (JFC July 2013)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 15.02 |
Lidocaine 4% solution Laryngojet® |
Provider notes |
| 15.02 |
Lidocaine 5% + Phenylephrine 0.5% topical solution |
Provider notes - NMUH:
- Formulary for ENT use only
- RFL:
- RNOH:
- UCLH:
- WH:
|
| 15.02 |
Lidocaine 5% ointment |
Provider notes |
| 04.14 |
Lidocaine infusion |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Approved for chronic pain (JFC July 2018)
- Approved for use in neurology for the treatment of intractable headaches - see local protocol
- RNOH:
- UCLH:
- Approved for
- Chronic pain (RESTRICTED to Pain Management Centre at Cleveland Street for chronic pain; UMC May 2018)
- Perioperative pain (RESTRICTED to UCH and Westmoreland Street Operating Theatres in line with guideline only; UMC July 2018)
- WH:
|
| 02.03.02 |
Lidocaine injection |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- Ampoules are Formulary but infusions are non formulary.
- RFL:
- Lidocaine ampoules and infusion available
- RNOH:
- UCLH:
- WH:
|
| 15.01.01 |
Lidocaine injection |
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- The use of lidocaine (lignocaine) 2% cartridge, bupivacaine 0.0625% infusion andropivacaine is restricted to theatres only.
|
|
